<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20449979</PMID><DateCompleted><Year>2010</Year><Month>05</Month><Day>24</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0033-2674</ISSN><JournalIssue CitedMedium="Print"><Volume>44</Volume><Issue>1</Issue><PubDate><MedlineDate>2010 Jan-Feb</MedlineDate></PubDate></JournalIssue><Title>Psychiatria polska</Title><ISOAbbreviation>Psychiatr Pol</ISOAbbreviation></Journal><ArticleTitle>[Hypomania Check List (HCL-32)--hypomania symptoms questionnaire: description and application].</ArticleTitle><Pagination><MedlinePgn>39-46</MedlinePgn></Pagination><Abstract><AbstractText>In current diagnostic classifications such as the International Classification of Diseases (ICD-10) and the American Diagnostic and Statistical Manual (DSM-IV), unipolar and bipolar mood disorders are mentioned, where the differentiating factor is occurrence of mania or hypomania. In DSM-IV, bipolar mood disorder type I (bipolar I), with the episodes of mania, and bipolar mood disorder type II (bipolar II) with hypomania, have been separated. Clinical and epidemiological studies performed in recent decades using more sensitive measures of the assessment of hypomania suggest a marked prevalence of bipolar disorders of not-bipolar I type, amounting to about 3-5% of population. In 2005, Angst and collaborators introduced the Hypomania Check List-32 scale (HCL-32) aimed at a better identification of the occurrence of hypomania symptoms in patients with affective disorders. The studies carried out in many countries have demonstrated a significant sensitivity and specificity of the scale and its usefulness for the assessment of bipolar affective disorders. In the present paper, the Polish version of HCL-32 scale is presented. This version has been already employed in the all-country Polish project TRES-DEP where the features of bipolarity were assessed in depressive patients in whom treatment with antidepressant drugs was unsuccessful.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Łojko</LastName><ForeName>Dorota</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Klinika Psychiatrii Dorosłych UM w Poznaniu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rybakowski</LastName><ForeName>Janusz</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Dudek</LastName><ForeName>Dominika</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Pawłowski</LastName><ForeName>Tomasz</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Siwek</LastName><ForeName>Marcin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Kiejna</LastName><ForeName>Andrzej</ForeName><Initials>A</Initials></Author></AuthorList><Language>pol</Language><PublicationTypeList><PublicationType UI="D023362">Evaluation Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Hypomania Check List (HCL-32)--kwestionariusz objawów hipomanii: charakterystyka i zastosowanie.</VernacularTitle></Article><MedlineJournalInfo><Country>Poland</Country><MedlineTA>Psychiatr Pol</MedlineTA><NlmUniqueID>0103314</NlmUniqueID><ISSNLinking>0033-2674</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011044" MajorTopicYN="N" Type="Geographic">Poland</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="Y">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009626" MajorTopicYN="N">Terminology as Topic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>5</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>5</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>5</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20449979</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">7583474</PMID><DateCompleted><Year>1995</Year><Month>12</Month><Day>01</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1075-2730</ISSN><JournalIssue CitedMedium="Print"><Volume>46</Volume><Issue>8</Issue><PubDate><Year>1995</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Psychiatric services (Washington, D.C.)</Title><ISOAbbreviation>Psychiatr Serv</ISOAbbreviation></Journal><ArticleTitle>Psychiatric kibitzing.</ArticleTitle><Pagination><MedlinePgn>764-5</MedlinePgn></Pagination><Abstract><AbstractText>Foreword from Dr. Sharfstein: In this era of managed care, utilization review, and concerns about costs, a clinician-reviewer who knows little about a case may make a decision that profoundly affects the course of a patient's treatment. Although Dr. Houghton's timely essay does not involve a managed care or utilization reviewer, it serves to remind us about the dangers inherent in criticizing the work and the judgment of other clinicians.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Houghton</LastName><ForeName>M A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Medical College of Wisconsin, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Psychiatr Serv</MedlineTA><NlmUniqueID>9502838</NlmUniqueID><ISSNLinking>1075-2730</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>2BMD2GNA4V</RegistryNumber><NameOfSubstance UI="D016651">Lithium Carbonate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007400" MajorTopicYN="Y">Interprofessional Relations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016651" MajorTopicYN="N">Lithium Carbonate</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010348" MajorTopicYN="Y">Patient Care Team</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010817" MajorTopicYN="N">Physician-Patient Relations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011613" MajorTopicYN="Y">Psychotherapy</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1995</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1995</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1995</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7583474</ArticleId><ArticleId IdType="doi">10.1176/ps.46.8.764</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">3414856</PMID><DateCompleted><Year>1988</Year><Month>09</Month><Day>29</Day></DateCompleted><DateRevised><Year>2004</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>145</Volume><Issue>9</Issue><PubDate><Year>1988</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>A new and timely delusion: the complaint of having AIDS.</ArticleTitle><Pagination><MedlinePgn>1130-2</MedlinePgn></Pagination><Abstract><AbstractText>Delusions presented by patients with psychiatric disorders are often a combination of psychopathology and current events. The authors present three cases that document the delusion of having acquired immune deficiency syndrome (AIDS) in patients who were not members of high-risk groups but had psychiatric disorders. This clinical phenomenon raises psychodynamic issues as well as adds a new dimension to the controversy over AIDS testing.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mahorney</LastName><ForeName>S L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Psychiatry Service, VA Medical Center, Durham, NC 27705.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cavenar</LastName><ForeName>J O</ForeName><Initials>JO</Initials><Suffix>Jr</Suffix></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><CitationSubset>X</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000163" MajorTopicYN="Y">Acquired Immunodeficiency Syndrome</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1988</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>3</Month><Day>28</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1988</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3414856</ArticleId><ArticleId IdType="doi">10.1176/ajp.145.9.1130</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8723047</PMID><DateCompleted><Year>1996</Year><Month>10</Month><Day>24</Day></DateCompleted><DateRevised><Year>2016</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0148-7299</ISSN><JournalIssue CitedMedium="Print"><Volume>67</Volume><Issue>2</Issue><PubDate><Year>1996</Year><Month>Apr</Month><Day>09</Day></PubDate></JournalIssue><Title>American journal of medical genetics</Title><ISOAbbreviation>Am J Med Genet</ISOAbbreviation></Journal><ArticleTitle>Familial alcoholism in manic-depressive (bipolar) disease.</ArticleTitle><Pagination><MedlinePgn>197-201</MedlinePgn></Pagination><Abstract><AbstractText>A previous analysis found a relatively high rate of alcoholism in a cohort of bipolar I subjects, and a trend for increased rates of alcoholism in relatives of subjects with both bipolar I disorder and alcoholism, compared to relatives of subjects with bipolar I disorder and no alcoholism. The sample of subjects with bipolar I disorder has been enlarged through continued follow-up, permitting new analyses to address the association and heritability of bipolar I disorder with alcoholism. Probands with bipolar I disorder were followed for 10 years as part of the NIMH Collaborative Depression Study. The rate of alcoholism in relatives of probands with both bipolar I disorder and alcoholism was compared to the rate of alcoholism in relatives of probands with bipolar disorder and no alcoholism. The prevalence of alcoholism in relatives of subjects with bipolar I disorder was compared to the rate of alcoholism in relatives of control subjects. Relatives of probands with bipolar I disorder showed a higher rate of alcoholism than relatives of controls. Relatives of probands with bipolar I disorder and alcoholism showed a higher rate of alcoholism than relatives of probands with bipolar I disorder without alcoholism. These data suggest that familial alcoholism may contribute to a vulnerability to bipolar I disorder, and that there is a shared heritability for the two disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Winokur</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>National Institute of Mental Health Collaborative Program on the Psychobiology of Depression, Clinical Studies, Washington, DC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coryell</LastName><ForeName>W</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Endicott</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Keller</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Akiskal</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Solomon</LastName><ForeName>D</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH025478</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Med Genet</MedlineTA><NlmUniqueID>7708900</NlmUniqueID><ISSNLinking>0148-7299</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000437" MajorTopicYN="N">Alcoholism</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1996</Year><Month>4</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>6</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1996</Year><Month>4</Month><Day>9</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8723047</ArticleId><ArticleId IdType="pii">10.1002/(SICI)1096-8628(19960409)67:2&lt;197::AID-AJMG10&gt;3.0.CO;2-E</ArticleId><ArticleId IdType="doi">10.1002/(SICI)1096-8628(19960409)67:2&lt;197::AID-AJMG10&gt;3.0.CO;2-E</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">9220125</PMID><DateCompleted><Year>1997</Year><Month>09</Month><Day>05</Day></DateCompleted><DateRevised><Year>2007</Year><Month>08</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0706-7437</ISSN><JournalIssue CitedMedium="Print"><Volume>42 Suppl 1</Volume><PubDate><Year>1997</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Canadian journal of psychiatry. Revue canadienne de psychiatrie</Title><ISOAbbreviation>Can J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Pharmacotherapy of affective disorders in old age.</ArticleTitle><Pagination><MedlinePgn>10S-18S</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To present a clinical guide for the selection of safe and effective pharmacological treatment for depressed geriatric patients.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">A review of the use of antidepressants in the elderly is presented based on clinical experience and a search of MEDLINE and PsychInfo data bases. Emphasis is placed on the following newer antidepressants: fluvoxamine, sertraline, paroxetine, nefazodone, venlafaxine, and moclobemide.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">With the advent of newer antidepressants, physicians have been given a wider range of generally safer antidepressant medications. Although these medications appear to have favourable side effect profile in elderly patients, this review is limited because there are few published studies of the use of these newer antidepressants in the elderly.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Depression is a common psychiatric problem in old age, but it can usually be treated successfully. Although the use of antidepressants in geriatric populations is more likely to be complicated by poorly tolerated side effects and drug interactions than in younger patients, this review should help clinicians use currently available medications to the best advantage of their geriatric patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tourigny-Rivard</LastName><ForeName>M F</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Ottawa, Ontario.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Can J Psychiatry</MedlineTA><NlmUniqueID>7904187</NlmUniqueID><ISSNLinking>0706-7437</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018687">Antidepressive Agents, Second-Generation</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018687" MajorTopicYN="N">Antidepressive Agents, Second-Generation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>107</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1997</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1997</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1997</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9220125</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12680904</PMID><DateCompleted><Year>2003</Year><Month>08</Month><Day>20</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1398-5647</ISSN><JournalIssue CitedMedium="Print"><Volume>5</Volume><Issue>2</Issue><PubDate><Year>2003</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Impaired heart rate variability in euthymic bipolar patients.</ArticleTitle><Pagination><MedlinePgn>138-43</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Power spectral analysis of heart rate variability (HRV) has recently been shown to be a reliable non-invasive test for quantitative assessment of the central sympathovagal interaction that modulates cardiovascular autonomic function.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We studied 39 euthymic bipolar patients and 39 controls, matched for age and sex. A high-resolution electrocardiogram was obtained during complete rest. Spectral analysis of R-R intervals was performed by the fast Fourier transform algorithm.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Euthymic bipolar patients at rest are characterized by markedly low HRV, independent of specific drug treatments.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">While these results of autonomic stability in euthymic bipolar patients are counter-intuitive, the findings may be important in understanding pathophysiology of bipolar affective illness.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Hagit</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Ministry of Health Mental Health Center, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer-Sheva, Israel. hagitc@bgumail.bgu.ac.il</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaplan</LastName><ForeName>Zeev</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Kotler</LastName><ForeName>Moshe</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Mittelman</LastName><ForeName>Irena</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Osher</LastName><ForeName>Yamima</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Bersudsky</LastName><ForeName>Yuly</ForeName><Initials>Y</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004562" MajorTopicYN="N">Electrocardiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005583" MajorTopicYN="N">Fourier Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006339" MajorTopicYN="N">Heart Rate</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008133" MajorTopicYN="N">Long QT Syndrome</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>4</Month><Day>12</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>8</Month><Day>21</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>4</Month><Day>12</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12680904</ArticleId><ArticleId IdType="pii">027</ArticleId><ArticleId IdType="doi">10.1034/j.1399-5618.2003.00027.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18452449</PMID><DateCompleted><Year>2008</Year><Month>08</Month><Day>07</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>4</Issue><PubDate><Year>2008</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Comorbid anxiety in bipolar disorder: does it have an independent effect on suicidality?</ArticleTitle><Pagination><MedlinePgn>530-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1399-5618.2008.00590.x</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Comorbid anxiety disorder is reported to increase suicidality in bipolar disorder. However, studies of the impact of anxiety disorders on suicidal behavior in mood disorders have shown mixed results. The presence of personality disorders, often comorbid with anxiety and bipolar disorders, may explain these inconsistencies. This study examined the impact of comorbid Cluster B personality disorder and anxiety disorder on suicidality in bipolar disorder.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A total of 116 depressed bipolar patients with and without lifetime anxiety disorder were compared. Multiple regression analysis tested the association of comorbid anxiety disorder with past suicide attempts and severity of suicidal ideation, adjusting for the effect of Cluster B personality disorder. The specific effect of panic disorder was also explored.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Bipolar patients with and without anxiety disorders did not differ in the rate of past suicide attempt. Suicidal ideation was less severe in those with anxiety disorders. In multiple regression analysis, anxiety disorder was not associated with past suicide attempts or with the severity of suicidal ideation, whereas Cluster B personality disorder was associated with both. The results were comparable when comorbid panic disorder was examined.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Comorbid Cluster B personality disorder appears to exert a stronger influence on suicidality than comorbid anxiety disorder in persons with bipolar disorder. Assessment of suicide risk in patients with bipolar disorder should include evaluation and treatment of Cluster B psychopathology.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nakagawa</LastName><ForeName>Atsuo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neuropsychiatry, School of Medicine, Keio University, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grunebaum</LastName><ForeName>Michael F</ForeName><Initials>MF</Initials></Author><Author ValidYN="Y"><LastName>Sullivan</LastName><ForeName>Gregory M</ForeName><Initials>GM</Initials></Author><Author ValidYN="Y"><LastName>Currier</LastName><ForeName>Dianne</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Ellis</LastName><ForeName>Steven P</ForeName><Initials>SP</Initials></Author><Author ValidYN="Y"><LastName>Burke</LastName><ForeName>Ainsley K</ForeName><Initials>AK</Initials></Author><Author ValidYN="Y"><LastName>Brent</LastName><ForeName>David A</ForeName><Initials>DA</Initials></Author><Author ValidYN="Y"><LastName>Mann</LastName><ForeName>J John</ForeName><Initials>JJ</Initials></Author><Author ValidYN="Y"><LastName>Oquendo</LastName><ForeName>Maria A</ForeName><Initials>MA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23 MH076049-01</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH056612-10</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH059710</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R10 MH056612-05</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 MH062185-06</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R10 MH056612-01A1</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R10 MH056612-04</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH056612-07</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R10 MH056612-03</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH-48514</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH048514-08</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH-59710</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH059710-01A2</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 MH062185</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH056612-09</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH056612</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH056612-06</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 MH076049</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R10 MH056612</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH048514</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH-56612</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH-62185</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH056612-08</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001007" MajorTopicYN="N">Anxiety</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010555" MajorTopicYN="N">Personality Inventory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012044" MajorTopicYN="N">Regression Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013405" MajorTopicYN="N">Suicide</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>5</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>8</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>5</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18452449</ArticleId><ArticleId IdType="pii">BDI590</ArticleId><ArticleId IdType="doi">10.1111/j.1399-5618.2008.00590.x</ArticleId><ArticleId IdType="pmc">PMC2746654</ArticleId><ArticleId IdType="mid">NIHMS101365</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Affect Disord. 2003 Jul;75(2):181-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12798258</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 1979 Oct;1(2):131-9</Citation><ArticleIdList><ArticleId IdType="pubmed">95232</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Clin North Am. 2001 Mar;24(1):19-39</Citation><ArticleIdList><ArticleId IdType="pubmed">11225507</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2006 Oct;8(5 Pt 2):576-85</Citation><ArticleIdList><ArticleId IdType="pubmed">17042831</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 2003 Sep;191(9):582-8</Citation><ArticleIdList><ArticleId IdType="pubmed">14504567</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1995 Feb;152(2):232-8</Citation><ArticleIdList><ArticleId IdType="pubmed">7840357</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 1998 Mar-Apr;39(2):72-4</Citation><ArticleIdList><ArticleId IdType="pubmed">9515191</ArticleId></ArticleIdList></Reference><Reference><Citation>J Consult Clin Psychol. 1974 Dec;42(6):861-5</Citation><ArticleIdList><ArticleId IdType="pubmed">4436473</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2004 Aug;65(8):1106-13</Citation><ArticleIdList><ArticleId IdType="pubmed">15323597</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2006 Jul;189:20-5</Citation><ArticleIdList><ArticleId IdType="pubmed">16816301</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 2005 Jul;193(7):450-4</Citation><ArticleIdList><ArticleId IdType="pubmed">15985839</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2003 May;64(5):506-15</Citation><ArticleIdList><ArticleId IdType="pubmed">12755652</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2000 Oct;157(10):1614-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11007715</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1992 May;149(5):680-5</Citation><ArticleIdList><ArticleId IdType="pubmed">1575260</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2005 Jun;62(6):617-27</Citation><ArticleIdList><ArticleId IdType="pubmed">15939839</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosp Community Psychiatry. 1991 Oct;42(10):1015-21</Citation><ArticleIdList><ArticleId IdType="pubmed">1959892</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2004 Dec;161(12):2222-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15569893</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2001 Nov-Dec;35(6):307-12</Citation><ArticleIdList><ArticleId IdType="pubmed">11684137</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pers Disord. 2003 Feb;17(1):60-72</Citation><ArticleIdList><ArticleId IdType="pubmed">12659547</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pers Disord. 2006 Jun;20(3):247-60</Citation><ArticleIdList><ArticleId IdType="pubmed">16776554</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2006 Oct;8(5 Pt 2):566-75</Citation><ArticleIdList><ArticleId IdType="pubmed">17042830</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2005 Jul;87(1):17-23</Citation><ArticleIdList><ArticleId IdType="pubmed">15967232</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2003 Mar;64(3):331-5</Citation><ArticleIdList><ArticleId IdType="pubmed">12716276</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Rep. 1965 Apr;16:547-54</Citation><ArticleIdList><ArticleId IdType="pubmed">14285869</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychopharmacol. 1996 Apr;16(2 Suppl 1):4S-14S</Citation><ArticleIdList><ArticleId IdType="pubmed">8707999</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2005 May 25;293(20):2487-95</Citation><ArticleIdList><ArticleId IdType="pubmed">15914749</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2000 Jun;176:544-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10974960</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2004 Aug;65(8):1035-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15323586</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1975 Mar;132(3):285-7</Citation><ArticleIdList><ArticleId IdType="pubmed">1115273</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62</Citation><ArticleIdList><ArticleId IdType="pubmed">14399272</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Child Adolesc Psychiatry. 1998 Dec;7(4):201-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9879842</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1993 Sep;29(1):49-52</Citation><ArticleIdList><ArticleId IdType="pubmed">8254143</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2007 Apr-Jun;41(3-4):255-64</Citation><ArticleIdList><ArticleId IdType="pubmed">17052730</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2004 Apr;6(2):130-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15005751</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1999 Feb;156(2):181-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9989552</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2005 Jun;66(6):693-704</Citation><ArticleIdList><ArticleId IdType="pubmed">15960561</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1991 Aug;48(8):720-8</Citation><ArticleIdList><ArticleId IdType="pubmed">1883255</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 2004 Nov;113(4):582-91</Citation><ArticleIdList><ArticleId IdType="pubmed">15535790</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pers Disord. 2003 Dec;17(6):568-73</Citation><ArticleIdList><ArticleId IdType="pubmed">14744082</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1995 Jul;167(1):76-9</Citation><ArticleIdList><ArticleId IdType="pubmed">7551614</ArticleId></ArticleIdList></Reference><Reference><Citation>J Anxiety Disord. 2006;20(4):408-26</Citation><ArticleIdList><ArticleId IdType="pubmed">16054332</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1999 Jul;56(7):617-26</Citation><ArticleIdList><ArticleId IdType="pubmed">10401507</ArticleId></ArticleIdList></Reference><Reference><Citation>J Consult Clin Psychol. 1979 Apr;47(2):343-52</Citation><ArticleIdList><ArticleId IdType="pubmed">469082</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1993 Feb;50(2):144-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8427555</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2005 Jul;87(1):73-82</Citation><ArticleIdList><ArticleId IdType="pubmed">15923041</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2000 Mar;176:229-35</Citation><ArticleIdList><ArticleId IdType="pubmed">10755069</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2005 Mar;66(3):339-45</Citation><ArticleIdList><ArticleId IdType="pubmed">15766300</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2005 Jul;87(1):11-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15944138</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1990 Sep;147(9):1189-94</Citation><ArticleIdList><ArticleId IdType="pubmed">2104515</ArticleId></ArticleIdList></Reference><Reference><Citation>Suicide Life Threat Behav. 2004 Summer;34(2):172-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15191273</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1996 Feb;53(2):159-68</Citation><ArticleIdList><ArticleId IdType="pubmed">8629891</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1990 Sep;47(9):805-8</Citation><ArticleIdList><ArticleId IdType="pubmed">2393338</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1989 Nov 2;321(18):1209-14</Citation><ArticleIdList><ArticleId IdType="pubmed">2797086</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2001 Mar;158(3):420-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11229983</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2005 Mar;162(3):560-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15741474</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1998 Dec;155(12):1733-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9842784</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1996 May 15;39(10):896-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8860192</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1994 Mar;164(3):349-54</Citation><ArticleIdList><ArticleId IdType="pubmed">8199788</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1999 Mar;156(3):474-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10080568</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">24752620</PMID><DateCompleted><Year>2015</Year><Month>10</Month><Day>06</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1708-0428</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>11</Issue><PubDate><Year>2014</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Obesity surgery</Title><ISOAbbreviation>Obes Surg</ISOAbbreviation></Journal><ArticleTitle>Bipolar disorder symptoms in patients seeking bariatric surgery.</ArticleTitle><Pagination><MedlinePgn>1909-14</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11695-014-1262-6</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Mood disorders are common among patients seeking bariatric surgery although little data exist regarding the prevalence of bipolar symptoms in this population and how they influence surgical outcomes. Our aim was to describe baseline rates of bipolar symptoms and their relationship to psychological factors and completing surgery in a sample of adults seeking bariatric surgery at an academic medical center.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We retrospectively reviewed the relationship of bipolar symptoms to demographic characteristics, baseline weight, psychological factors, and bariatric surgery completion.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Nine hundred thirty-five patients completed the preoperative psychological evaluation. Six percent of the preoperative sample screened positive for symptoms of bipolar disorder. Patients with bipolar symptoms endorsed more robust psychopathology, trauma history, and problematic eating behaviors than patients without bipolar symptoms. Twenty-two percent of the patients with bipolar symptoms underwent bariatric surgery (n = 12), yet only 13 % were denied bariatric surgery for psychiatric reasons, suggesting that other variables may influence the completion of bariatric surgery for these patients.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Prevalence rates of bipolar symptoms may be greater in patients seeking bariatric surgery compared with the general population, and few patients with bipolar symptoms actually undergo bariatric surgery. Psychological factors differentiate patients with bipolar symptoms who undergo bariatric surgery vs those who do not.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Grothe</LastName><ForeName>Karen B</ForeName><Initials>KB</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychology, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA, grothe.karen@mayo.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mundi</LastName><ForeName>Manpreet S</ForeName><Initials>MS</Initials></Author><Author ValidYN="Y"><LastName>Himes</LastName><ForeName>Susan M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Sarr</LastName><ForeName>Michael G</ForeName><Initials>MG</Initials></Author><Author ValidYN="Y"><LastName>Clark</LastName><ForeName>Matthew M</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Geske</LastName><ForeName>Jennifer R</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Kalsy</LastName><ForeName>Sarah A</ForeName><Initials>SA</Initials></Author><Author ValidYN="Y"><LastName>Frye</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Obes Surg</MedlineTA><NlmUniqueID>9106714</NlmUniqueID><ISSNLinking>0960-8923</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050110" MajorTopicYN="N">Bariatric Surgery</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005247" MajorTopicYN="N">Feeding Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008910" MajorTopicYN="N">Minnesota</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009767" MajorTopicYN="N">Obesity, Morbid</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>10</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24752620</ArticleId><ArticleId IdType="doi">10.1007/s11695-014-1262-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bipolar Disord. 2011 Jun;13(4):387-95</Citation><ArticleIdList><ArticleId IdType="pubmed">21843278</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2008 Feb;69(2):295-301</Citation><ArticleIdList><ArticleId IdType="pubmed">18251626</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2003 Jan;160(1):178-80</Citation><ArticleIdList><ArticleId IdType="pubmed">12505821</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2000 Nov;157(11):1873-5</Citation><ArticleIdList><ArticleId IdType="pubmed">11058490</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 2011 Nov-Dec;52(6):600-6</Citation><ArticleIdList><ArticleId IdType="pubmed">21406301</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2005 Jun;86(2-3):107-27</Citation><ArticleIdList><ArticleId IdType="pubmed">15935230</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2011 Feb;128(3):191-8</Citation><ArticleIdList><ArticleId IdType="pubmed">20674033</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1994 Aug;151(8):1132-6</Citation><ArticleIdList><ArticleId IdType="pubmed">8037246</ArticleId></ArticleIdList></Reference><Reference><Citation>Obes Surg. 2007 Dec;17(12):1578-83</Citation><ArticleIdList><ArticleId IdType="pubmed">18000719</ArticleId></ArticleIdList></Reference><Reference><Citation>Adv Ther. 2011 May;28(5):389-400</Citation><ArticleIdList><ArticleId IdType="pubmed">21479752</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2013 Nov;15(7):753-63</Citation><ArticleIdList><ArticleId IdType="pubmed">23909994</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2007 Feb;164(2):328-34; quiz 374</Citation><ArticleIdList><ArticleId IdType="pubmed">17267797</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Intern Med. 2006 May 22;166(10):1092-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16717171</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Psychiatry Med. 2011;41(2):155-71</Citation><ArticleIdList><ArticleId IdType="pubmed">21675347</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2012 Sep 19;308(11):1122-31</Citation><ArticleIdList><ArticleId IdType="pubmed">22990271</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Psychiatry. 2007 Jul;20(4):406-16</Citation><ArticleIdList><ArticleId IdType="pubmed">17551358</ArticleId></ArticleIdList></Reference><Reference><Citation>Gen Hosp Psychiatry. 2009 Sep-Oct;31(5):414-21</Citation><ArticleIdList><ArticleId IdType="pubmed">19703634</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Psychiatry Rep. 2012 Dec;14(6):650-8</Citation><ArticleIdList><ArticleId IdType="pubmed">22903246</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Eat Disord. 2006 Mar;39(2):141-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16231349</ArticleId></ArticleIdList></Reference><Reference><Citation>Appetite. 2009 Jun;52(3):637-645</Citation><ArticleIdList><ArticleId IdType="pubmed">19501761</ArticleId></ArticleIdList></Reference><Reference><Citation>J Consult Clin Psychol. 1991 Oct;59(5):739-44</Citation><ArticleIdList><ArticleId IdType="pubmed">1955608</ArticleId></ArticleIdList></Reference><Reference><Citation>Obes Surg. 2011 Sep;21(9):1323-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21380795</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2007 Aug;101(1-3):131-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17229468</ArticleId></ArticleIdList></Reference><Reference><Citation>Obesity (Silver Spring). 2008 Apr;16(4):763-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18379561</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 2004 Jan;55(1):54-8</Citation><ArticleIdList><ArticleId IdType="pubmed">14699201</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2003 Jan;73(1-2):123-31</Citation><ArticleIdList><ArticleId IdType="pubmed">12507745</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2009 Sep;11(6):650-6</Citation><ArticleIdList><ArticleId IdType="pubmed">19689507</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1994 Jan;51(1):8-19</Citation><ArticleIdList><ArticleId IdType="pubmed">8279933</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2012 Jun 20;307(23):2516-25</Citation><ArticleIdList><ArticleId IdType="pubmed">22710289</ArticleId></ArticleIdList></Reference><Reference><Citation>World Psychiatry. 2011 Oct;10(3):181-6</Citation><ArticleIdList><ArticleId IdType="pubmed">21991268</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2002 Mar;63(3):207-13</Citation><ArticleIdList><ArticleId IdType="pubmed">11926719</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2003 Jan;73(1-2):133-46</Citation><ArticleIdList><ArticleId IdType="pubmed">12507746</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2004 Oct 13;292(14):1724-37</Citation><ArticleIdList><ArticleId IdType="pubmed">15479938</ArticleId></ArticleIdList></Reference><Reference><Citation>Surg Obes Relat Dis. 2010 Mar 4;6(2):191-6</Citation><ArticleIdList><ArticleId IdType="pubmed">20189470</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2011 Jan 6;364(1):51-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21208108</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychosom Med. 2005 Sep-Oct;67(5):825-32</Citation><ArticleIdList><ArticleId IdType="pubmed">16204445</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12014266</PMID><DateCompleted><Year>2002</Year><Month>07</Month><Day>08</Day></DateCompleted><DateRevised><Year>2015</Year><Month>08</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0370-629X</ISSN><JournalIssue CitedMedium="Print"><Volume>57</Volume><Issue>3</Issue><PubDate><Year>2002</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Revue medicale de Liege</Title><ISOAbbreviation>Rev Med Liege</ISOAbbreviation></Journal><ArticleTitle>[Influence of heredity, sex and season on the type of episode of bipolar disorder].</ArticleTitle><Pagination><MedlinePgn>171-5</MedlinePgn></Pagination><Abstract><AbstractText>The aim of this work was to investigate if sex, age, family history, season and hypothyroidism have any influence on the type of episodes (manic, depressive, mixed) seen in bipolar patients. This retrospective study concerns a sample of 208 patients with a diagnosis of bipolar disorder (type I or II), who were admitted in one of two psychiatric centers between July 1996 and June 2000. The sex-ratio was 2.8 females for 1 male. Sex, family history and hypothyroidism were not associated with any type of episode. A higher percentage of depressive episodes was observed in the patients who were older than 50 and the average age of depressive patients was higher than that of other patients. There was no seasonal pattern in this study and the season did not influence the type of episode. The results indicate no influence of sex, season, family history and hypothyroidism on the type of episode presented. On the opposite, age seems to favour depression episode.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mortazi</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Université de Liège.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bertrand</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Triffaux</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Troisfontaines</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Kempeneers</LastName><ForeName>J L</ForeName><Initials>JL</Initials></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Influence de l'hérédité, du sexe et de la saison sur le type d'épisode dans le trouble bipolaire.</VernacularTitle></Article><MedlineJournalInfo><Country>Belgium</Country><MedlineTA>Rev Med Liege</MedlineTA><NlmUniqueID>0404317</NlmUniqueID><ISSNLinking>0370-629X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005192" MajorTopicYN="N">Family Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007037" MajorTopicYN="N">Hypothyroidism</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012621" MajorTopicYN="N">Seasons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>5</Month><Day>17</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>7</Month><Day>9</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>5</Month><Day>17</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12014266</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25778474</PMID><DateCompleted><Year>2016</Year><Month>10</Month><Day>19</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5578</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>2</Issue><PubDate><Year>2016</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Molecular psychiatry</Title><ISOAbbreviation>Mol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Multi-state outcome analysis of treatments (MOAT): application of a new approach to evaluate outcomes in longitudinal studies of bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>237-42</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/mp.2015.21</ELocationID><Abstract><AbstractText>Survival analyzes are usually based on a single point in time predefined event. Dissatisfied with this approach to evaluating maintenance treatment outcomes, we developed the Multi-state Outcome Analysis of Treatments (MOAT) methodology using a combined database from two FDA registration studies of lamotrigine, lithium and placebo. MOAT partitions total survival time into clinically distinct periods operationally defined by cutpoints on rating scales. For bipolar disorder (BD), the clinical states are remission, subsyndromal and syndromal mania, mixed states or depression. MOAT results can be crossed with information about tolerability and functioning to yield an outcome system integrating efficacy and tolerability. As found in the original analysis, both drugs were associated with longer time in study compared with the placebo. MOAT supplements this by finding that both drugs increased the time remitted compared with placebo. However, a substantial amount of time in all three treatments was spent in subsyndromal depression. Time with manic symptoms was reduced with lithium, but not lamotrigine. Patients on placebo neither benefitted nor had adverse effects from the assignment but experienced more syndromal levels of symptoms and were terminated from the study sooner than either drug treated group. Lithium was associated with both benefit in time manic and worse tolerability compared with placebo. In summary, lamotrigine was associated with limited therapeutic benefit but not harm; lithium with both benefit and harm; and placebo with neither. MOAT describes not only quantity but also quality of time spent in longitudinal studies, providing a more clinically informative picture than Kaplan-Meier survival analysis. </AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bowden</LastName><ForeName>C L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Division of Mood and Anxiety Disorders, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mintz</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Division of Mood and Anxiety Disorders, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tohen</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of New Mexico Health Sciences Center, Albuquerque, NM, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 MH086045</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC1 MH088431</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC1MH088431</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>03</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Psychiatry</MedlineTA><NlmUniqueID>9607835</NlmUniqueID><ISSNLinking>1359-4184</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014227">Triazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical><Chemical><RegistryNumber>U3H27498KS</RegistryNumber><NameOfSubstance UI="D000077213">Lamotrigine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077213" MajorTopicYN="N">Lamotrigine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014227" MajorTopicYN="N">Triazines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>04</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>12</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>12</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>3</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>3</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>11</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25778474</ArticleId><ArticleId IdType="pii">mp201521</ArticleId><ArticleId IdType="doi">10.1038/mp.2015.21</ArticleId><ArticleId IdType="pmc">PMC4573671</ArticleId><ArticleId IdType="mid">NIHMS650920</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nat Genet. 2008 Sep;40(9):1056-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18711365</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Methods Psychiatr Res. 2008;17(4):198-209</Citation><ArticleIdList><ArticleId IdType="pubmed">18792087</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2009 Aug;11(5):453-73</Citation><ArticleIdList><ArticleId IdType="pubmed">19624385</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Trials. 2009 Dec;6(6):637-48</Citation><ArticleIdList><ArticleId IdType="pubmed">19933719</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2010 Feb 28;175(3):221-6</Citation><ArticleIdList><ArticleId IdType="pubmed">20022384</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2011 May;13(3):250-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21676128</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Ther. 2011 Dec;33(12):B40-8</Citation><ArticleIdList><ArticleId IdType="pubmed">22177379</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2013 Feb;127(2):145-52</Citation><ArticleIdList><ArticleId IdType="pubmed">22774941</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2002 Jun;59(6):530-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12044195</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2003 Apr;60(4):392-400</Citation><ArticleIdList><ArticleId IdType="pubmed">12695317</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2003 Sep;64(9):1013-24</Citation><ArticleIdList><ArticleId IdType="pubmed">14628976</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2004 Apr;6(2):115-21</Citation><ArticleIdList><ArticleId IdType="pubmed">15005749</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1990 Dec;47(12):1106-11</Citation><ArticleIdList><ArticleId IdType="pubmed">2244795</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1978 Jul;35(7):837-44</Citation><ArticleIdList><ArticleId IdType="pubmed">678037</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2004 Mar;65(3):432-41</Citation><ArticleIdList><ArticleId IdType="pubmed">15096085</ArticleId></ArticleIdList></Reference><Reference><Citation>Stat Med. 1990 Nov;9(11):1259-76</Citation><ArticleIdList><ArticleId IdType="pubmed">2277877</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62</Citation><ArticleIdList><ArticleId IdType="pubmed">14399272</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2008 Jun;13(6):558-69</Citation><ArticleIdList><ArticleId IdType="pubmed">18317468</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2009 Apr;166(4):476-88</Citation><ArticleIdList><ArticleId IdType="pubmed">19289454</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29581538</PMID><DateCompleted><Year>2019</Year><Month>02</Month><Day>14</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1740-634X</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>8</Issue><PubDate><Year>2018</Year><Month>07</Month></PubDate></JournalIssue><Title>Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology</Title><ISOAbbreviation>Neuropsychopharmacology</ISOAbbreviation></Journal><ArticleTitle>Brain lactate and pH in schizophrenia and bipolar disorder: a systematic review of findings from magnetic resonance studies.</ArticleTitle><Pagination><MedlinePgn>1681-1690</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41386-018-0041-9</ELocationID><Abstract><AbstractText>Converging evidence from molecular to neuroimaging studies suggests brain energy metabolism abnormalities in both schizophrenia and bipolar disorder. One emerging hypothesis is: decreased oxidative phosphorylation leading to accumulation of lactic acid from glycolysis and subsequent acidification of tissue. In this regard, integrating lactate and pH data from magnetic resonance spectroscopy (MRS) studies in both diseases may help us understand underlying neurobiological mechanisms. In order to achieve this goal, we performed a systematic search of case-control studies examining brain lactate or pH among schizophrenia and/or bipolar patients by using MRS. Medline/Pubmed and EBSCO databases were searched separately for both diseases and outcomes. Our search yielded 33 studies in total composed of 7 lactate and 26 pH studies. In bipolar disorder, 5 out of 6 studies have found elevated lactate levels especially in the cingulate cortex and 4 out of 13 studies reported reduced pH in the frontal lobe. In contrast, in schizophrenia a single study has examined lactate and reported elevation, while only 2 out of 13 studies examining pH have reported reduction in this measure. There were no consistent patterns for the relationship between lactate or pH levels and medication use, disease type, mood state, and other clinical variables. We highlight the need for future studies combining <sup>1</sup>H-MRS and <sup>31</sup>P-MRS approaches, using longitudinal designs to examine lactate and pH in disease progression across both schizophrenia and bipolar disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dogan</LastName><ForeName>Asli Ercan</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>McLean Hospital, 115 Mill Street, Belmont, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuksel</LastName><ForeName>Cagri</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>McLean Hospital, 115 Mill Street, Belmont, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, 25 Shattuck Street, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Du</LastName><ForeName>Fei</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>McLean Hospital, 115 Mill Street, Belmont, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, 25 Shattuck Street, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chouinard</LastName><ForeName>Virginie-Anne</ForeName><Initials>VA</Initials><AffiliationInfo><Affiliation>McLean Hospital, 115 Mill Street, Belmont, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, 25 Shattuck Street, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Öngür</LastName><ForeName>Dost</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>McLean Hospital, 115 Mill Street, Belmont, MA, USA. dongur@partners.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, 25 Shattuck Street, Boston, MA, USA. dongur@partners.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K24 MH104449</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 MH114020</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 MH016259</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>03</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Neuropsychopharmacology</MedlineTA><NlmUniqueID>8904907</NlmUniqueID><ISSNLinking>0893-133X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>33X04XA5AT</RegistryNumber><NameOfSubstance UI="D019344">Lactic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006863" MajorTopicYN="N">Hydrogen-Ion Concentration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019344" MajorTopicYN="N">Lactic Acid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>09</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>02</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>02</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29581538</ArticleId><ArticleId IdType="doi">10.1038/s41386-018-0041-9</ArticleId><ArticleId IdType="pii">10.1038/s41386-018-0041-9</ArticleId><ArticleId IdType="pmc">PMC6006165</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Eur J Neurosci. 2004 Aug;20(3):749-56</Citation><ArticleIdList><ArticleId IdType="pubmed">15255985</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2004 May;61(5):450-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15123489</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Arch Psychiatry Clin Neurosci. 1998;248(6):301-6</Citation><ArticleIdList><ArticleId IdType="pubmed">9928909</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1995 Jun;152(6):915-8</Citation><ArticleIdList><ArticleId IdType="pubmed">7755123</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1998 Sep 15;44(6):399-404</Citation><ArticleIdList><ArticleId IdType="pubmed">9777168</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 1995 Sep 29;61(3):151-60</Citation><ArticleIdList><ArticleId IdType="pubmed">8545499</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2007 Aug 15;31(6):1182-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17532107</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2007 Oct;164(10):1557-60</Citation><ArticleIdList><ArticleId IdType="pubmed">17898347</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2016 Aug 12;19(8):</Citation><ArticleIdList><ArticleId IdType="pubmed">27207914</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Clin Psychopharmacol. 2008 Jun;16(3):199-206</Citation><ArticleIdList><ArticleId IdType="pubmed">18540779</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Psychiatry. 2014 Jan;71(1):19-27</Citation><ArticleIdList><ArticleId IdType="pubmed">24196348</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Clin Neurosci. 2004 Feb;58(1):82-8</Citation><ArticleIdList><ArticleId IdType="pubmed">14678462</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1991 Jun;48(6):578</Citation><ArticleIdList><ArticleId IdType="pubmed">1898225</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 1992 Dec;86(6):455-62</Citation><ArticleIdList><ArticleId IdType="pubmed">1471539</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychopharmacol. 2017 Feb;37(1):40-45</Citation><ArticleIdList><ArticleId IdType="pubmed">27902528</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2013 Sep 30;213(3):230-4</Citation><ArticleIdList><ArticleId IdType="pubmed">23810640</ArticleId></ArticleIdList></Reference><Reference><Citation>Transl Psychiatry. 2012 Sep 11;2:e160</Citation><ArticleIdList><ArticleId IdType="pubmed">22968227</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1995 Mar 14;33(3):195-9</Citation><ArticleIdList><ArticleId IdType="pubmed">7790672</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 1994 Dec;55(4):223-35</Citation><ArticleIdList><ArticleId IdType="pubmed">7701036</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1991 Jun;48(6):563-8</Citation><ArticleIdList><ArticleId IdType="pubmed">1898445</ArticleId></ArticleIdList></Reference><Reference><Citation>Transl Psychiatry. 2016 Nov 29;6(11):e967</Citation><ArticleIdList><ArticleId IdType="pubmed">27898072</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2003 Feb;160(2):284-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12562574</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2012 May 22;109 (21):8270-3</Citation><ArticleIdList><ArticleId IdType="pubmed">22566645</ArticleId></ArticleIdList></Reference><Reference><Citation>Depress Anxiety. 2001;14(4):251-4</Citation><ArticleIdList><ArticleId IdType="pubmed">11754135</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 1994 Mar;55(1):41-50</Citation><ArticleIdList><ArticleId IdType="pubmed">8047628</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2004 Sep 1;56(5):340-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15336516</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1992 Jul 1;32(1):26-32</Citation><ArticleIdList><ArticleId IdType="pubmed">1391294</ArticleId></ArticleIdList></Reference><Reference><Citation>Metab Brain Dis. 2015 Feb;30(1):25-30</Citation><ArticleIdList><ArticleId IdType="pubmed">25034458</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Rev Neurobiol. 2005;63:21-40</Citation><ArticleIdList><ArticleId IdType="pubmed">15797464</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1988 Jun 3;240(4857):1326-8</Citation><ArticleIdList><ArticleId IdType="pubmed">3375817</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2015 Nov;17(7):743-52</Citation><ArticleIdList><ArticleId IdType="pubmed">26477793</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2000 Feb;157(2):220-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10671390</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 1997 Dec 30;76(2-3):123-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9522404</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2017 Sep;187:11-16</Citation><ArticleIdList><ArticleId IdType="pubmed">28258794</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2002 Jun 15;114(2):113-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12036511</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1994 Jun;31(2):125-33</Citation><ArticleIdList><ArticleId IdType="pubmed">8071475</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cereb Blood Flow Metab. 2012 Jul;32(7):1107-38</Citation><ArticleIdList><ArticleId IdType="pubmed">22186669</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Radiol. 2014 Feb;83(2):e106-12</Citation><ArticleIdList><ArticleId IdType="pubmed">24331847</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2015 Sep;20(9):1079-84</Citation><ArticleIdList><ArticleId IdType="pubmed">25754079</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Physiol. 2014 Feb 13;5:43</Citation><ArticleIdList><ArticleId IdType="pubmed">24592239</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1997 Mar 15;41(6):644-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9066987</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1994 Oct 15;36(8):503-10</Citation><ArticleIdList><ArticleId IdType="pubmed">7827212</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2013 Sep 30;213(3):235-41</Citation><ArticleIdList><ArticleId IdType="pubmed">23810639</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2007 Mar;164(3):428-36</Citation><ArticleIdList><ArticleId IdType="pubmed">17329467</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2018 Feb;43(3):459-468</Citation><ArticleIdList><ArticleId IdType="pubmed">28776581</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1993 Jan;27(1):53-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8432961</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1991 Jun 1;29(11):1149-52</Citation><ArticleIdList><ArticleId IdType="pubmed">1873375</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2001 May 30;106(3):181-91</Citation><ArticleIdList><ArticleId IdType="pubmed">11382540</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2009 Jul;70(7):997-1000</Citation><ArticleIdList><ArticleId IdType="pubmed">19497246</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1992 Dec;26(4):223-30</Citation><ArticleIdList><ArticleId IdType="pubmed">1479134</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2000 Jan;30(1):107-15</Citation><ArticleIdList><ArticleId IdType="pubmed">10722181</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 1997 Dec 30;76(2-3):89-99</Citation><ArticleIdList><ArticleId IdType="pubmed">9522401</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2013 Jun 1;73(11):1111-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23332354</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Dev Neurosci. 2011 May;29(3):311-24</Citation><ArticleIdList><ArticleId IdType="pubmed">20833242</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1995 May;152(5):666-72</Citation><ArticleIdList><ArticleId IdType="pubmed">7726305</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22269982</PMID><DateCompleted><Year>2012</Year><Month>06</Month><Day>18</Day></DateCompleted><DateRevised><Year>2014</Year><Month>07</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1423-033X</ISSN><JournalIssue CitedMedium="Internet"><Volume>45</Volume><Issue>2</Issue><PubDate><Year>2012</Year></PubDate></JournalIssue><Title>Psychopathology</Title><ISOAbbreviation>Psychopathology</ISOAbbreviation></Journal><ArticleTitle>Syndromal and subsyndromal illness status and five-year morbidity using criteria of the International Society for Bipolar Disorders compared to alternative criteria.</ArticleTitle><Pagination><MedlinePgn>102-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1159/000329740</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Subsyndromal symptoms have been recognized as relevant in the course and outcome of bipolar disorder (BD) patients. Nevertheless, their definition and cutoff points on current depression and mania scales are uncertain. The recently defined International Society for Bipolar Disorders (ISBD) operational criteria for the assessment of the course and outcome of bipolar illness have never been tested until now.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A naturalistic longitudinal follow-up study of up to 5 years included a cohort of 317 DSM-IV-TR BD outpatients. For the first time, we assessed the proportion of visits in different affective states using the ISBD criteria. Secondarily, we compared the results with those obtained applying other cutoff points.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Patients were symptomatic in 39.1% (95% CI 35.3-42.9) of the visits. Subsyndromal symptoms, primarily subsyndromal depression, were present in 15.9% of patients (95% CI 13.4-18.4). No significant differences were found between bipolar I patients and bipolar II patients. There were differences in the total percentage of visits in euthymia depending on the cutoff points (p &lt; 0.05).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Applying ISBD criteria, bipolar patients have significant clinical morbidity and are often symptomatic, both with threshold symptoms and with subthreshold symptoms, especially with depression. The chosen cutoff points modify the apparent results.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">The cutoff points used have not been validated. Psychopharmacologic treatments were naturalistic.</AbstractText><CopyrightInformation>Copyright © 2012 S. Karger AG, Basel.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>De Dios</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>University Hospital La Paz, IDIPAZ, Madrid, Spain. cdios.scsm@salud.madrid.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agud</LastName><ForeName>J L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Ezquiaga</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>García-López</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Soler</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Vieta</LastName><ForeName>E</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>01</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Psychopathology</MedlineTA><NlmUniqueID>8401537</NlmUniqueID><ISSNLinking>0254-4962</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="Y">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>11</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>05</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>1</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>1</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>6</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22269982</ArticleId><ArticleId IdType="pii">000329740</ArticleId><ArticleId IdType="doi">10.1159/000329740</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17178644</PMID><DateCompleted><Year>2007</Year><Month>05</Month><Day>02</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1381-1118</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2007</Year></PubDate></JournalIssue><Title>Archives of suicide research : official journal of the International Academy for Suicide Research</Title><ISOAbbreviation>Arch Suicide Res</ISOAbbreviation></Journal><ArticleTitle>Cluster C personality disorders in major depressive episodes: the relationship between hostility and suicidal behavior.</ArticleTitle><Pagination><MedlinePgn>83-90</MedlinePgn></Pagination><Abstract><AbstractText>There is some evidence for an association between Cluster C Personality Disorders (CCPD) and suicidal behavior. We compared depressed inpatients with and without CCPD in terms of suicidal behavior and associated psychopathology. Cluster A or B personality disorder co-morbidity were exclusion criteria for both groups (cases and controls). Depressed inpatients with "pure" CCPD had higher levels of suicidal ideation but not more previous suicide attempts compared with patients without CCPD. Greater suicidal ideation in depressed patients with CCPD in our study was associated with more hostility. Future studies examining the relationship between suicidal ideation and hostility in CCPD may clarify whether treatment focused on hostility might be of use for decreasing suicidal ideation in depressed patients with CCPD (Spitzer, Williams, Gibbon et al., 1990).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dervic</LastName><ForeName>Kanita</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Child and Adolescent Neuropsychiatry/University Hospital, Medical University of Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grunebaum</LastName><ForeName>Michael F</ForeName><Initials>MF</Initials></Author><Author ValidYN="Y"><LastName>Burke</LastName><ForeName>Ainsley K</ForeName><Initials>AK</Initials></Author><Author ValidYN="Y"><LastName>Mann</LastName><ForeName>J John</ForeName><Initials>JJ</Initials></Author><Author ValidYN="Y"><LastName>Oquendo</LastName><ForeName>Maria A</ForeName><Initials>MA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH059710</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH59710</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Arch Suicide Res</MedlineTA><NlmUniqueID>9504451</NlmUniqueID><ISSNLinking>1381-1118</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006791" MajorTopicYN="Y">Hostility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010343" MajorTopicYN="N">Patient Admission</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010552" MajorTopicYN="N">Personality Assessment</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010554" MajorTopicYN="N">Personality Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013406" MajorTopicYN="N">Suicide, Attempted</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>12</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>5</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>12</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17178644</ArticleId><ArticleId IdType="pii">JU1722774321512H</ArticleId><ArticleId IdType="doi">10.1080/13811110600992928</ArticleId><ArticleId IdType="pmc">PMC3779124</ArticleId><ArticleId IdType="mid">NIHMS510671</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Psychiatry Res. 1979 Oct;1(2):131-9</Citation><ArticleIdList><ArticleId IdType="pubmed">95232</ArticleId></ArticleIdList></Reference><Reference><Citation>J Consult Clin Psychol. 1979 Apr;47(2):343-52</Citation><ArticleIdList><ArticleId IdType="pubmed">469082</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1994 Dec 14;272(22):1757-62</Citation><ArticleIdList><ArticleId IdType="pubmed">7966924</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1994 Oct;33(8):1080-6</Citation><ArticleIdList><ArticleId IdType="pubmed">7982858</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 1994 Nov;103(4):819-24</Citation><ArticleIdList><ArticleId IdType="pubmed">7822585</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1996 May;153(5):667-73</Citation><ArticleIdList><ArticleId IdType="pubmed">8615412</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1996 Jun 20;39(1):31-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8835651</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1996 Jun 20;39(1):61-72</Citation><ArticleIdList><ArticleId IdType="pubmed">8835655</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1997 Feb;154(2):199-204</Citation><ArticleIdList><ArticleId IdType="pubmed">9016268</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 1997 Oct;96(4):254-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9350953</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1998;59 Suppl 18:18-22</Citation><ArticleIdList><ArticleId IdType="pubmed">9840194</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1999 Feb;156(2):181-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9989552</ArticleId></ArticleIdList></Reference><Reference><Citation>J Consult Psychol. 1957 Aug;21(4):343-9</Citation><ArticleIdList><ArticleId IdType="pubmed">13463189</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Rep. 1965 Apr;16:547-54</Citation><ArticleIdList><ArticleId IdType="pubmed">14285869</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62</Citation><ArticleIdList><ArticleId IdType="pubmed">14399272</ArticleId></ArticleIdList></Reference><Reference><Citation>Suicide Life Threat Behav. 2004 Winter;34(4):363-73</Citation><ArticleIdList><ArticleId IdType="pubmed">15585458</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2005 Jul;87(1):73-82</Citation><ArticleIdList><ArticleId IdType="pubmed">15923041</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Arch Psychiatry Clin Neurosci. 2006 Feb;256(1):17-27</Citation><ArticleIdList><ArticleId IdType="pubmed">16133739</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1976 Jun;33(6):766-71</Citation><ArticleIdList><ArticleId IdType="pubmed">938196</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1999 Aug;175:175-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10627802</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Drug Alcohol Abuse. 2001 Feb;27(1):45-64</Citation><ArticleIdList><ArticleId IdType="pubmed">11373036</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Rep. 2001 Jun;88(3 Pt 1):863-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11508036</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Psychiatry. 2001 Nov;16(7):395-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11728851</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2003 May;64(5):506-15</Citation><ArticleIdList><ArticleId IdType="pubmed">12755652</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2003 May;64(5):554-61</Citation><ArticleIdList><ArticleId IdType="pubmed">12755659</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1999 Sep;56(9):805-11</Citation><ArticleIdList><ArticleId IdType="pubmed">12884886</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2003 Oct 15;120(3):247-55</Citation><ArticleIdList><ArticleId IdType="pubmed">14561436</ArticleId></ArticleIdList></Reference><Reference><Citation>Addiction. 2004 Oct;99(10):1306-14</Citation><ArticleIdList><ArticleId IdType="pubmed">15369569</ArticleId></ArticleIdList></Reference><Reference><Citation>J Consult Clin Psychol. 1983 Apr;51(2):276-86</Citation><ArticleIdList><ArticleId IdType="pubmed">6841772</ArticleId></ArticleIdList></Reference><Reference><Citation>J Consult Clin Psychol. 1974 Dec;42(6):861-5</Citation><ArticleIdList><ArticleId IdType="pubmed">4436473</ArticleId></ArticleIdList></Reference><Reference><Citation>Crisis. 2004;25(3):128-33</Citation><ArticleIdList><ArticleId IdType="pubmed">15387239</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24961959</PMID><DateCompleted><Year>2015</Year><Month>05</Month><Day>25</Day></DateCompleted><DateRevised><Year>2014</Year><Month>09</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1600-0447</ISSN><JournalIssue CitedMedium="Internet"><Volume>130</Volume><Issue>4</Issue><PubDate><Year>2014</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Acta psychiatrica Scandinavica</Title><ISOAbbreviation>Acta Psychiatr Scand</ISOAbbreviation></Journal><ArticleTitle>Polygenic risk score and the psychosis continuum model.</ArticleTitle><Pagination><MedlinePgn>311-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/acps.12307</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Schizophrenia (SZ) and bipolar disorder (BD) are heritable, polygenic disorders with shared clinical characteristics and genetic risk indicating a psychosis continuum. This is the first study using polygenic risk score (PGRS) to investigate the localization of diagnostic subcategories along the entire psychosis spectrum.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Based on results from the Psychiatric Genomics Consortium (PGC), we assigned a SZ and BD PGRS to each individual in our independent sample [N=570 BD spectrum cases, 452 SZ spectrum cases and 415 healthy controls (CTR)]. Potential differences in mean SZ and BD PGRS across diagnostic spectrums and subcategories were explored.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">SZ and BD PGRSs were significantly associated with both SZ and BD spectrums compared with CTR. For the subcategories, SZ PGRS was significantly associated with SZ, schizoaffective disorder, psychosis not otherwise specified, and BD1, while BD PGRS was significantly associated with BD1 and BD2. There were no significant differences between any of the diagnostic spectrums or subgroups for neither the SZ nor BD PGRS. Lifetime psychosis was significantly associated with SZ PGRS but not with BD PGRS.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These findings further support the psychosis continuum model and provide molecular polygenetic validation of the localization of diagnostic subcategories within this continuum.</AbstractText><CopyrightInformation>© 2014 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tesli</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>NORMENT, KG Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Espeseth</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Bettella</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Mattingsdal</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Aas</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Melle</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Djurovic</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Andreassen</LastName><ForeName>O A</ForeName><Initials>OA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>06</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Acta Psychiatr Scand</MedlineTA><NlmUniqueID>0370364</NlmUniqueID><ISSNLinking>0001-690X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Acta Psychiatr Scand. 2014 Oct;130(4):243</RefSource><PMID Version="1">25130610</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="Y">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020412" MajorTopicYN="N">Multifactorial Inheritance</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">bipolar disorder</Keyword><Keyword MajorTopicYN="N">polygenic risk</Keyword><Keyword MajorTopicYN="N">psychosis spectrum</Keyword><Keyword MajorTopicYN="N">schizophrenia</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>06</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>6</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>6</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24961959</ArticleId><ArticleId IdType="doi">10.1111/acps.12307</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19906347</PMID><DateCompleted><Year>2009</Year><Month>11</Month><Day>23</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1555-2101</ISSN><JournalIssue CitedMedium="Internet"><Volume>70</Volume><Issue>10</Issue><PubDate><Year>2009</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Life events, medical comorbidity, and somatic symptoms in pediatric mood disorders.</ArticleTitle><Pagination><MedlinePgn>1439-40</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4088/JCP.09f05642gre</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wagner</LastName><ForeName>Karen Dineen</ForeName><Initials>KD</Initials><AffiliationInfo><Affiliation>kwagner@psychiatrist.com</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D054711">Introductory Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015363">Quinolones</NameOfSubstance></Chemical><Chemical><RegistryNumber>82VFR53I78</RegistryNumber><NameOfSubstance UI="D000068180">Aripiprazole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068180" MajorTopicYN="N">Aripiprazole</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006814" MajorTopicYN="N" Type="Geographic">Hungary</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008016" MajorTopicYN="Y">Life Change Events</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015363" MajorTopicYN="N">Quinolones</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013001" MajorTopicYN="N">Somatoform Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>11</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>11</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19906347</ArticleId><ArticleId IdType="doi">10.4088/JCP.09f05642gre</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21437990</PMID><DateCompleted><Year>2012</Year><Month>03</Month><Day>30</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1099-1077</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>2</Issue><PubDate><Year>2011</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Human psychopharmacology</Title><ISOAbbreviation>Hum Psychopharmacol</ISOAbbreviation></Journal><ArticleTitle>Functional polymorphism of matrix metalloproteinase-9 (MMP-9) gene and response to lithium prophylaxis in bipolar patients.</ArticleTitle><Pagination><MedlinePgn>168-71</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/hup.1182</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Matrix metalloproteinase 9 (MMP-9) has been implicated in a number of pathological conditions including cancer and heart diseases, and recently also in such neuropsychiatric disorders as schizophrenia and bipolar illness. Therefore, we investigated a possible association between functional polymorphisms of the MMP-9 gene and the response to lithium, the main mood-stabilizing drug in bipolar illness.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">One hundred and nine bipolar patients treated with lithium for at least 5 years were analyzed. The lithium response was assessed as--excellent: no affective episodes during lithium treatment; partial: 50% or more reduction in the episode index; no response: less than 50% reduction, no change or worsening in the episode index. The -1562C/T MMP-9 gene polymorphism (rs3918242) was assessed by PCR-RFLP method.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Genotype distributions were not in Hardy-Weinberg equilibrium. No association was found between polymorphism studied and the quality of response to prophylactic lithium administration.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The functional polymorphism of the MMP-9 gene, analyzed in this study, may not be associated with the treatment response to lithium in bipolar patients.</AbstractText><CopyrightInformation>Copyright © 2011 John Wiley &amp; Sons, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rybakowski</LastName><ForeName>Janusz K</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Department of Adult Psychiatry, Poznan University of Medical Sciences, Poland. rybakows@wlkp.top.pl</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skibinska</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Suwalska</LastName><ForeName>Aleksandra</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Leszczynska-Rodziewicz</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Kaczmarek</LastName><ForeName>Leszek</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Hauser</LastName><ForeName>Joanna</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>03</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Hum Psychopharmacol</MedlineTA><NlmUniqueID>8702539</NlmUniqueID><ISSNLinking>0885-6222</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>2BMD2GNA4V</RegistryNumber><NameOfSubstance UI="D016651">Lithium Carbonate</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.35</RegistryNumber><NameOfSubstance UI="D020780">Matrix Metalloproteinase 9</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016651" MajorTopicYN="N">Lithium Carbonate</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020780" MajorTopicYN="N">Matrix Metalloproteinase 9</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>07</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>01</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>3</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>3</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21437990</ArticleId><ArticleId IdType="doi">10.1002/hup.1182</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15529089</PMID><DateCompleted><Year>2005</Year><Month>02</Month><Day>01</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1092-8529</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>11 Suppl 12</Issue><PubDate><Year>2004</Year><Month>Nov</Month></PubDate></JournalIssue><Title>CNS spectrums</Title><ISOAbbreviation>CNS Spectr</ISOAbbreviation></Journal><ArticleTitle>Safety considerations in pharmacotherapy of bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>16-26</MedlinePgn></Pagination><Abstract><AbstractText>Bipolar disorder is a chronic, frequently relapsing illness with a prevalence of 1.2% to 3.4% in the general population. It is associated with high disability, higher comorbidity due to medical illnesses, and significant social and economical consequences for patients, their families, and society. The episodic nature of this disease warrants rational use of medications and proper monitoring for adverse events. Various drug classes, such as mood stabilizers, antipsychotics, benzodiazepines, and antidepressants, are used for the acute and maintenance treatment of bipolar disorder. Each group of drugs is associated with wide array of adverse events and drug interactions, which are the main hurdles in treatment outcome and compliance. Common side effects seen with several agents, particularly antipsychotics, are somnolence, weight gain, extrapyramidal symptoms, dyslipidemia, type-2 diabetes, and hyperprolactinemia. Major drug interactions are seen with drugs such as carbamazepine, due to hepatic enzyme induction. Adverse effects such as somnolence are tolerability concerns and can be managed easily; others, such as diabetes mellitus, are safety concerns. It is prudent to have precise knowledge of the individual drug's side-effect profile, pharmacokinetics, and pharmacodynamics, to plan a treatment regimen. More research is needed to understand potential risks of various drugs and to devise and incorporate monitoring protocols in the treatment regimen.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Masand</LastName><ForeName>Prakash S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Duke University Medical Center, 110 Swift Ave, Suite 1, Durham, NC 27705, USA. pmasand@psychcme.net</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fazal</LastName><ForeName>Farhan S</ForeName><Initials>FS</Initials></Author><Author ValidYN="Y"><LastName>Patkar</LastName><ForeName>Ashwin A</ForeName><Initials>AA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>CNS Spectr</MedlineTA><NlmUniqueID>9702877</NlmUniqueID><ISSNLinking>1092-8529</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="Y">Drug-Related Side Effects and Adverse Reactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>84</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>11</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>2</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>11</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15529089</ArticleId><ArticleId IdType="doi">10.1017/s1092852900028856</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16249909</PMID><DateCompleted><Year>2006</Year><Month>01</Month><Day>04</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0033-3158</ISSN><JournalIssue CitedMedium="Print"><Volume>183</Volume><Issue>3</Issue><PubDate><Year>2005</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Psychopharmacology</Title><ISOAbbreviation>Psychopharmacology (Berl)</ISOAbbreviation></Journal><ArticleTitle>Preliminary evidence for medication effects on functional abnormalities in the amygdala and anterior cingulate in bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>308-13</MedlinePgn></Pagination><Abstract><AbstractText Label="RATIONALE" NlmCategory="BACKGROUND">Abnormal amygdala and frontocortical responses to emotional stimuli are implicated in bipolar disorder (BD) and have been proposed as potential treatment targets.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The aim of this study was to investigate amygdala and frontocortical responses to emotional face stimuli in BD and the influences of mood-stabilizing medications on these responses.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Functional magnetic resonance imaging was performed while 17 BD participants (5 unmedicated) and 17 healthy comparison (HC) participants viewed faces with happy, sad, fearful, or neutral expressions.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The group by stimulus-condition interaction was significant (p&lt;0.01) for amygdala activation, with the greatest effects in the happy face condition. Relative to HC, amygdala increases were greater in unmedicated BD, but lower in medicated BD. Rostral anterior cingulate (rAC) activation was decreased in unmedicated BD compared to HC; however, BD participants taking medication demonstrated rAC activation similar to HC participants.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Although the sample sizes were small, these preliminary results suggest that BD is associated with increased amygdala and decreased rAC response to emotional faces. The findings also provide preliminary evidence that mood-stabilizing medications may reverse abnormalities in BD in the response of an amygdala-frontal neural system to emotional stimuli.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Blumberg</LastName><ForeName>Hilary P</ForeName><Initials>HP</Initials><AffiliationInfo><Affiliation>Mood Disorders Research Program, Department of Psychiatry, Yale University School of Medicine, 300 George Street, Suite 901, New Haven, CT 06511, USA. hilary.blumberg@yale.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Donegan</LastName><ForeName>Nelson H</ForeName><Initials>NH</Initials></Author><Author ValidYN="Y"><LastName>Sanislow</LastName><ForeName>Charles A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Collins</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Lacadie</LastName><ForeName>Cheryl</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Skudlarski</LastName><ForeName>Pawel</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Gueorguieva</LastName><ForeName>Ralitza</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Fulbright</LastName><ForeName>Robert K</ForeName><Initials>RK</Initials></Author><Author ValidYN="Y"><LastName>McGlashan</LastName><ForeName>Thomas H</ForeName><Initials>TH</Initials></Author><Author ValidYN="Y"><LastName>Gore</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Krystal</LastName><ForeName>John H</ForeName><Initials>JH</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K05MH01654</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01MH070902</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01MH69747</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 MH073708-05</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 MH073708</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 MH073708-04</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 MH073708-01</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 MH073708-02</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 MH073708-03</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K05AA14906-01</GrantID><Acronym>AA</Acronym><Agency>NIAAA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH070902</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2005</Year><Month>10</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Psychopharmacology (Berl)</MedlineTA><NlmUniqueID>7608025</NlmUniqueID><ISSNLinking>0033-3158</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000679" MajorTopicYN="N">Amygdala</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004644" MajorTopicYN="N">Emotions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005149" MajorTopicYN="N">Facial Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006179" MajorTopicYN="N">Gyrus Cinguli</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>04</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>07</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>10</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>1</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>10</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16249909</ArticleId><ArticleId IdType="doi">10.1007/s00213-005-0156-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Biol Psychiatry. 2002 May 1;51(9):693-707</Citation><ArticleIdList><ArticleId IdType="pubmed">11983183</ArticleId></ArticleIdList></Reference><Reference><Citation>Semin Clin Neuropsychiatry. 2002 Oct;7(4):243-54</Citation><ArticleIdList><ArticleId IdType="pubmed">12382207</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2001 Apr;24(4):359-69</Citation><ArticleIdList><ArticleId IdType="pubmed">11182531</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2003 Dec 1;54(11):1284-93</Citation><ArticleIdList><ArticleId IdType="pubmed">14643096</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2003 Jun;60(6):601-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12796223</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 1995 Feb;118 ( Pt 1):279-306</Citation><ArticleIdList><ArticleId IdType="pubmed">7895011</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2004 Jul;34(5):795-802</Citation><ArticleIdList><ArticleId IdType="pubmed">15500300</ArticleId></ArticleIdList></Reference><Reference><Citation>Am Psychol. 2000 Nov;55(11):1196-214</Citation><ArticleIdList><ArticleId IdType="pubmed">11280935</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1999 Dec;156(12 ):1986-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10588416</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 1982 Dec;170(12):717-31</Citation><ArticleIdList><ArticleId IdType="pubmed">6754868</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2001 Dec;124(Pt 12):2550-63</Citation><ArticleIdList><ArticleId IdType="pubmed">11701607</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1994 Jul 15;36(2):124-34</Citation><ArticleIdList><ArticleId IdType="pubmed">7948445</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2004 Mar 15;55(6):578-87</Citation><ArticleIdList><ArticleId IdType="pubmed">15013826</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2002;63 Suppl 3:21-5</Citation><ArticleIdList><ArticleId IdType="pubmed">11908918</ArticleId></ArticleIdList></Reference><Reference><Citation>J Comp Neurol. 1984 Dec 20;230(4):465-96</Citation><ArticleIdList><ArticleId IdType="pubmed">6520247</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1997 May;170:426-30</Citation><ArticleIdList><ArticleId IdType="pubmed">9307691</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2003 Jun 1;53(11):1009-20</Citation><ArticleIdList><ArticleId IdType="pubmed">12788246</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2002;7 Suppl 1:S71-80</Citation><ArticleIdList><ArticleId IdType="pubmed">11986998</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2004 Sep;29(9):1734-40</Citation><ArticleIdList><ArticleId IdType="pubmed">15173843</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Biochem Behav. 2002 Mar;71(3):431-47</Citation><ArticleIdList><ArticleId IdType="pubmed">11830178</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 1999 Nov;29(6):1307-21</Citation><ArticleIdList><ArticleId IdType="pubmed">10616937</ArticleId></ArticleIdList></Reference><Reference><Citation>Semin Clin Neuropsychiatry. 2002 Oct;7(4):255-68</Citation><ArticleIdList><ArticleId IdType="pubmed">12382208</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2002 Feb;159(2):302-4</Citation><ArticleIdList><ArticleId IdType="pubmed">11823275</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1997 Apr 24;386(6627):824-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9126739</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2000 Sep;2(3 Pt 2):237-48</Citation><ArticleIdList><ArticleId IdType="pubmed">11249801</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">5051619</PMID><DateCompleted><Year>1972</Year><Month>10</Month><Day>04</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-990X</ISSN><JournalIssue CitedMedium="Print"><Volume>27</Volume><Issue>3</Issue><PubDate><Year>1972</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Archives of general psychiatry</Title><ISOAbbreviation>Arch Gen Psychiatry</ISOAbbreviation></Journal><ArticleTitle>The "switch process" in manic-depressive illness. 3. Theoretical implications.</ArticleTitle><Pagination><MedlinePgn>312-7</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bunney</LastName><ForeName>W E</ForeName><Initials>WE</Initials><Suffix>Jr</Suffix></Author><Author ValidYN="Y"><LastName>Goodwin</LastName><ForeName>F K</ForeName><Initials>FK</Initials></Author><Author ValidYN="Y"><LastName>Murphy</LastName><ForeName>D L</ForeName><Initials>DL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Gen Psychiatry</MedlineTA><NlmUniqueID>0372435</NlmUniqueID><ISSNLinking>0003-990X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002254">Carbonates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002395">Catecholamines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011955">Receptors, Drug</NameOfSubstance></Chemical><Chemical><RegistryNumber>63-84-3</RegistryNumber><NameOfSubstance UI="D004295">Dihydroxyphenylalanine</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical><Chemical><RegistryNumber>9NEZ333N27</RegistryNumber><NameOfSubstance UI="D012964">Sodium</NameOfSubstance></Chemical><Chemical><RegistryNumber>I38ZP9992A</RegistryNumber><NameOfSubstance UI="D008274">Magnesium</NameOfSubstance></Chemical><Chemical><RegistryNumber>RWP5GA015D</RegistryNumber><NameOfSubstance UI="D011188">Potassium</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical><Chemical><RegistryNumber>X4W3ENH1CV</RegistryNumber><NameOfSubstance UI="D009638">Norepinephrine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001693" MajorTopicYN="N">Biological Transport, Active</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001923" MajorTopicYN="N">Brain Chemistry</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002254" MajorTopicYN="N">Carbonates</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002395" MajorTopicYN="N">Catecholamines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004295" MajorTopicYN="N">Dihydroxyphenylalanine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008274" MajorTopicYN="N">Magnesium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009638" MajorTopicYN="N">Norepinephrine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011188" MajorTopicYN="N">Potassium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011955" MajorTopicYN="N">Receptors, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012964" MajorTopicYN="N">Sodium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019966" MajorTopicYN="N">Substance-Related Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1972</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>3</Month><Day>28</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1972</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">5051619</ArticleId><ArticleId IdType="doi">10.1001/archpsyc.1972.01750270022003</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22451354</PMID><DateCompleted><Year>2013</Year><Month>07</Month><Day>08</Day></DateCompleted><DateRevised><Year>2013</Year><Month>01</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1099-1166</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>2</Issue><PubDate><Year>2013</Year><Month>Feb</Month></PubDate></JournalIssue><Title>International journal of geriatric psychiatry</Title><ISOAbbreviation>Int J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Neurocognitive functioning in early-onset and late-onset older patients with euthymic bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>142-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/gps.3801</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Most neurocognitive studies have not taken into account the fact that older patients with bipolar disorder (BD) are a heterogeneous population. The main goal of this study was to compare neurocognitive performance and extrapyramidal symptoms in older patients with early-onset BD (EO-BD) and late-onset BD (LO-BD).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Euthymic older patients with EO-BD (n = 20), LO-BD (n = 20), and healthy controls (n = 20) were evaluated with traditional clinical instruments and measures of exposure to psychotropic drugs, as well as extrapyramidal symptoms. All subjects completed an extensive neuropsychological battery.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Patients with EO-BD showed poorer performance than healthy controls in two measures of verbal memory and two measures of executive functions, whereas patients with LO-BD exhibited lower performance scores than healthy controls in almost all of the measures assessed. Impairments in the LO-BD group included even neurocognitive domains typically spared in mixed-age patients. Additionally, there was a trend toward displaying higher extrapyramidal symptoms in the LO-BD group compared with both EO-BD and healthy control groups. In both patient groups, psychosocial functioning was related with executive dysfunction and extrapyramidal symptoms.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Patients with LO-BD may have more extensive and severe cognitive impairments, as well as higher vulnerability to extrapyramidal symptoms, compared with patients with EO-BD. Cognitive-motor disturbances may help to explain impairments in daily functioning among older patients with EO-BD and LO-BD during remission.</AbstractText><CopyrightInformation>Copyright © 2012 John Wiley &amp; Sons, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Martino</LastName><ForeName>Diego J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Bipolar Disorder Program, Institute of Neurosciences, Favaloro University, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strejilevich</LastName><ForeName>Sergio A</ForeName><Initials>SA</Initials></Author><Author ValidYN="Y"><LastName>Manes</LastName><ForeName>Facundo</ForeName><Initials>F</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>03</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Geriatr Psychiatry</MedlineTA><NlmUniqueID>8710629</NlmUniqueID><ISSNLinking>0885-6230</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056344" MajorTopicYN="N">Executive Function</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012917" MajorTopicYN="N">Social Adjustment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>11</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>02</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22451354</ArticleId><ArticleId IdType="doi">10.1002/gps.3801</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">9563292</PMID><DateCompleted><Year>1998</Year><Month>06</Month><Day>01</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0145-4455</ISSN><JournalIssue CitedMedium="Print"><Volume>22</Volume><Issue>2</Issue><PubDate><Year>1998</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Behavior modification</Title><ISOAbbreviation>Behav Modif</ISOAbbreviation></Journal><ArticleTitle>Abnormal facial emotion recognition in depression: serial testing in an ultra-rapid-cycling patient.</ArticleTitle><Pagination><MedlinePgn>192-204</MedlinePgn></Pagination><Abstract><AbstractText>Normal subjects use the right insula and bilateral anterior temporal and prefrontal cortices to recognize the emotion expressed in a human face. Mood disorder subjects have a selective deficit in recognizing human facial emotion. Brain imaging studies show that they fail to activate the right insula to the same degree as controls, even when accurately assessing facial emotion. Many issues remain, however, including whether the facial emotion recognition errors in mood disorder subjects are state dependent or persist during normal mood states (and, thus, reflect a trait abnormality). To probe this issue, we repeatedly studied a male bipolar II patient's ability to recognize faces' emotional content. This patient made significantly more errors in facial emotion recognition during the depressed state. He also demonstrated a significant negative bias when he was depressed compared with nondepressed states. This case study demonstrates the state dependency of the defect in human facial emotion recognition.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>George</LastName><ForeName>M S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Radiology, Medical University of South Carolina, Charleston 29425, USA. georgem@musc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huggins</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>McDermut</LastName><ForeName>W</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Parekh</LastName><ForeName>P I</ForeName><Initials>PI</Initials></Author><Author ValidYN="Y"><LastName>Rubinow</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Post</LastName><ForeName>R M</ForeName><Initials>RM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Behav Modif</MedlineTA><NlmUniqueID>7803043</NlmUniqueID><ISSNLinking>0145-4455</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001288" MajorTopicYN="N">Attention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004193" MajorTopicYN="Y">Discrimination Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005149" MajorTopicYN="Y">Facial Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010364" MajorTopicYN="N">Pattern Recognition, Visual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1998</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1998</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1998</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9563292</ArticleId><ArticleId IdType="doi">10.1177/01454455980222007</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">31443935</PMID><DateCompleted><Year>2021</Year><Month>01</Month><Day>06</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2402</ISSN><JournalIssue CitedMedium="Internet"><Volume>87</Volume><Issue>3</Issue><PubDate><Year>2020</Year><Month>02</Month><Day>01</Day></PubDate></JournalIssue><Title>Biological psychiatry</Title><ISOAbbreviation>Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>The Electroretinogram May Differentiate Schizophrenia From Bipolar Disorder.</ArticleTitle><Pagination><MedlinePgn>263-270</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0006-3223(19)31476-3</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.biopsych.2019.06.014</ELocationID><Abstract><AbstractText Label="BACKGROUND">The retina is recognized as an approachable part of the brain owing to their common embryonic origin. The electroretinogram (ERG) has proved to be a valuable tool to investigate psychiatric disorders. We therefore investigated its accuracy as a tool to differentiate schizophrenia (SZ) from bipolar disorder (BP) even after balancing patients for their main antipsychotic medication.</AbstractText><AbstractText Label="METHODS">ERG cone and rod luminance response functions were recorded in 150 patients with SZ and 151 patients with BP and compared with 200 control subjects. We created a subgroup of subjects-45 with SZ and 45 with BP-balanced for their main antipsychotic medication.</AbstractText><AbstractText Label="RESULTS">A reduced cone a-wave amplitude and a prolonged b-wave latency were observed in both disorders, whereas a reduced cone b-wave amplitude was present in SZ only. Reduced mixed rod-cone a- and b-wave amplitudes were observed in both disorders. Patients with SZ were distinguishable from control subjects with 0.91 accuracy, 77% sensitivity, and 91% specificity with similar numbers for patients with BP (0.89, 76%, and 88%, respectively). Patients with SZ and patients with BP could be differentiated with an accuracy of 0.86 (whole sample) and 0.83 (subsamples of 45 patients with 80% sensitivity and 82% specificity). Antipsychotic dosages were not correlated with ERG parameters.</AbstractText><AbstractText Label="CONCLUSIONS">The ERG waveform parameters used in this study provided a very accurate distinction between the two disorders when using a logistic regression model. This supports the ERG as a tool that could aid the clinician in the differential diagnosis of SZ and BP in stabilized medicated patients.</AbstractText><CopyrightInformation>Copyright © 2019. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hébert</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Centre de Recherche CERVO, Centre Intégré Universitaire de Santé et des Services Sociaux de la Capitale Nationale, Québec, Quebec, Canada; Département d'Ophtalmologie et d'Oto-Rhino-Laryngologie-Chirurgie Cervico-Faciale, Faculté de Médecine, Université Laval, Québec, Quebec, Canada. Electronic address: marc.hebert@fmed.ulaval.ca.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mérette</LastName><ForeName>Chantal</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Centre de Recherche CERVO, Centre Intégré Universitaire de Santé et des Services Sociaux de la Capitale Nationale, Québec, Quebec, Canada; Département de Psychiatrie et Neurosciences, Faculté de Médecine, Université Laval, Québec, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gagné</LastName><ForeName>Anne-Marie</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Centre de Recherche CERVO, Centre Intégré Universitaire de Santé et des Services Sociaux de la Capitale Nationale, Québec, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paccalet</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institut National de Santé Publique du Québec, Québec, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moreau</LastName><ForeName>Isabel</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Centre de Recherche CERVO, Centre Intégré Universitaire de Santé et des Services Sociaux de la Capitale Nationale, Québec, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lavoie</LastName><ForeName>Joëlle</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Sinai Health System, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maziade</LastName><ForeName>Michel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Centre de Recherche CERVO, Centre Intégré Universitaire de Santé et des Services Sociaux de la Capitale Nationale, Québec, Quebec, Canada; Département de Psychiatrie et Neurosciences, Faculté de Médecine, Université Laval, Québec, Quebec, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>06</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biol Psychiatry</MedlineTA><NlmUniqueID>0213264</NlmUniqueID><ISSNLinking>0006-3223</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Biol Psychiatry. 2020 Feb 1;87(3):202-203</RefSource><PMID Version="1">31908288</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004596" MajorTopicYN="N">Electroretinography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012160" MajorTopicYN="N">Retina</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="Y">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Biomarker</Keyword><Keyword MajorTopicYN="Y">Bipolar disorders</Keyword><Keyword MajorTopicYN="Y">Electroretinogram</Keyword><Keyword MajorTopicYN="Y">Psychosis</Keyword><Keyword MajorTopicYN="Y">Retina</Keyword><Keyword MajorTopicYN="Y">Schizophrenia</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>11</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>06</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>06</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>8</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>1</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>8</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31443935</ArticleId><ArticleId IdType="pii">S0006-3223(19)31476-3</ArticleId><ArticleId IdType="doi">10.1016/j.biopsych.2019.06.014</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21829907</PMID><DateCompleted><Year>2012</Year><Month>03</Month><Day>07</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>27</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1809-452X</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>2</Issue><PubDate><Year>2011</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999)</Title><ISOAbbreviation>Braz J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>The effectiveness of cognitive behavioral group therapy in treating bipolar disorder: a randomized controlled study.</ArticleTitle><Pagination><MedlinePgn>144-9</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S1516-44462011000200009</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Recent studies suggest that, when combined with pharmacotherapy, structured psychotherapy may modify the course of bipolar disorder. However, there are few studies that have examined the effects of cognitive behavioral group therapy on the course of this disorder. The aim of the present study was to evaluate the effectiveness of 14 sessions of cognitive behavioral group therapy, combined with pharmacotherapy, on the treatment of patients with bipolar disorder, and to compare our results against those from the use of pharmacotherapy alone.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Forty-one patients with bipolar I and II disorder participated in the study and were randomly allocated to one of two treatment groups; thirty-seven patients remained in the study until its completion. Mood and anxiety symptoms were measured in all subjects. Statistical analysis was used to investigate if the groups differed with respect to demographic characteristics and the scores recorded in the pre- and post-treatment stages, as well as during treatment (intra/inter groups).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Patients showed statistically similar population characteristics. The association of cognitive behavioral group therapy and pharmacological treatment proved to be effective. Patients who had undergone cognitive behavioral group therapy presented fewer symptoms of mania, depression and anxiety, as well as fewer and shorter mood change episodes.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Cognitive behavioral group therapy sessions substantially contributed to the improvement of depression symptoms.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Costa</LastName><ForeName>Rafael Thomaz da</ForeName><Initials>RT</Initials><AffiliationInfo><Affiliation>Institute of Psychiatry, Universidade Federal do Rio de Janeiro, Brazil. faelthomaz@ig.com.br</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheniaux</LastName><ForeName>Elie</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Rosaes</LastName><ForeName>Pedro Augusto Legnani</ForeName><Initials>PA</Initials></Author><Author ValidYN="Y"><LastName>Carvalho</LastName><ForeName>Marcele Regine de</ForeName><Initials>MR</Initials></Author><Author ValidYN="Y"><LastName>Freire</LastName><ForeName>Rafael Christophe da Rocha</ForeName><Initials>RC</Initials></Author><Author ValidYN="Y"><LastName>Versiani</LastName><ForeName>Márcio</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Rangé</LastName><ForeName>Bernard Pimentel</ForeName><Initials>BP</Initials></Author><Author ValidYN="Y"><LastName>Nardi</LastName><ForeName>Antonio Egidio</ForeName><Initials>AE</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Brazil</Country><MedlineTA>Braz J Psychiatry</MedlineTA><NlmUniqueID>100895975</NlmUniqueID><ISSNLinking>1516-4446</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015928" MajorTopicYN="N">Cognitive Behavioral Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011615" MajorTopicYN="N">Psychotherapy, Group</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012919" MajorTopicYN="N">Social Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>03</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>04</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21829907</ArticleId><ArticleId IdType="pii">S1516-44462011000200009</ArticleId><ArticleId IdType="doi">10.1590/s1516-44462011000200009</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15482580</PMID><DateCompleted><Year>2005</Year><Month>02</Month><Day>03</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1323-1316</ISSN><JournalIssue CitedMedium="Print"><Volume>58</Volume><Issue>5</Issue><PubDate><Year>2004</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Psychiatry and clinical neurosciences</Title><ISOAbbreviation>Psychiatry Clin Neurosci</ISOAbbreviation></Journal><ArticleTitle>Family functioning perceived by patients and their family members in three Diagnostic and Statistical Manual-IV diagnostic groups.</ArticleTitle><Pagination><MedlinePgn>495-500</MedlinePgn></Pagination><Abstract><AbstractText>The aim of this study was to clarify the difference in the perception of family functioning measured on the Family Assessment Device (FAD) by Diagnostic and Statistical Manual-IV diagnoses (i.e. schizophrenia, major depressive disorder and bipolar disorder) and by raters (patients and family members). The subjects were 70 psychiatric outpatients paired with their family members (i.e. principal caretaker), divided into three groups based on the patient's diagnosis of schizophrenia (24 pairs), major depressive disorder (28 pairs) or bipolar disorder (18 pairs). They rated their perceived family functioning on the FAD. There was no significant difference in perceptions of family functioning between the three groups of family members, while there were differences between the patient groups in some FAD dimensions. Perceptions of family functioning were not significantly correlated between the schizophrenic patients and their family members. The perceptions of family functioning were correlated more strongly between patients and their family members in the bipolar group than between patients and family members in the other two diagnostic groups. As for the FAD Problem Solving dimension, the schizophrenia patients saw it more negatively than did their family members, whereas the depressive patients saw it more positively than did their family members. These results might reflect psychopathological characteristics of each disorder. When clinicians evaluate the family functioning of psychiatric patients, it is important to consider the diagnoses of patients as well as who assesses it.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Koyama</LastName><ForeName>Asuka</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Mental Health, Graduate School of Medicine, University of Tokyo, Tokyo, Japan. asuka-k@umin.ac.jp</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akiyama</LastName><ForeName>Tsuyoshi</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Miyake</LastName><ForeName>Yuko</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Kurita</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Psychiatry Clin Neurosci</MedlineTA><NlmUniqueID>9513551</NlmUniqueID><ISSNLinking>1323-1316</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="N">Affect</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001294" MajorTopicYN="Y">Attitude to Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017028" MajorTopicYN="N">Caregivers</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="Y">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005195" MajorTopicYN="Y">Family Relations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007389" MajorTopicYN="N">Internal-External Control</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010552" MajorTopicYN="N">Personality Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011340" MajorTopicYN="N">Problem Solving</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="Y">Schizophrenic Psychology</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>10</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>2</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>10</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15482580</ArticleId><ArticleId IdType="pii">PCN1291</ArticleId><ArticleId IdType="doi">10.1111/j.1440-1819.2004.01291.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24359854</PMID><DateCompleted><Year>2014</Year><Month>09</Month><Day>22</Day></DateCompleted><DateRevised><Year>2013</Year><Month>12</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0013-7006</ISSN><JournalIssue CitedMedium="Internet"><Volume>39 Suppl 3</Volume><PubDate><Year>2013</Year><Month>Dec</Month></PubDate></JournalIssue><Title>L'Encephale</Title><ISOAbbreviation>Encephale</ISOAbbreviation></Journal><ArticleTitle>[Neurocognitive fuctioning in pure mania and mixed mania].</ArticleTitle><Pagination><MedlinePgn>S157-61</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S0013-7006(13)70115-5</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0013-7006(13)70115-5</ELocationID><Abstract><AbstractText>Neurocognitive dysfunction is increasingly recognized as a prominent feature of bipolar disorder. Cognitive function seems to be impaired across different states of bipolar illness. Nervertheless, research that studies neuropsychological functioning in acute phases is scarce. Acutely ill patients have shown dysfunctions in several cognitive areas. We reviewed the literature on neuropsychological studies of acute phases to highlight neurocognitive deficits in mixed and pure mania. The results show dysfunctions in sustained attention that are significantly more important in mixed mania rather than in pure mania. Impulsive pattern of responding seems to characterize pure manic state. We also found impairments in processing speed, verbal and spatial learning/memory and executive functions, including cognitive flexibility, inhibitory control, conceptual reasoning, planning and problem solving. Disturbance in executive functioning seems to be more important in pure mania rather than mixed mania.</AbstractText><CopyrightInformation>Copyright © 2013 Sociedade Brasileira de Farmacognosia. Published by Elsevier Masson SAS.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Corréarda</LastName><ForeName>N</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>SHU psychiatrie adultes, Solaris, Hôpital Sainte- Marguerite, 13274 Marseille cedex 09, France. Electronic address: nadia.correard@ap-hm.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Azorin</LastName><ForeName>J-M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>SHU psychiatrie adultes, Solaris, Hôpital Sainte- Marguerite, 13274 Marseille cedex 09, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belzeaux</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>SHU psychiatrie adultes, Solaris, Hôpital Sainte- Marguerite, 13274 Marseille cedex 09, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cermolacce</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>SHU psychiatrie adultes, Solaris, Hôpital Sainte- Marguerite, 13274 Marseille cedex 09, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fakra</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>SHU psychiatrie adultes, Solaris, Hôpital Sainte- Marguerite, 13274 Marseille cedex 09, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Micoulaud-Franchi</LastName><ForeName>J-A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>SHU psychiatrie adultes, Solaris, Hôpital Sainte- Marguerite, 13274 Marseille cedex 09, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dassa</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Pôle de psychiatrie centre, Hôpital de La Conception, Boulevard Baille, 13006 Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dubois</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Pôle de psychiatrie centre, Hôpital de La Conception, Boulevard Baille, 13006 Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pringuey</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Clinique de psychiatrie et de psychologie médicale, CHU Pasteur, 06002 Nice cedex, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaladjian</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Pôle de psychiatrie des adultes, CHU Robert- Debré, Avenue du Général- Koenig, 51092 Reims cedex, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Fonctionnement neurocognitif dans la manie pure et la manie mixte.</VernacularTitle></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Encephale</MedlineTA><NlmUniqueID>7505643</NlmUniqueID><ISSNLinking>0013-7006</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="N">Affect</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001143" MajorTopicYN="N">Arousal</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001288" MajorTopicYN="N">Attention</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058068" MajorTopicYN="N">Endophenotypes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056344" MajorTopicYN="N">Executive Function</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011939" MajorTopicYN="N">Mental Recall</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="Y">Neuropsychological Tests</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011597" MajorTopicYN="N">Psychomotor Performance</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012016" MajorTopicYN="N">Reference Values</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bipolar disorders</Keyword><Keyword MajorTopicYN="N">Mania</Keyword><Keyword MajorTopicYN="N">Manie</Keyword><Keyword MajorTopicYN="N">Mixed states</Keyword><Keyword MajorTopicYN="N">Neurocognition</Keyword><Keyword MajorTopicYN="N">Troubles bipolaires</Keyword><Keyword MajorTopicYN="N">États mixtes</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24359854</ArticleId><ArticleId IdType="pii">S0013-7006(13)70115-5</ArticleId><ArticleId IdType="doi">10.1016/S0013-7006(13)70115-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27813593</PMID><DateCompleted><Year>2017</Year><Month>02</Month><Day>27</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1676-5680</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>4</Issue><PubDate><Year>2016</Year><Month>Oct</Month><Day>17</Day></PubDate></JournalIssue><Title>Genetics and molecular research : GMR</Title><ISOAbbreviation>Genet Mol Res</ISOAbbreviation></Journal><ArticleTitle>CASE-REPORT Case study of a patient presenting both type II bipolar affective disorder and Klinefelter syndrome.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.4238/gmr15048872</ELocationID><Abstract><AbstractText>Klinefelter syndrome (KS) is the most common sex chromosomal disorder with an estimated prevalence of 1 in 500-1000. Increased incidences of anxiety, depression, substance abuse, psychotic and behavioral disorders, and sexual disorders have been reported in patients with KS. The aim of this case study was to report a case of a man with untreated KS who was also diagnosed with type II bipolar disorder. This case report raises awareness regarding psychiatric diagnoses that may be associated with such a highly prevalent condition. A 46-year-old man who had previously been diagnosed with an untreated KS was examined in our Psychiatric Department with an acute hypomanic episode. Clinical improvement was observed within 4 days and psychiatric symptoms were resolved in 7 days without use of medication. A psychiatric history of a depressive episode and at least two hypomanic episodes, as well as a family history of two relatives diagnosed with bipolar disorder, strongly suggest that our patient has type II bipolar disorder. Bipolar disorder may be a comorbid disorder in patients with KS. Routine screening for mood disorders and appropriate referral and evaluation should be performed. Future genetic research is warranted to explore why some chromosomal abnormalities (e.g., duplications), especially those located on the X chromosome, such as Klinefelter syndrome, may be associated with a bipolar or psychotic disorder in some individuals but not in others.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Delavenne</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Departamento de Psiquiatria e Programa de Pós-Graduação em Medicina Molecular, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khoury</LastName><ForeName>J M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Departamento de Psiquiatria e Programa de Pós-Graduação em Medicina Molecular, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thibaut</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University Hospital Cochin (site Tarnier), University of Paris-Descartes, INSERM U 894 Centre Psychiatry and Neurosciences, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garcia</LastName><ForeName>F D</ForeName><Initials>FD</Initials><AffiliationInfo><Affiliation>Departamento de Psiquiatria e Programa de Pós-Graduação em Medicina Molecular, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brasil fredgarcia@ufmg.br.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Research and Innovation in Biomedicine, Rouen University, INSERM Unit 1073, Rouen, France fredgarcia@ufmg.br.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>10</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Brazil</Country><MedlineTA>Genet Mol Res</MedlineTA><NlmUniqueID>101169387</NlmUniqueID><ISSNLinking>1676-5680</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007713" MajorTopicYN="N">Klinefelter Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>11</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>11</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>2</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27813593</ArticleId><ArticleId IdType="pii">gmr-15-gmr15048872</ArticleId><ArticleId IdType="doi">10.4238/gmr15048872</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25640248</PMID><DateCompleted><Year>2016</Year><Month>12</Month><Day>13</Day></DateCompleted><DateRevised><Year>2016</Year><Month>12</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1469-8978</ISSN><JournalIssue CitedMedium="Internet"><Volume>45</Volume><Issue>10</Issue><PubDate><Year>2015</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Psychological medicine</Title><ISOAbbreviation>Psychol Med</ISOAbbreviation></Journal><ArticleTitle>Changes in neurocognitive functioning during transition to manifest disease: comparison of individuals at risk for schizophrenic and bipolar affective psychoses.</ArticleTitle><Pagination><MedlinePgn>2123-34</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1017/S0033291715000057</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Neurocognitive deficits are important aspects of schizophrenic disorder because they have a strong impact on social and vocational outcomes. Previously it was assumed that cognitive abilities progressively deteriorate with illness onset. However, recent research results have contradicted this with observations of continuous or even improved performance in individuals at risk for psychosis or manifest schizophrenia. The objective of our longitudinal study was to examine neurocognitive functioning in help-seeking individuals meeting basic symptoms or ultra-high-risk criteria for schizophrenic psychosis (HRSchiz) or risk criteria for affective psychosis (HRBip). The progression of cognitive functioning in individuals converting to psychosis was compared with that of at-risk individuals who did not convert during the follow-up period.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Data were available from 86 study participants who completed neurocognitive and clinical assessments at baseline and, on average, 12.8 (s.d. = 1.5) months later. Neurocognitive measures were grouped according to their load in factor analysis to five cognitive domains: speed, attention, fluency, learning and memory, and working memory.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Neurocognitive functioning in HRSchiz and HRBip individuals generally improved over time. Subjects converting to manifest psychosis displayed a stable neurocognitive profile from baseline to follow-up. Compared with non-converters, they had already demonstrated a significantly lower level of performance during their baseline examinations.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our data provide no evidence for a progressive cognitive decline in individuals at risk of psychosis. In line with the neurodevelopmental model, our findings suggest that cognitive deficits are already present very early, before or during the prodromal stage of the illness.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Metzler</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The Zurich Program for Sustainable Development of Mental Health Services (ZInEP),University Hospital of Psychiatry Zurich,Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dvorsky</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>The Zurich Program for Sustainable Development of Mental Health Services (ZInEP),University Hospital of Psychiatry Zurich,Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wyss</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>The Zurich Program for Sustainable Development of Mental Health Services (ZInEP),University Hospital of Psychiatry Zurich,Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Müller</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>The Zurich Program for Sustainable Development of Mental Health Services (ZInEP),University Hospital of Psychiatry Zurich,Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gerstenberg</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>The Zurich Program for Sustainable Development of Mental Health Services (ZInEP),University Hospital of Psychiatry Zurich,Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Traber-Walker</LastName><ForeName>N</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>The Zurich Program for Sustainable Development of Mental Health Services (ZInEP),University Hospital of Psychiatry Zurich,Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walitza</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Child and Adolescent Psychiatry,University of Zurich,Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Theodoridou</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>The Zurich Program for Sustainable Development of Mental Health Services (ZInEP),University Hospital of Psychiatry Zurich,Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rössler</LastName><ForeName>W</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>The Zurich Program for Sustainable Development of Mental Health Services (ZInEP),University Hospital of Psychiatry Zurich,Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heekeren</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>The Zurich Program for Sustainable Development of Mental Health Services (ZInEP),University Hospital of Psychiatry Zurich,Switzerland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>02</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Psychol Med</MedlineTA><NlmUniqueID>1254142</NlmUniqueID><ISSNLinking>0033-2917</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019965" MajorTopicYN="N">Neurocognitive Disorders</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062706" MajorTopicYN="N">Prodromal Symptoms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="N">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013557" MajorTopicYN="N">Switzerland</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cognition</Keyword><Keyword MajorTopicYN="N">help-seeking</Keyword><Keyword MajorTopicYN="N">neuropsychology</Keyword><Keyword MajorTopicYN="N">prodrome</Keyword><Keyword MajorTopicYN="N">psychosis/bipolar</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25640248</ArticleId><ArticleId IdType="pii">S0033291715000057</ArticleId><ArticleId IdType="doi">10.1017/S0033291715000057</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16958037</PMID><DateCompleted><Year>2007</Year><Month>02</Month><Day>27</Day></DateCompleted><DateRevised><Year>2020</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1552-4841</ISSN><JournalIssue CitedMedium="Print"><Volume>144B</Volume><Issue>1</Issue><PubDate><Year>2007</Year><Month>Jan</Month><Day>05</Day></PubDate></JournalIssue><Title>American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics</Title><ISOAbbreviation>Am J Med Genet B Neuropsychiatr Genet</ISOAbbreviation></Journal><ArticleTitle>Further evidence of MAO-A gene variants associated with bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>37-40</MedlinePgn></Pagination><Abstract><AbstractText>The aim of this study was to investigate MAOA gene variants in bipolar disorder by using a family-based association approach. The first sample included 331 nuclear families from Western and Central Canada with at least 1 offspring affected with bipolar disorder comprising a total of 1,044 individuals. All subjects were genotyped for MAOA-941T &gt; G and -uVNTR gene variants using PCR techniques. Haplotype TDT was statistically significant (LRS = 12.17; df = 3; P = 0.0068; permutation global significance = 0.00098), with the T-4 haplotype significantly associated with bipolar disorder (OR = 1.63, 95% CI = 1.11-2.37). Single marker analysis evidenced a borderline association for MAOA-941T &gt; G (P = 0.04), but not for the uVNTR. Pooling the Canadian sample with a second previously reported Italian sample genotyped for the uVNTR variant, negative results were obtained as well. No different results were detected when analyzing female subjects separately. In conclusion, our family-based association study gives mild but further support of the involvement of MAOA variants in bipolar disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Müller</LastName><ForeName>Daniel J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Charité University Medicine Berlin, PUK der Charité im SHK, Charité Campus Mitte, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serretti</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Sicard</LastName><ForeName>Tricia</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Tharmalingam</LastName><ForeName>Subi</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>King</LastName><ForeName>Nicole</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Artioli</LastName><ForeName>Paola</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Mandelli</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Lorenzi</LastName><ForeName>Cristina</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Kennedy</LastName><ForeName>James L</ForeName><Initials>JL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Med Genet B Neuropsychiatr Genet</MedlineTA><NlmUniqueID>101235742</NlmUniqueID><ISSNLinking>1552-4841</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9007-49-2</RegistryNumber><NameOfSubstance UI="D004247">DNA</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.4.3.4</RegistryNumber><NameOfSubstance UI="D008995">Monoamine Oxidase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N" Type="Geographic">Canada</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005190" MajorTopicYN="N">Family</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014644" MajorTopicYN="N">Genetic Variation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006239" MajorTopicYN="N">Haplotypes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007558" MajorTopicYN="N" Type="Geographic">Italy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015810" MajorTopicYN="N">Linkage Disequilibrium</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018598" MajorTopicYN="N">Minisatellite Repeats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008995" MajorTopicYN="N">Monoamine Oxidase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>9</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>2</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>9</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16958037</ArticleId><ArticleId IdType="doi">10.1002/ajmg.b.30380</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8601549</PMID><DateCompleted><Year>1996</Year><Month>05</Month><Day>09</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>57</Volume><Issue>4</Issue><PubDate><Year>1996</Year><Month>Apr</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Factors associated with maintenance antipsychotic treatment of patients with bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>147-51</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Although recent surveys suggest that a substantial number of patients with bipolar disorder receive maintenance treatment with antipsychotic agents, little is known about the clinical factors associated with such treatment in this patient population. The purpose of this study was to identify clinical factors associated with maintenance antipsychotic treatment in patients with bipolar disorder.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Seventy-seven patients who had bipolar disorder and were hospitalized for acute manic or mixed episodes were evaluated according to demographic, diagnostic, illness severity, treatment, and compliance variables at admission and at follow-up 6 months after discharge to determine differences between patients receiving ongoing antipsychotic medications and those maintained on thymoleptics alone.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Fifty-two patients (68%) continued to receive antipsychotics 6 months after discharge. Maintenance antipsychotic treatment at 6-month follow-up was associated with being male, medication noncompliance in the month prior to the index hospitalization, severity of manic symptoms, and prescription of antipsychotic medication at time of discharge.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Despite the risks of neurologic and behavioral side effects associated with protracted antipsychotic treatment and the availability of agents with mood-stabilizing properties such as lithium, valproate, and carbamazepine, antipsychotic maintenance treatment of bipolar disorder is common and associated with several important clinical factors.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Keck</LastName><ForeName>P E</ForeName><Initials>PE</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Cincinnati College of Medicine, Ohio, 45267-0559, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McElroy</LastName><ForeName>S L</ForeName><Initials>SL</Initials></Author><Author ValidYN="Y"><LastName>Strakowski</LastName><ForeName>S M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Balistreri</LastName><ForeName>T M</ForeName><Initials>TM</Initials></Author><Author ValidYN="Y"><LastName>Kizer</LastName><ForeName>D I</ForeName><Initials>DI</Initials></Author><Author ValidYN="Y"><LastName>West</LastName><ForeName>S A</ForeName><Initials>SA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003692">Delayed-Action Preparations</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003692" MajorTopicYN="N">Delayed-Action Preparations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010349" MajorTopicYN="N">Patient Compliance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1996</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1996</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1996</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8601549</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32458337</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>20</Day></DateCompleted><DateRevised><Year>2021</Year><Month>08</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-7365</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>7</Issue><PubDate><Year>2020</Year><Month>10</Month></PubDate></JournalIssue><Title>Metabolic brain disease</Title><ISOAbbreviation>Metab Brain Dis</ISOAbbreviation></Journal><ArticleTitle>The role of long non-coding RNA MALAT1 in patients with bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>1077-1083</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11011-020-00580-9</ELocationID><Abstract><AbstractText>Bipolar disorders are known as chronic, recurrent, and heterogenic diseases. Regarding, diagnosis and treatment of them are very complex. The molecular mechanism and pathophysiology of bipolar disorder are slightly known. Accordingly, long noncoding RNAs are considered as one of the main factors that are dysfunctional in many diseases such as the nervous system diseases. Hence, we aim to investigate the expression of two long non coding RNAs, MALAT1 and UCA1, in patients in bipolar disorder. The levels of MALAT1 and UCA1 lncRNA were evaluated in peripheral blood mononuclear cells (PBMCs) of 50 bipolar patients and 50 healthy controls with real-time PCR. Also, ROC curve analysis and correlation analysis were performed between the gene expression and some clinical features of bipolar individuals. The significant decline of MALAT1 expression level was found in the patients compared to controls; but no significant difference was observed in the UCA1 expression level between the patients and controls. Furthermore, computational analysis of CpG Islands and miRNAs binding sites on LncRNAs, MALAT1, and UCA1 was conducted. Also, The ROC curve area (AUC) of MALAT1 was 0.80. The current results suggest that the expression level of MALAT1 could serve as a potential diagnostic biomarker for bipolar patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shirvani Farsani</LastName><ForeName>Zeinab</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0003-2071-1208</Identifier><AffiliationInfo><Affiliation>Department of Cell and Molecular Biology, Faculty of Life Sciences and Biotechnology, Shahid Beheshti University G.C, Tehran, IR, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zahirodin</LastName><ForeName>Alireza</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Behavioral Science Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IR, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghaderian</LastName><ForeName>Sayyed Mohammad Hossein</ForeName><Initials>SMH</Initials><AffiliationInfo><Affiliation>Urogenital Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IR, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shams</LastName><ForeName>Jamal</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IR, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naghavi Gargari</LastName><ForeName>Bahar</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Basic Sciences, Faculty of Nursing &amp; Midwifery, Shahid Beheshti University of Medical Sciences, IR, Tehran, Iran. bnaghavi@sbmu.ac.ir.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Metab Brain Dis</MedlineTA><NlmUniqueID>8610370</NlmUniqueID><ISSNLinking>0885-7490</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C557041">MALAT1 long non-coding RNA, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D062085">RNA, Long Noncoding</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C515159">UCA1 RNA, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007963" MajorTopicYN="N">Leukocytes, Mononuclear</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062085" MajorTopicYN="N">RNA, Long Noncoding</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Biomarker</Keyword><Keyword MajorTopicYN="Y">Bipolar disorder</Keyword><Keyword MajorTopicYN="Y">Gene expression</Keyword><Keyword MajorTopicYN="Y">Long non-coding RNA</Keyword><Keyword MajorTopicYN="Y">MALAT1</Keyword><Keyword MajorTopicYN="Y">UCA1</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>02</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>05</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32458337</ArticleId><ArticleId IdType="doi">10.1007/s11011-020-00580-9</ArticleId><ArticleId IdType="pii">10.1007/s11011-020-00580-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24947278</PMID><DateCompleted><Year>2016</Year><Month>04</Month><Day>12</Day></DateCompleted><DateRevised><Year>2015</Year><Month>08</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1440-1614</ISSN><JournalIssue CitedMedium="Internet"><Volume>48</Volume><Issue>8</Issue><PubDate><Year>2014</Year><Month>Aug</Month></PubDate></JournalIssue><Title>The Australian and New Zealand journal of psychiatry</Title><ISOAbbreviation>Aust N Z J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Clinical applications of herbal medicines for anxiety and insomnia; targeting patients with bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>705-15</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/0004867414539198</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Patients with bipolar disorder frequently continue to experience residual anxiety and insomnia between mood episodes. In real-world practice, patients increasingly self-prescribe alternative medicines.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We reviewed case reports, open-label, and placebo-controlled trials investigating the use of herbal medicines to treat anxiety and insomnia, and discussed their potential applications for bipolar disorder.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Eleven herbal medicines that have been studied in human subjects are included in this review. Mechanisms of action, efficacy, side effects, and drug-drug interactions are discussed. Based on currently available evidence, valerian seems to be the most promising candidate for insomnia and anxiety in bipolar disorder.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Adjunctive herbal medicines may have the potential to alleviate these symptoms and improve the outcomes of standard treatment, despite limited evidence. Physicians need to have a more in-depth understanding of the evidence of benefits, risks, and drug interactions of alternative treatments.</AbstractText><CopyrightInformation>© The Royal Australian and New Zealand College of Psychiatrists 2014.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Baek</LastName><ForeName>Ji Hyun</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Bipolar Clinic and Research Program, Massachusetts General Hospital, Boston, USA School of Medicine, Sungkyunkwan University, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nierenberg</LastName><ForeName>Andrew A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Bipolar Clinic and Research Program, Massachusetts General Hospital, Boston, USA Department of Psychiatry, Harvard Medical School, Boston, USA anierenberg@partners.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kinrys</LastName><ForeName>Gustavo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Bipolar Clinic and Research Program, Massachusetts General Hospital, Boston, USA Department of Psychiatry, Harvard Medical School, Boston, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>06</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Aust N Z J Psychiatry</MedlineTA><NlmUniqueID>0111052</NlmUniqueID><ISSNLinking>0004-8674</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001007" MajorTopicYN="N">Anxiety</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020843" MajorTopicYN="N">Chamomile</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029001" MajorTopicYN="Y">Herbal Medicine</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D031334" MajorTopicYN="N">Melissa</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029598" MajorTopicYN="N">Passiflora</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008517" MajorTopicYN="N">Phytotherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007319" MajorTopicYN="N">Sleep Initiation and Maintenance Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014632" MajorTopicYN="N">Valerian</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Herbal medicine</Keyword><Keyword MajorTopicYN="N">adjunctive treatment</Keyword><Keyword MajorTopicYN="N">anxiety</Keyword><Keyword MajorTopicYN="N">bipolar disorder</Keyword><Keyword MajorTopicYN="N">insomnia</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24947278</ArticleId><ArticleId IdType="pii">0004867414539198</ArticleId><ArticleId IdType="doi">10.1177/0004867414539198</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23320647</PMID><DateCompleted><Year>2013</Year><Month>08</Month><Day>29</Day></DateCompleted><DateRevised><Year>2013</Year><Month>02</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>2</Issue><PubDate><Year>2013</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Cognitive endophenotypes in a family with bipolar disorder with a risk locus on chromosome 4.</ArticleTitle><Pagination><MedlinePgn>215-22</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bdi.12040</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">  We studied cognitive function in high-risk relatives belonging to a single extended family showing linkage of bipolar disorder to a locus on chromosome 4. High-risk relatives were defined as those that carried the risk haplotype of polymorphic markers, identified in a previous linkage study. This family provided a rare opportunity to characterize a neuropsychological endophenotype in a homogeneous sample of relatives with a common genetic risk factor.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">  Fifteen family members carrying the risk haplotype (eight diagnosed with bipolar disorder or depression and seven with no psychiatric diagnosis), unrelated patients with bipolar disorder (n = 36) and major depressive disorder (n = 40), and healthy control subjects (n = 33) were administered the California Verbal Learning Test, Verbal Fluency Test, Hayling Sentence Completion Test, and Brixton Spatial Anticipation Test to assess verbal memory, verbal fluency, and executive function.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">  Compared with healthy controls, family members carrying the risk haplotype were impaired in indices of memory and executive function. There were no significant differences between unaffected and affected haplotype-carrying family members in any cognitive measure. Pronounced deficits in the encoding stage of verbal memory and category verbal fluency were evident in individuals with the risk haplotype.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">  Verbal learning and semantic verbal fluency impairments may represent a cognitive endophenotype for both bipolar disorder and major depression in relatives of bipolar disorder patients, as impairment was also present in high-risk relatives who had not developed any affective disorder symptoms. These findings suggest that impairment in semantic organization may be linked to the genetic aetiology of bipolar disorder.</AbstractText><CopyrightInformation>© 2013 John Wiley &amp; Sons A/S. Published by Blackwell Publishing Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Drysdale</LastName><ForeName>Emma</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Psychiatry, University of Edinburgh, Royal Edinburgh Hospital, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knight</LastName><ForeName>Helen M</ForeName><Initials>HM</Initials></Author><Author ValidYN="Y"><LastName>McIntosh</LastName><ForeName>Andrew M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Blackwood</LastName><ForeName>Douglas H R</ForeName><Initials>DH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>01</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002894" MajorTopicYN="N">Chromosomes, Human, Pair 4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058068" MajorTopicYN="Y">Endophenotypes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005192" MajorTopicYN="Y">Family Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014706" MajorTopicYN="N">Verbal Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>1</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>1</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>8</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23320647</ArticleId><ArticleId IdType="doi">10.1111/bdi.12040</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">3711035</PMID><DateCompleted><Year>1986</Year><Month>07</Month><Day>09</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>47</Volume><Issue>6</Issue><PubDate><Year>1986</Year><Month>Jun</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Elevated blood neutrophil concentration in mania.</ArticleTitle><Pagination><MedlinePgn>331</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wolf</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007964" MajorTopicYN="N">Leukocytosis</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009504" MajorTopicYN="Y">Neutrophils</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1986</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1986</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1986</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3711035</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27293065</PMID><DateCompleted><Year>2017</Year><Month>09</Month><Day>20</Day></DateCompleted><DateRevised><Year>2017</Year><Month>09</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0013-7006</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>4</Issue><PubDate><Year>2016</Year><Month>Aug</Month></PubDate></JournalIssue><Title>L'Encephale</Title><ISOAbbreviation>Encephale</ISOAbbreviation></Journal><ArticleTitle>[Manic symptoms induced by high doses of baclofen: A case report].</ArticleTitle><Pagination><MedlinePgn>382-3</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.encep.2016.03.015</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0013-7006(16)30088-4</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rivollier</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Inserm UMR 894, laboratoire « physiopathologie des maladies psychiatriques », université Paris Descartes, PRES Sorbonne Paris Cité, Paris, France; Service hospitalo-universitaire, hôpital Sainte-Anne, université Paris Descartes, Paris, France. Electronic address: f.rivollier@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masson</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Service hospitalo-universitaire, hôpital Sainte-Anne, université Paris Descartes, Paris, France; Clinique du Château-de-Garches, 92380 Garches, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><VernacularTitle>Symptômes maniaques induits par de fortes doses de baclofène : à propos d'un cas.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2016</Year><Month>06</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Encephale</MedlineTA><NlmUniqueID>7505643</NlmUniqueID><ISSNLinking>0013-7006</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018755">GABA Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>H789N3FKE8</RegistryNumber><NameOfSubstance UI="D001418">Baclofen</NameOfSubstance></Chemical><Chemical><RegistryNumber>X015L14V0O</RegistryNumber><NameOfSubstance UI="D001960">Bromazepam</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000437" MajorTopicYN="N">Alcoholism</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001418" MajorTopicYN="N">Baclofen</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001960" MajorTopicYN="N">Bromazepam</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018755" MajorTopicYN="N">GABA Agonists</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>03</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>03</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>6</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>6</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27293065</ArticleId><ArticleId IdType="pii">S0013-7006(16)30088-4</ArticleId><ArticleId IdType="doi">10.1016/j.encep.2016.03.015</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8562488</PMID><DateCompleted><Year>1996</Year><Month>03</Month><Day>05</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0920-9964</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><Issue>2</Issue><PubDate><Year>1995</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Schizophrenia research</Title><ISOAbbreviation>Schizophr Res</ISOAbbreviation></Journal><ArticleTitle>A continuum of psychosis, one human gene, and not much else--the case for homogeneity.</ArticleTitle><Pagination><MedlinePgn>135-45</MedlinePgn></Pagination><Abstract><AbstractText>The contention of this paper is that psychoses are not a collection of separate and unrelated diseases, but a set of diverse expressions of a single underlying entity. It will be argued that there is a basic homogeneity of pathogenesis, that there are not multiple predisposing genes but a single gene that is associated with significant diversity. Therefore the problem is a unitary one. The challenge is to identify the nature and function of the gene. It will be argued that the gene is that by which homo sapiens has separated from other primate species, and that the diversity arises from selective pressures which continue to act on this specifically human gene.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Crow</LastName><ForeName>T J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>University Department of Psychiatry, Warneford Hospital, Oxford, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Schizophr Res</MedlineTA><NlmUniqueID>8804207</NlmUniqueID><ISSNLinking>0920-9964</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004292" MajorTopicYN="N">Dominance, Cerebral</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005796" MajorTopicYN="Y">Genes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008957" MajorTopicYN="N">Models, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012641" MajorTopicYN="N">Selection, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012729" MajorTopicYN="N">Sex Chromosome Aberrations</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013045" MajorTopicYN="N">Species Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014960" MajorTopicYN="N">X Chromosome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014998" MajorTopicYN="N">Y Chromosome</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>85</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1995</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1995</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1995</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8562488</ArticleId><ArticleId IdType="pii">0920-9964(95)00059-U</ArticleId><ArticleId IdType="doi">10.1016/0920-9964(95)00059-u</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23920885</PMID><DateCompleted><Year>2015</Year><Month>04</Month><Day>10</Day></DateCompleted><DateRevised><Year>2013</Year><Month>08</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>192</Volume><PubDate><Year>2013</Year></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>Mobile-supported life charting for bipolar patients - user requirements study.</ArticleTitle><Pagination><MedlinePgn>1111</MedlinePgn></Pagination><Abstract><AbstractText>It is assumed that bipolar disorder patients can benefit from monitoring their mood, sleep, medicine intake and behavior which could be both done by patients themselves and in cooperation with health care professionals. This study aims at understanding what is required from a computerized system, as seen from the view of therapists and the patients, and how the newer mobile technologies (smart phones and tablets) can be utilized to support development of such a system. The study focuses on several existing solutions available either freely or on the market. Then these solutions are evaluated by both patients and medical professionals as a part of the system requirements study to be used in a new system development that will utilize mobile technologies to support the performance and patient outcomes. </AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Andersen</LastName><ForeName>Per-Øivin Berg</ForeName><Initials>PØ</Initials><AffiliationInfo><Affiliation>Department of Information Science and Media Studies, University of Bergen, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Babic</LastName><ForeName>Ankica</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><CitationSubset>T</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034201" MajorTopicYN="Y">Computers, Handheld</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016903" MajorTopicYN="N">Drug Monitoring</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016247" MajorTopicYN="N">Information Storage and Retrieval</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008499" MajorTopicYN="Y">Medical Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D063731" MajorTopicYN="Y">Mobile Applications</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020380" MajorTopicYN="N">Needs Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019114" MajorTopicYN="N">Remote Consultation</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="Y">organization &amp; administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014584" MajorTopicYN="N">User-Computer Interface</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>8</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>8</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>4</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23920885</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">3449871</PMID><DateCompleted><Year>1988</Year><Month>06</Month><Day>13</Day></DateCompleted><DateRevised><Year>2018</Year><Month>02</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0254-4962</ISSN><JournalIssue CitedMedium="Print"><Volume>20</Volume><Issue>3-4</Issue><PubDate><Year>1987</Year></PubDate></JournalIssue><Title>Psychopathology</Title><ISOAbbreviation>Psychopathology</ISOAbbreviation></Journal><ArticleTitle>Measurement of subclinical changes during lithium prophylaxis: a longitudinal study.</ArticleTitle><Pagination><MedlinePgn>155-61</MedlinePgn></Pagination><Abstract><AbstractText>Psychological distress was observer-rated with the Brief Psychiatric Rating Scale (BPRS) and self-rated with the Symptom Questionnaire (SQ) every other week for a 6-month period in 9 apparently remitted bipolar patients attending a lithium clinic. Substantial clinical fluctuations in psychopathology were observed with both rating methods. Compared to normal control subjects, patients suffering from bipolar disorder displayed significantly higher BPRS and SQ anxiety, somatization and total distress scores.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Molnar</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, State University of New York, Buffalo.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fava</LastName><ForeName>G A</ForeName><Initials>GA</Initials></Author><Author ValidYN="Y"><LastName>Zielezny</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Spinks</LastName><ForeName>M T</ForeName><Initials>MT</Initials></Author><Author ValidYN="Y"><LastName>Loretan</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Psychopathology</MedlineTA><NlmUniqueID>8401537</NlmUniqueID><ISSNLinking>0254-4962</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>1806D8D52K</RegistryNumber><NameOfSubstance UI="D000639">Amitriptyline</NameOfSubstance></Chemical><Chemical><RegistryNumber>6RZ6XEZ3CR</RegistryNumber><NameOfSubstance UI="D002707">Chlordiazepoxide</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical><Chemical><RegistryNumber>Q3JTX2Q7TU</RegistryNumber><NameOfSubstance UI="D003975">Diazepam</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000639" MajorTopicYN="N">Amitriptyline</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002707" MajorTopicYN="N">Chlordiazepoxide</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003975" MajorTopicYN="N">Diazepam</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="Y">Psychiatric Status Rating Scales</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1987</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1987</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1987</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3449871</ArticleId><ArticleId IdType="doi">10.1159/000284494</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">26417752</PMID><DateCompleted><Year>2015</Year><Month>12</Month><Day>17</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0353-5053</ISSN><JournalIssue CitedMedium="Print"><Volume>27 Suppl 1</Volume><PubDate><Year>2015</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Psychiatria Danubina</Title><ISOAbbreviation>Psychiatr Danub</ISOAbbreviation></Journal><ArticleTitle>'Craziness' and creativity: Psychopathology and Poetry.</ArticleTitle><Pagination><MedlinePgn>S151-4</MedlinePgn></Pagination><Abstract><AbstractText>Not all poets have experienced psychopathology. Conversely, not all those who have experienced psychopathology become poets. The notion, nonetheless, of there being an association between 'craziness' and creativity, contentious though it may be, remains a seductive one. Poetry is both beneficial for the person who is composing or reciting it as well as the person who may be reading or listening to it. Poetry Therapy, which falls under the remit of Art Therapy, is increasingly being recognised as an effective form of adjunctive therapy for the treatment of mental health problems. The main aims of this paper are to explore (and to attempt to elucidate) if there is indeed a relationship between the artistic temperament and mental illness and to comment on the rise and recognition of Art Therapy. </AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hankir</LastName><ForeName>Ahmed</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Bedfordshire Centre for Mental Health Research in Association with Cambridge University, Cambridge, UK, ahmedzakaria@doctors.org.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zaman</LastName><ForeName>Rashid</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Croatia</Country><MedlineTA>Psychiatr Danub</MedlineTA><NlmUniqueID>9424753</NlmUniqueID><ISSNLinking>0353-5053</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001155" MajorTopicYN="N">Art Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003405" MajorTopicYN="Y">Creativity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011037" MajorTopicYN="Y">Poetry as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011599" MajorTopicYN="Y">Psychopathology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="N">Schizophrenic Psychology</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>12</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26417752</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17848830</PMID><DateCompleted><Year>2007</Year><Month>10</Month><Day>29</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1423-033X</ISSN><JournalIssue CitedMedium="Internet"><Volume>40</Volume><Issue>6</Issue><PubDate><Year>2007</Year></PubDate></JournalIssue><Title>Psychopathology</Title><ISOAbbreviation>Psychopathology</ISOAbbreviation></Journal><ArticleTitle>A special coincidence of erotomania and Fregoli syndrome.</ArticleTitle><Pagination><MedlinePgn>468</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brüggemann</LastName><ForeName>Bernd Rüdiger</ForeName><Initials>BR</Initials></Author><Author ValidYN="Y"><LastName>Garlipp</LastName><ForeName>Petra</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>09</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Psychopathology</MedlineTA><NlmUniqueID>8401537</NlmUniqueID><ISSNLinking>0254-4962</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="Y">Delusions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004882" MajorTopicYN="N">Erotica</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007398" MajorTopicYN="N">Interpersonal Relations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021641" MajorTopicYN="N">Recognition, Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012563" MajorTopicYN="N">Schizophrenia, Paranoid</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013577" MajorTopicYN="N">Syndrome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>09</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>09</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>9</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>10</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>9</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17848830</ArticleId><ArticleId IdType="pii">000108127</ArticleId><ArticleId IdType="doi">10.1159/000108127</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11763015</PMID><DateCompleted><Year>2002</Year><Month>05</Month><Day>07</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0271-0749</ISSN><JournalIssue CitedMedium="Print"><Volume>21</Volume><Issue>6</Issue><PubDate><Year>2001</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of clinical psychopharmacology</Title><ISOAbbreviation>J Clin Psychopharmacol</ISOAbbreviation></Journal><ArticleTitle>Therapeutic efficacy of allopurinol in mania associated with hyperuricemia.</ArticleTitle><Pagination><MedlinePgn>621-2</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Machado-Vieira</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Lara</LastName><ForeName>D R</ForeName><Initials>DR</Initials></Author><Author ValidYN="Y"><LastName>Souza</LastName><ForeName>D O</ForeName><Initials>DO</Initials></Author><Author ValidYN="Y"><LastName>Kapczinski</LastName><ForeName>F</ForeName><Initials>F</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychopharmacol</MedlineTA><NlmUniqueID>8109496</NlmUniqueID><ISSNLinking>0271-0749</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>268B43MJ25</RegistryNumber><NameOfSubstance UI="D014527">Uric Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>63CZ7GJN5I</RegistryNumber><NameOfSubstance UI="D000493">Allopurinol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000493" MajorTopicYN="N">Allopurinol</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014527" MajorTopicYN="N">Uric Acid</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>1</Month><Day>5</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>5</Month><Day>8</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>1</Month><Day>5</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11763015</ArticleId><ArticleId IdType="doi">10.1097/00004714-200112000-00017</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">1313210</PMID><DateCompleted><Year>1992</Year><Month>04</Month><Day>29</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>27</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>149</Volume><Issue>4</Issue><PubDate><Year>1992</Year><Month>Apr</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Blunting of clonidine-stimulated growth hormone release in mania.</ArticleTitle><Pagination><MedlinePgn>584</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ansseau</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016420">Comment</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011942">Receptors, Adrenergic, alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>9002-72-6</RegistryNumber><NameOfSubstance UI="D013006">Growth Hormone</NameOfSubstance></Chemical><Chemical><RegistryNumber>MN3L5RMN02</RegistryNumber><NameOfSubstance UI="D003000">Clonidine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Am J Psychiatry. 1991 Jul;148(7):936-8</RefSource><PMID Version="1">1647142</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003000" MajorTopicYN="N">Clonidine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013006" MajorTopicYN="N">Growth Hormone</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011942" MajorTopicYN="N">Receptors, Adrenergic, alpha</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1992</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1992</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1992</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1313210</ArticleId><ArticleId IdType="doi">10.1176/ajp.149.4.584a</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">6504203</PMID><DateCompleted><Year>1985</Year><Month>01</Month><Day>22</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-2162</ISSN><JournalIssue CitedMedium="Print"><Volume>128</Volume><Issue>44</Issue><PubDate><Year>1984</Year><Month>Nov</Month><Day>03</Day></PubDate></JournalIssue><Title>Nederlands tijdschrift voor geneeskunde</Title><ISOAbbreviation>Ned Tijdschr Geneeskd</ISOAbbreviation></Journal><ArticleTitle>[Lithium and pregnancy; psychiatric aspects].</ArticleTitle><Pagination><MedlinePgn>2089-92</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>van Gent</LastName><ForeName>E M</ForeName><Initials>EM</Initials></Author><Author ValidYN="Y"><LastName>Nabarro</LastName><ForeName>G</ForeName><Initials>G</Initials></Author></AuthorList><Language>dut</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Lithium en zwangerschap; psychiatrische aspecten.</VernacularTitle></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Ned Tijdschr Geneeskd</MedlineTA><NlmUniqueID>0400770</NlmUniqueID><ISSNLinking>0028-2162</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000014" MajorTopicYN="N">Abnormalities, Drug-Induced</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005817" MajorTopicYN="N">Genetic Counseling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011248" MajorTopicYN="N">Pregnancy Complications</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1984</Year><Month>11</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1984</Year><Month>11</Month><Day>3</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1984</Year><Month>11</Month><Day>3</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">6504203</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">44865</PMID><DateCompleted><Year>1980</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0013-7006</ISSN><JournalIssue CitedMedium="Print"><Volume>5</Volume><Issue>5 Suppl</Issue><PubDate><Year>1979</Year></PubDate></JournalIssue><Title>L'Encephale</Title><ISOAbbreviation>Encephale</ISOAbbreviation></Journal><ArticleTitle>[Discussion of reports on the pathogenesis of affective disorders].</ArticleTitle><Pagination><MedlinePgn>579-87</MedlinePgn></Pagination><Language>fre</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Discussion des rapports sur les abords pathogéniques des troubles de l'humeur.</VernacularTitle></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Encephale</MedlineTA><NlmUniqueID>7505643</NlmUniqueID><ISSNLinking>0013-7006</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000929">Antidepressive Agents, Tricyclic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018377">Neurotransmitter Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000929" MajorTopicYN="N">Antidepressive Agents, Tricyclic</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002657" MajorTopicYN="N">Child Development</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019965" MajorTopicYN="N">Neurocognitive Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018377" MajorTopicYN="N">Neurotransmitter Agents</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011574" MajorTopicYN="N">Psychoanalytic Theory</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1979</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1979</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1979</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">44865</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31902051</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>29</Day></DateCompleted><DateRevised><Year>2021</Year><Month>03</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1573-076X</ISSN><JournalIssue CitedMedium="Internet"><Volume>44</Volume><Issue>3</Issue><PubDate><Year>2020</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Culture, medicine and psychiatry</Title><ISOAbbreviation>Cult Med Psychiatry</ISOAbbreviation></Journal><ArticleTitle>The Globalization of Biological Psychiatry and the Rise of Bipolar Spectrum Disorder in Iran.</ArticleTitle><Pagination><MedlinePgn>404-432</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11013-019-09665-2</ELocationID><Abstract><AbstractText>In recent years, psychiatry in Iran witnessed a dramatic increase in the use of the diagnosis of bipolar spectrum disorder (BSD). This qualitative study maps the journey of the BSD diagnosis from the West to Iran, examines the controversy surrounding the diagnosis and its treatment, and explores some of the structural factors that facilitate and maintain the widespread use of the BSD diagnosis in Iran and related practices of prescribing neuroleptic and mood stabilizers. The study methods include archival research and semi-structured interviews with 25 prominent Iranian psychiatrists in the field of mood disorders. Results show the importance of factors in addition to economics in driving changes in diagnostic fashion. Most psychiatrists interviewed reported what they viewed as an over-diagnosis of bipolar disorder and over-prescription of mood stabilizers and atypical antipsychotics among Iranian psychiatrists over the past decade. In addition to the influence of leading figures of American psychiatry, the dominance of Western psychiatric classifications and textbooks in Iran's psychiatry, and indirect intervention by pharmaceutical companies, local structural and political factors have played a significant role in the Iranian psychiatric system's embrace of the new concept of bipolarity. In Iran, the medicalization of social conflict has been embraced by government, families, and psychiatrists for cross-cutting purposes. These challenges and the continued controversy over the adoption of American psychiatric fads in a non-Western country like Iran point to the importance of elaborating a more ecosocial and cultural view of psychiatric practice to disentangle some of the complex trade-offs involved in adopting particular modes of diagnostic practice.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mianji</LastName><ForeName>Fahimeh</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Division of Social and Transcultural Psychiatry, Department of Psychiatry, McGill University, Montreal, Canada. fahimehmianji@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Culture and Mental Health Research Unit, Institute of Community and Family Psychiatry, 4333 Chemin de la Côte Ste-Catherine, Montreal, QC, H3T 1E4, Canada. fahimehmianji@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirmayer</LastName><ForeName>Laurence J</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>Division of Social and Transcultural Psychiatry, Department of Psychiatry, McGill University, Montreal, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Culture and Mental Health Research Unit, Institute of Community and Family Psychiatry, 4333 Chemin de la Côte Ste-Catherine, Montreal, QC, H3T 1E4, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Cult Med Psychiatry</MedlineTA><NlmUniqueID>7707467</NlmUniqueID><ISSNLinking>0165-005X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001689" MajorTopicYN="Y">Biological Psychiatry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D038622" MajorTopicYN="Y">Internationality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007492" MajorTopicYN="N" Type="Geographic">Iran</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062528" MajorTopicYN="N">Medicalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bipolar spectrum disorder</Keyword><Keyword MajorTopicYN="N">Global mental health</Keyword><Keyword MajorTopicYN="N">Globalization of American psychiatry</Keyword><Keyword MajorTopicYN="N">Iranian psychiatric system</Keyword><Keyword MajorTopicYN="N">Medicalization</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>1</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>1</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31902051</ArticleId><ArticleId IdType="doi">10.1007/s11013-019-09665-2</ArticleId><ArticleId IdType="pii">10.1007/s11013-019-09665-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12450630</PMID><DateCompleted><Year>2003</Year><Month>04</Month><Day>17</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-1781</ISSN><JournalIssue CitedMedium="Print"><Volume>112</Volume><Issue>3</Issue><PubDate><Year>2002</Year><Month>Nov</Month><Day>15</Day></PubDate></JournalIssue><Title>Psychiatry research</Title><ISOAbbreviation>Psychiatry Res</ISOAbbreviation></Journal><ArticleTitle>Psychomotor changes in melancholic and atypical depression: unipolar and bipolar-II subtypes.</ArticleTitle><Pagination><MedlinePgn>211-20</MedlinePgn></Pagination><Abstract><AbstractText>Psychomotor changes are reported to be 'nearly always present' in the melancholic subtype of major depressive episode (MDE) in DSM-IV-TR, and are believed by some researchers to be markers of melancholia. The aim of this study was to compare melancholic and atypical forms of MDE and to determine whether psychomotor changes are core features of melancholic MDE. The Structured Clinical Interview of DSM-IV was used to consecutively assess 107 unipolar and 164 bipolar-II MDE outpatients. The criteria used to define melancholic and atypical MDE followed DSM-IV-TR. Melancholic MDE was present in 17.7% of patients; atypical MDE, in 35.0%. The group of patients with melancholic MDE had the following differences from the atypical group: higher age, higher age at onset, fewer females, more unipolar cases, fewer bipolar-II cases, lower Global Assessment of Functioning scores, more MDE symptoms, and more psychotic features. Percentages of observable and marked psychomotor changes (agitation and retardation combined) did not differ significantly between the two groups, though the melancholic group tended to have more symptoms. Retardation was significantly more common in melancholic MDE, but its frequency was very low in both melancholic and atypical cases (12.5 vs. 0.0%). Logistic regression controlling for age, gender and illness duration had little effect on the findings, which suggests that psychomotor changes are not core features of melancholic MDE.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Benazzi</LastName><ForeName>Franco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, National Health Service, and Outpatient Psychiatry Private Center, Forlì, Italy. f.benazzi@fo.nettuno.it</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Psychiatry Res</MedlineTA><NlmUniqueID>7911385</NlmUniqueID><ISSNLinking>0165-1781</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019263" MajorTopicYN="N">Dysthymic Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011596" MajorTopicYN="N">Psychomotor Disorders</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>11</Month><Day>27</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>4</Month><Day>18</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>11</Month><Day>27</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12450630</ArticleId><ArticleId IdType="pii">S016517810200241X</ArticleId><ArticleId IdType="doi">10.1016/s0165-1781(02)00241-x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2798596</PMID><DateCompleted><Year>1989</Year><Month>10</Month><Day>31</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-1781</ISSN><JournalIssue CitedMedium="Print"><Volume>29</Volume><Issue>2</Issue><PubDate><Year>1989</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Psychiatry research</Title><ISOAbbreviation>Psychiatry Res</ISOAbbreviation></Journal><ArticleTitle>Specificity of plasma HVA response to dexamethasone in psychotic depression.</ArticleTitle><Pagination><MedlinePgn>177-86</MedlinePgn></Pagination><Abstract><AbstractText>Earlier reports have suggested that dexamethasone significantly increases levels of plasma homovanillic acid (HVA) in normal subjects, but that this effect may be altered in some depressed patients. To investigate the specificity of such alterations, we administered dexamethasone (1 mg p.o. at 11 p.m.) to 33 normal subjects, 27 depressed patients (8 with psychotic features), and 16 schizophrenic patients. Plasma for assay of cortisol and HVA was obtained at 4 p.m. before and on the day following dexamethasone administration. Dexamethasone induced significant increases in plasma HVA in the normal subjects and in the schizophrenic patients, but not in the depressed patients. Indeed, psychotically depressed patients tended to show a dexamethasone-associated decrease in plasma levels of HVA. In contrast to cortisol "suppression" or "nonsuppression," dexamethasone-induced changes in plasma levels of HVA (i.e., increases or decreases) sensitively and specifically discriminated between patients with affective and nonaffective psychoses.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wolkowitz</LastName><ForeName>O M</ForeName><Initials>OM</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of California, San Francisco 94143.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doran</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Breier</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Roy</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Pickar</LastName><ForeName>D</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Psychiatry Res</MedlineTA><NlmUniqueID>7911385</NlmUniqueID><ISSNLinking>0165-1781</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>7S5I7G3JQL</RegistryNumber><NameOfSubstance UI="D003907">Dexamethasone</NameOfSubstance></Chemical><Chemical><RegistryNumber>X77S6GMS36</RegistryNumber><NameOfSubstance UI="D006719">Homovanillic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000341" MajorTopicYN="N">Affective Disorders, Psychotic</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003907" MajorTopicYN="Y">Dexamethasone</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006719" MajorTopicYN="N">Homovanillic Acid</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="N">Schizophrenic Psychology</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1989</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1989</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1989</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2798596</ArticleId><ArticleId IdType="pii">0165-1781(89)90032-2</ArticleId><ArticleId IdType="doi">10.1016/0165-1781(89)90032-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">4037984</PMID><DateCompleted><Year>1985</Year><Month>10</Month><Day>22</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-990X</ISSN><JournalIssue CitedMedium="Print"><Volume>42</Volume><Issue>10</Issue><PubDate><Year>1985</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Archives of general psychiatry</Title><ISOAbbreviation>Arch Gen Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Thought disorder in children at risk for psychosis.</ArticleTitle><Pagination><MedlinePgn>1004-13</MedlinePgn></Pagination><Abstract><AbstractText>The Thought Disorder Index, which has been shown to be a reliable and valid measure of the degree of thought disorder in adult psychotic patients, was used to assess thought disorder in children. Normal children aged 5 to 16 years, hospitalized psychotic children, children hospitalized for nonpsychotic behavioral problems, and children born to a psychotic mother (high-risk) were tested. In the normal sample, thought disorder decreases with age. The level of thought disorder in psychotic children and high-risk children was about three times higher than that of the normal children, whereas the level of thought disorder of the nonpsychotic hospitalized children was no different from that of the normal children. The study also detected differences in the kinds of thought disorder that characterize the psychotic and high-risk groups vs the other children. The presence of thought disorder may be thought of as a useful indicator of the diathesis for functional psychosis. The Thought Disorder Index merits selection as a tool for investigating thought disorder as a potential precursor variable in studies of children at risk for schizophrenia and manic-depressive illness.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Arboleda</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Holzman</LastName><ForeName>P S</ForeName><Initials>PS</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH-31154</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH-31340</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Gen Psychiatry</MedlineTA><NlmUniqueID>0372435</NlmUniqueID><ISSNLinking>0003-990X</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002657" MajorTopicYN="N">Child Development</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007361" MajorTopicYN="N">Intelligence Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012392" MajorTopicYN="N">Rorschach Test</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="N">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013850" MajorTopicYN="Y">Thinking</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014705" MajorTopicYN="N">Verbal Behavior</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1985</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1985</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1985</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">4037984</ArticleId><ArticleId IdType="doi">10.1001/archpsyc.1985.01790330084010</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">3117777</PMID><DateCompleted><Year>1987</Year><Month>11</Month><Day>25</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>48</Volume><Issue>10</Issue><PubDate><Year>1987</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Clonazepam in the treatment of bipolar disorder in patients with non-lithium-induced renal insufficiency.</ArticleTitle><Pagination><MedlinePgn>424</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Amiel</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Bryan</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Herjanic</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>2BMD2GNA4V</RegistryNumber><NameOfSubstance UI="D016651">Lithium Carbonate</NameOfSubstance></Chemical><Chemical><RegistryNumber>5PE9FDE8GB</RegistryNumber><NameOfSubstance UI="D002998">Clonazepam</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002998" MajorTopicYN="N">Clonazepam</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007674" MajorTopicYN="N">Kidney Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016651" MajorTopicYN="N">Lithium Carbonate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1987</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1987</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1987</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3117777</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">27243619</PMID><DateCompleted><Year>2017</Year><Month>10</Month><Day>02</Day></DateCompleted><DateRevised><Year>2019</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>201</Volume><PubDate><Year>2016</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Empirically supported psychosocial interventions for bipolar disorder: Current state of the research.</ArticleTitle><Pagination><MedlinePgn>203-14</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2016.05.018</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0165-0327(16)30374-3</ELocationID><Abstract><AbstractText Label="OBJECTIVES">Bipolar disorder requires psychiatric medications, but even guideline-concordant treatment fails to bring many patients to remission or keep them euthymic. To address this gap, researchers have developed adjunctive psychotherapies. The purpose of this paper is to critically review the evidence for the efficacy of manualized psychosocial interventions for bipolar disorder.</AbstractText><AbstractText Label="METHODS">We conducted a search of the literature to examine recent (2007-present), randomized controlled studies of the following psychotherapy interventions for bipolar disorder: psychoeducation (PE), cognitive behavioral therapy (CBT), interpersonal and social rhythm therapy (IPSRT), dialectical behavior therapy (DBT), mindfulness-based cognitive therapy (MBCT), and family therapies such as family focused therapy (FFT).</AbstractText><AbstractText Label="RESULTS">All of the psychotherapy interventions appear to be effective in reducing depressive symptoms. Psychoeducation and CBT are associated with increased time to mood episode relapse or recurrence. MBCT has demonstrated a particular effectiveness in improving depressive and anxiety symptoms. Online psychotherapy interventions, programs combining one or more psychotherapy interventions, and targeted interventions centering on particular symptoms have been the focus of recent, randomized controlled studies in bipolar disorder.</AbstractText><AbstractText Label="CONCLUSIONS">Psychotherapy interventions for the treatment of bipolar disorder have substantial evidence for efficacy. The next challenge will to disseminate these psychotherapies into the community.</AbstractText><CopyrightInformation>Copyright © 2016 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Salcedo</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychology and Neuroscience, University of North Carolina, Chapel Hill, Chapel Hill, NC, USA. Electronic address: ssalcedo@email.unc.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gold</LastName><ForeName>Alexandra K</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sheikh</LastName><ForeName>Sana</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA; Department of Psychology, Suffolk University, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marcus</LastName><ForeName>Peter H</ForeName><Initials>PH</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nierenberg</LastName><ForeName>Andrew A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deckersbach</LastName><ForeName>Thilo</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sylvia</LastName><ForeName>Louisa G</ForeName><Initials>LG</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>05</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015928" MajorTopicYN="N">Cognitive Behavioral Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036262" MajorTopicYN="Y">Empirical Research</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005196" MajorTopicYN="N">Family Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064866" MajorTopicYN="N">Mindfulness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011613" MajorTopicYN="Y">Psychotherapy</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Bipolar disorder</Keyword><Keyword MajorTopicYN="Y">Cognitive behavior therapy</Keyword><Keyword MajorTopicYN="Y">Dialectical behavior therapy</Keyword><Keyword MajorTopicYN="Y">Family therapy</Keyword><Keyword MajorTopicYN="Y">Interpersonal and social rhythm therapy</Keyword><Keyword MajorTopicYN="Y">Psychosocial interventions</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>03</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>04</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>05</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>6</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>6</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>10</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27243619</ArticleId><ArticleId IdType="pii">S0165-0327(16)30374-3</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2016.05.018</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16903925</PMID><DateCompleted><Year>2008</Year><Month>06</Month><Day>23</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>8 Suppl 1</Volume><PubDate><Year>2006</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Abstracts of the 2nd Biennial Conference of the International Society for Bipolar Disorders, Edinburgh, Scotland, 2-4 August 2006.</ArticleTitle><Pagination><MedlinePgn>1-72</MedlinePgn></Pagination><Language>eng</Language><PublicationTypeList><PublicationType UI="D016423">Congress</PublicationType><PublicationType UI="D016424">Overall</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>8</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>6</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>8</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16903925</ArticleId><ArticleId IdType="pii">BDI379_1</ArticleId><ArticleId IdType="doi">10.1111/j.1399-5618.2006.00379_1.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16542181</PMID><DateCompleted><Year>2006</Year><Month>08</Month><Day>11</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1398-5647</ISSN><JournalIssue CitedMedium="Print"><Volume>8</Volume><Issue>2</Issue><PubDate><Year>2006</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Differential working memory impairment in bipolar disorder and schizophrenia: effects of lifetime history of psychosis.</ArticleTitle><Pagination><MedlinePgn>117-23</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Although bipolar disorder and schizophrenia have long been viewed as distinct illnesses, there is growing evidence that these two complex diseases share some common genes, which may manifest as overlapping neuropsychological impairments. Although working memory dysfunction has been proposed to be central to the pathophysiology of schizophrenia, it has received less attention in studies of bipolar disorder.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">We applied measures of working memory to patients with schizophrenia (n = 15), patients with schizoaffective disorder (n = 15), patients with psychotic (n = 11) and non-psychotic (n = 15) bipolar disorder, and demographically matched healthy subjects (n = 32), in order to determine the extent to which these groups show common or unique impairments.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">While patients with bipolar disorder (with and without psychotic features) and those with schizophrenia/schizoaffective disorder were impaired on backward digit span, only patients with a lifetime history of psychotic features, regardless of diagnosis, were impaired on spatial delayed response task.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Backward digit span performance is comparable in bipolar disorder and schizophrenia, and may be an appropriate endophenotypic marker that cuts across diagnostic categories. In contrast, spatial working memory performance clearly distinguishes non-psychotic bipolar disorder patients from patients with functional psychosis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Glahn</LastName><ForeName>David C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>Division of Schizophrenia and Related Disorders, Department of Psychiatry, The University of Texas Health Science Center at San Antonio, San Antonio, TX 78229-3900, USA. glahn@uthscsa.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bearden</LastName><ForeName>Carrie E</ForeName><Initials>CE</Initials></Author><Author ValidYN="Y"><LastName>Cakir</LastName><ForeName>Sibel</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Barrett</LastName><ForeName>Jennifer A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Najt</LastName><ForeName>Pablo</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Serap Monkul</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Maples</LastName><ForeName>Natalie</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Velligan</LastName><ForeName>Dawn I</ForeName><Initials>DI</Initials></Author><Author ValidYN="Y"><LastName>Soares</LastName><ForeName>Jair C</ForeName><Initials>JC</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>M01-RR-01346</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH 01736</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH 068662</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="Y">Schizophrenia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="Y">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>3</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>8</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>3</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16542181</ArticleId><ArticleId IdType="pii">BDI296</ArticleId><ArticleId IdType="doi">10.1111/j.1399-5618.2006.00296.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2608788</PMID><DateCompleted><Year>1990</Year><Month>02</Month><Day>21</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-1781</ISSN><JournalIssue CitedMedium="Print"><Volume>29</Volume><Issue>3</Issue><PubDate><Year>1989</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Psychiatry research</Title><ISOAbbreviation>Psychiatry Res</ISOAbbreviation></Journal><ArticleTitle>Clinical correlates of cerebral blood flow in depression.</ArticleTitle><Pagination><MedlinePgn>323-6</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reischies</LastName><ForeName>F M</ForeName><Initials>FM</Initials><AffiliationInfo><Affiliation>Dept. of Psychiatry, Free University of Berlin, FRG.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hedde</LastName><ForeName>J P</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Drochner</LastName><ForeName>R</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Psychiatry Res</MedlineTA><NlmUniqueID>7911385</NlmUniqueID><ISSNLinking>0165-1781</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014980">Xenon Radioisotopes</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002560" MajorTopicYN="N">Cerebrovascular Circulation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="Y">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012039" MajorTopicYN="N">Regional Blood Flow</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015899" MajorTopicYN="Y">Tomography, Emission-Computed, Single-Photon</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014980" MajorTopicYN="N">Xenon Radioisotopes</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1989</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1989</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1989</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2608788</ArticleId><ArticleId IdType="pii">0165-1781(89)90078-4</ArticleId><ArticleId IdType="doi">10.1016/0165-1781(89)90078-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">3279721</PMID><DateCompleted><Year>1988</Year><Month>04</Month><Day>14</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0001-690X</ISSN><JournalIssue CitedMedium="Print"><Volume>77</Volume><Issue>1</Issue><PubDate><Year>1988</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Acta psychiatrica Scandinavica</Title><ISOAbbreviation>Acta Psychiatr Scand</ISOAbbreviation></Journal><ArticleTitle>Treatment of depression with clonazepam.</ArticleTitle><Pagination><MedlinePgn>81-6</MedlinePgn></Pagination><Abstract><AbstractText>The antidepressive effect of an anticonvulsant clonazepam was studied with maximum daily dose of 1.5 to 6.0 mg (mean 3.4 mg) in 27 patients with major depression (n = 18) or bipolar disorder (n = 9). Two of them dropped out at an early stage of the treatment, and the antidepressive effect of clonazepam was evaluated for the remaining 25 patients. A marked to moderate improvement was obtained for 21 patients (84%), and the onset of the antidepressive effect of clonazepam appeared within 1 week in most of the cases who responded to the therapy. The total scores on the Hamilton Depression Rating Scale and the Beck Self-Rating Scale were significantly reduced after the clonazepam treatment. Side effects occurred in 14 patients, but most of them were not severe. From these results, it is thought that clonazepam might be useful as an antidepressant for patients in whom conventional antidepressant treatment are contraindicated.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kishimoto</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neuropsychiatry, Tottori University School of Medicine, Yonago, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kamata</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Sugihara</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Ishiguro</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Hazama</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Mizukawa</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Kunimoto</LastName><ForeName>N</ForeName><Initials>N</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Acta Psychiatr Scand</MedlineTA><NlmUniqueID>0370364</NlmUniqueID><ISSNLinking>0001-690X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>5PE9FDE8GB</RegistryNumber><NameOfSubstance UI="D002998">Clonazepam</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002998" MajorTopicYN="N">Clonazepam</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011581" MajorTopicYN="N">Psychological Tests</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1988</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1988</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1988</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3279721</ArticleId><ArticleId IdType="doi">10.1111/j.1600-0447.1988.tb05082.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28139249</PMID><DateCompleted><Year>2017</Year><Month>11</Month><Day>09</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1545-7206</ISSN><JournalIssue CitedMedium="Internet"><Volume>58</Volume><Issue>2</Issue><PubDate><MedlineDate>2017 Mar - Apr</MedlineDate></PubDate></JournalIssue><Title>Psychosomatics</Title><ISOAbbreviation>Psychosomatics</ISOAbbreviation></Journal><ArticleTitle>Interventions to Improve Pharmacological Adherence Among Adults With Psychotic Spectrum Disorders and Bipolar Disorder: A Systematic Review.</ArticleTitle><Pagination><MedlinePgn>101-112</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0033-3182(16)30100-1</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.psym.2016.09.009</ELocationID><Abstract><AbstractText Label="BACKGROUND">It is unclear as to which interventions are effective at improving medication adherence in individuals with serious and persistent mental illness. The goal of this systematic review is to synthesize evidence examining the effectiveness, harms, and costs of interventions to improve medication adherence in patients with psychotic spectrum disorders and bipolar disorder.</AbstractText><AbstractText Label="METHODS">We conducted a systematic search of several electronic databases through January 2015 using a structured search strategy. Studies were included if they involved adult patients in general mental health settings, reported both measures of medication adherence and clinical outcomes, and were of sufficient methodological rigor. Studies were quality assessed and synthesized using established methods.</AbstractText><AbstractText Label="RESULTS">We identified 24 studies that met inclusion criteria. Overall, 20 studies addressed interventions in patients with psychotic spectrum disorders. These interventions varied widely, with generally mixed findings contributing to low or insufficient strength of evidence; studies involving family members and technology interventions were the most consistently associated with a positive effect; however, the strength of the evidence was low because of intervention heterogeneity. The evidence was insufficient to determine the effectiveness of interventions in patients with bipolar disorder.</AbstractText><AbstractText Label="CONCLUSIONS">In individuals with psychotic spectrum disorders, interventions with family members or technology had the most consistent positive effect on adherence, although replication with objective adherence measures along with evaluation of harms and costs is needed. There was insufficient evidence to draw conclusions about interventions in individuals with bipolar disorder.</AbstractText><CopyrightInformation>Copyright © 2017 The Academy of Psychosomatic Medicine. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hartung</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>College of Pharmacy, Oregon State University/Oregon Health &amp; Science University, Portland, OR.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Low</LastName><ForeName>Allison</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>VA Evidence-based Synthesis Program, Portland, OR.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jindai</LastName><ForeName>Kazuaki</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>VA Portland Health Care System, Portland, OR; Oregon Health &amp; Science University, Portland, OR.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mansoor</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>VA Portland Health Care System, Portland, OR; Oregon Health &amp; Science University, Portland, OR.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Judge</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>VA Portland Health Care System, Portland, OR; Oregon Health &amp; Science University, Portland, OR.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mendelson</LastName><ForeName>Aaron</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Oregon Health &amp; Science University, Portland, OR.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kansagara</LastName><ForeName>Devan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>VA Evidence-based Synthesis Program, Portland, OR; VA Portland Health Care System, Portland, OR; Oregon Health &amp; Science University, Portland, OR.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Motu Apuaka</LastName><ForeName>Makalapua</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>VA Evidence-based Synthesis Program, Portland, OR.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Freeman</LastName><ForeName>Michele</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>VA Evidence-based Synthesis Program, Portland, OR; Oregon Health &amp; Science University, Portland, OR.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kondo</LastName><ForeName>Karli</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>VA Evidence-based Synthesis Program, Portland, OR; Oregon Health &amp; Science University, Portland, OR. Electronic address: karli.kondo@va.gov.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>10</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Psychosomatics</MedlineTA><NlmUniqueID>0376506</NlmUniqueID><ISSNLinking>0033-3182</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003376" MajorTopicYN="N">Counseling</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055118" MajorTopicYN="N">Medication Adherence</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010353" MajorTopicYN="N">Patient Education as Topic</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011613" MajorTopicYN="N">Psychotherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">bipolar disorder</Keyword><Keyword MajorTopicYN="Y">medication adherence</Keyword><Keyword MajorTopicYN="Y">pharmacotherapy</Keyword><Keyword MajorTopicYN="Y">schizophrenia.</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>06</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>09</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>09</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>2</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>11</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>2</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28139249</ArticleId><ArticleId IdType="pii">S0033-3182(16)30100-1</ArticleId><ArticleId IdType="doi">10.1016/j.psym.2016.09.009</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19505727</PMID><DateCompleted><Year>2010</Year><Month>04</Month><Day>14</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>121</Volume><Issue>1-2</Issue><PubDate><Year>2010</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Clinical and neurocognitive predictors of functional outcome in bipolar euthymic patients: a long-term, follow-up study.</ArticleTitle><Pagination><MedlinePgn>156-60</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2009.05.014</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To identify clinical and neurocognitive predictors of long-term functional outcome in patients with bipolar disorder</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A total of 32 subjects who met criteria for bipolar I or II disorder were recruited from the Barcelona Bipolar Disorder Program and were assessed clinically and neuropsychologically at baseline. After an average 4-year follow-up, they were interviewed with the Functioning Assessment Short Test (FAST) to assess functional outcome. Multivariate analyses were applied to identify clinical and neurocognitive predictors of functional outcome.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The main regression model for predictors of overall psychosocial functioning identified subclinical depressive symptoms (beta=0.516, t=3.51, p=0.002), and free delayed recall in a verbal memory task (beta=-0.314, t=-2.144, p=0.041), accounting for 36% of the variance. Specific predictors of occupational functioning were, again, subthreshold depression (beta=0.435, t=2.8, p=0.009) and a measure of executive function, digits backwards (beta=-0.347, t=-2.23, p=0.034). This model explained around 28% of the variance (corrected R(2)=0.28; F=6.38, gl=2, p=0.004).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Subdepressive symptomatology together with neurocognitive impairments related to verbal memory and executive functions are predictor variables of long-term functional outcome in bipolar disorder.</AbstractText><CopyrightInformation>2009 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bonnín</LastName><ForeName>C M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Bipolar Disorders Program, Institute of Neurosciences, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martínez-Arán</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Torrent</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Pacchiarotti</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Rosa</LastName><ForeName>A R</ForeName><Initials>AR</Initials></Author><Author ValidYN="Y"><LastName>Franco</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Murru</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Sanchez-Moreno</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Vieta</LastName><ForeName>E</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>06</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014227">Triazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>2BMD2GNA4V</RegistryNumber><NameOfSubstance UI="D016651">Lithium Carbonate</NameOfSubstance></Chemical><Chemical><RegistryNumber>614OI1Z5WI</RegistryNumber><NameOfSubstance UI="D014635">Valproic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>U3H27498KS</RegistryNumber><NameOfSubstance UI="D000077213">Lamotrigine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="Y">Affect</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077213" MajorTopicYN="N">Lamotrigine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016651" MajorTopicYN="N">Lithium Carbonate</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011939" MajorTopicYN="N">Mental Recall</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012917" MajorTopicYN="N">Social Adjustment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014227" MajorTopicYN="N">Triazines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014635" MajorTopicYN="N">Valproic Acid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>03</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2009</Year><Month>05</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>05</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>6</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>6</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19505727</ArticleId><ArticleId IdType="pii">S0165-0327(09)00223-7</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2009.05.014</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">9063910</PMID><DateCompleted><Year>1997</Year><Month>03</Month><Day>14</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0940-1334</ISSN><JournalIssue CitedMedium="Print"><Volume>246</Volume><Issue>2</Issue><PubDate><Year>1996</Year></PubDate></JournalIssue><Title>European archives of psychiatry and clinical neuroscience</Title><ISOAbbreviation>Eur Arch Psychiatry Clin Neurosci</ISOAbbreviation></Journal><ArticleTitle>Diagnosis and six-month stability of negative symptoms in psychotic disorders.</ArticleTitle><Pagination><MedlinePgn>63-70</MedlinePgn></Pagination><Abstract><AbstractText>Negative symptoms were examined in 150 primarily first-admission patients diagnosed with schizophrenia, schizoaffective disorder, psychotic depression, psychotic bipolar disorder, and 'other' psychoses. The analysis focused on patients who were rated on the Scale for the Assessment of Negative Symptoms (SANS) within 45 days of admission and at follow-up 6 months later. Significantly more schizophrenics had moderate to severe negative symptoms at each time point compared with other psychotic patients. The SANS scores were found to be relatively stable over time in all five diagnostic groups. Although the DSM-IV includes alogia, affective flattening, and avolition in the A criterion for schizophrenia, only alogia and affective flattening were found to be specific to this disorder. Our results point to the existence and enduring quality of negative symptoms in the early phase of psychosis and its specificity to schizophrenia even at this early stage.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fennig</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Science, State University of New York at Stony Brook 11794-8790, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bromet</LastName><ForeName>E J</ForeName><Initials>EJ</Initials></Author><Author ValidYN="Y"><LastName>Galambos</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Putnam</LastName><ForeName>K</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>44801</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur Arch Psychiatry Clin Neurosci</MedlineTA><NlmUniqueID>9103030</NlmUniqueID><ISSNLinking>0940-1334</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="N">Schizophrenic Psychology</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1996</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1996</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1996</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9063910</ArticleId><ArticleId IdType="doi">10.1007/BF02274895</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Acta Psychiatr Scand. 1989 Jun;79(6):613-8</Citation><ArticleIdList><ArticleId IdType="pubmed">2763854</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 1988 Jun;176(6):359-63</Citation><ArticleIdList><ArticleId IdType="pubmed">3373198</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 1984;10(3):371-87</Citation><ArticleIdList><ArticleId IdType="pubmed">6474100</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1992 Aug;49(8):624-9</Citation><ArticleIdList><ArticleId IdType="pubmed">1637252</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 1987 May-Jun;28(3):229-35</Citation><ArticleIdList><ArticleId IdType="pubmed">3595110</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1979 Jul;136(7):944-7</Citation><ArticleIdList><ArticleId IdType="pubmed">453357</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Arch Psychiatry Neurol Sci. 1986;236(3):139-47</Citation><ArticleIdList><ArticleId IdType="pubmed">3803397</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 1992 Sep;43(3):215-22</Citation><ArticleIdList><ArticleId IdType="pubmed">1438621</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 1991 Jan-Feb;32(1):88-94</Citation><ArticleIdList><ArticleId IdType="pubmed">2001626</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1988 May;145(5):578-83</Citation><ArticleIdList><ArticleId IdType="pubmed">3358462</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 1991 Jul-Aug;5(1):51-9</Citation><ArticleIdList><ArticleId IdType="pubmed">1854677</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 1992 May;22(2):361-5</Citation><ArticleIdList><ArticleId IdType="pubmed">1615103</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 1986 Jul-Aug;27(4):276-86</Citation><ArticleIdList><ArticleId IdType="pubmed">3731764</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1989 Aug;46(8):711-8</Citation><ArticleIdList><ArticleId IdType="pubmed">2568824</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1994 Aug;151(8):1200-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8037256</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1989 Jan;154:52-7</Citation><ArticleIdList><ArticleId IdType="pubmed">2775975</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 1995 Sep;92(3):173-7</Citation><ArticleIdList><ArticleId IdType="pubmed">7484193</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 1992;18(2):243-55</Citation><ArticleIdList><ArticleId IdType="pubmed">1621071</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacol Bull. 1988;24(1):112-7</Citation><ArticleIdList><ArticleId IdType="pubmed">3387514</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62</Citation><ArticleIdList><ArticleId IdType="pubmed">14399272</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12507738</PMID><DateCompleted><Year>2003</Year><Month>04</Month><Day>23</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>73</Volume><Issue>1-2</Issue><PubDate><Year>2003</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>The dual factor structure of self-rated MDQ hypomania: energized-activity versus irritable-thought racing.</ArticleTitle><Pagination><MedlinePgn>59-64</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Bipolar II is diagnosed in a clinically depressed patient by documenting history of hypomania. Therefore, it is of great significance for both clinical and research purposes to characterize the factor structure of hypomania.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Among consecutive depressive outpatients-126 major depressives and 187 bipolar II-diagnosed by the Structured Clinical Interview for DSM-IV (Clinician Version), 181 who had clinically recovered from depression were administered the Mood Disorder Questionnaire (MDQ of. Am. J. Psychiatry 157, 1873). The MDQ is a newly developed, psychometrically validated self-report screening instrument for bipolar spectrum disorders. It screens for lifetime history of manic/hypomanic symptoms by including yes/no items covering all DSM-IV symptoms of mania/hypomania. The MDQ symptom interrelationships were studied by principal component analysis with varimax rotation.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Hypomanic symptoms occurring in &gt;50% were racing thoughts, increased energy and social activity, and irritability. Factor analysis revealed two factors: 'Energized-Activity' (eigenvalue=3.1) and 'Irritability-Racing Thoughts' (eigenvalue=1.5).</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Cross-sectional assessment.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Self-assessment of past hypomanic symptoms by patients, during clinical remission from depression, revealed two independent hypomanic factors, neither of which comprised euphoria. Hypomanic behavior appears to be more fundamental for the diagnosis of hypomania than elated mood accorded priority in DSM-IV; of hypomanic moods, irritability had greater significance than elation. It would appear that self-report of euphoria is less likely when hypomanias are brief (&gt;or=2 vs. &gt;or=4 days). The main implication for busy clinical practice is that energized activity and irritable mood associated with racing thoughts represent the modal experiences of hypomania among bipolar II outpatients; euphoria is neither sensitive, nor pathognomonic, in the diagnosis of these patients. These conclusions accord with recommendations made many years ago for the diagnosis of hypomania among cyclothymic patients [. Am. J. Psychiatry 134, 1227].</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Benazzi</LastName><ForeName>Franco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, National Health Service, Forlí, Italy. f.benazzi@fo.nettuno.it</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akiskal</LastName><ForeName>Hagop S</ForeName><Initials>HS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005163" MajorTopicYN="N">Factor Analysis, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007508" MajorTopicYN="N">Irritable Mood</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012647" MajorTopicYN="N">Self-Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012919" MajorTopicYN="N">Social Behavior</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>1</Month><Day>1</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>4</Month><Day>24</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>1</Month><Day>1</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12507738</ArticleId><ArticleId IdType="pii">S0165032702003336</ArticleId><ArticleId IdType="doi">10.1016/s0165-0327(02)00333-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16054228</PMID><DateCompleted><Year>2006</Year><Month>02</Month><Day>06</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>88</Volume><Issue>1</Issue><PubDate><Year>2005</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Screening for bipolar disorders using a French version of the Mood Disorder Questionnaire (MDQ).</ArticleTitle><Pagination><MedlinePgn>103-8</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Bipolar disorders remain much too often unrecognized and subsequently inappropriately treated. This paper presents the translation into French and validation of the MDQ, a screening instrument for bipolar spectrum disorders, in an adult psychiatric sample. Modifications of its criteria for a positive screening as well as its test-retest reliability are also addressed.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A sample of 96 patients, attending outpatient treatment programs and suffering from mood disorders, completed the MDQ before being interviewed according to the mood module of the structured clinical interview for DSM-IV (SCID). They completed the MDQ a second time 1 month later, in order to examine its stability over time.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">According to the SCID interview, 54 patients were suffering from bipolar disorder and 42 from unipolar disorder. Among the bipolar sample, the MDQ identified 74.1% of them, with higher sensitivity in bipolar I (90.3%) than bipolar II (52.4%) and 90.5% specificity. Lowering the level of impairment required for positive screening led to improved sensitivity for bipolar II patients (76.2%). The French MDQ demonstrated adequate internal consistency (Cronbach alpha=0.89). Its test-retest reliability proved to be satisfactory, with a kappa coefficient of 0.79. Similar stability over a 1-month interval was obtained for bipolar type I and type II (kappa=0.75 and 0.77, respectively).</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Similarly to the American version, the French MDQ has lower sensitivity for bipolar II disorders.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The performance of the French MDQ is comparable to the one reported in the original American study conducted with a similar patient population. In a psychiatric outpatient sample, the French MDQ proves to be a feasible and reliable screening instrument.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Weber Rouget</LastName><ForeName>Béatrice</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Programme bipolaire, Secteur 2-Jonction, Département de Psychiatrie, HUG, Geneva, Switzerland. beatrice.weber-rouget@hcuge.ch</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gervasoni</LastName><ForeName>Nicola</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Dubuis</LastName><ForeName>Vesselin</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Gex-Fabry</LastName><ForeName>Marianne</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Bondolfi</LastName><ForeName>Guido</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Aubry</LastName><ForeName>Jean-Michel</ForeName><Initials>JM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000553" MajorTopicYN="N">Ambulatory Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003155" MajorTopicYN="N">Community Mental Health Centers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003431" MajorTopicYN="Y">Cross-Cultural Comparison</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005240" MajorTopicYN="N">Feasibility Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007802" MajorTopicYN="Y">Language</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008403" MajorTopicYN="N">Mass Screening</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010555" MajorTopicYN="N">Personality Inventory</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="Y">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>02</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2005</Year><Month>06</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>06</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>8</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>2</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>8</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16054228</ArticleId><ArticleId IdType="pii">S0165-0327(05)00161-8</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2005.06.005</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19239828</PMID><DateCompleted><Year>2009</Year><Month>07</Month><Day>13</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1547-3325</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>1</Issue><PubDate><MedlineDate>2009 Jan-Mar</MedlineDate></PubDate></JournalIssue><Title>Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists</Title><ISOAbbreviation>Ann Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Association between antipsychotic combination therapy and treatment adherence among individuals with bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>3-16</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">This study investigated the effect on antipsychotic treatment adherence of combining quetiapine or risperidone with lithium, anticonvulsants, and/or antidepressants among bipolar individuals with predominantly manic/mixed or depressive symptoms.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Treatment episodes with quetiapine or risperidone were identified from individuals with medical claims for bipolar/manic disorder. Multiple regression analysis was used to evaluate the impact of antipsychotic combinations on treatment adherence, as measured by intensity (medication possession ratio [MPR]) and treatment duration.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among mixed/manic individuals, combination therapies were associated with lower antipsychotic MPRs than monotherapy (P&lt; .05), with MPR decreasing with number of medications. Quetiapine showed a similar pattern among depressed individuals, whereas risperidone showed a weaker association. For both subgroups, antipsychotic combinations with anticonvulsants were associated with lower MPRs than combinations with lithium. For manic/mixed individuals, combining quetiapine with an anticonvulsant and lithium was associated with shorter treatment durations than quetiapine alone (P &lt;or= .05). For manic/mixed individuals receiving risperidone, treatment duration was not affected by type of combination therapy. Among depressed subgroups, treatment duration was unrelated to combination therapy.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Adherence to quetiapine and risperidone may be affected by whether they are prescribed alone or as combination therapy, the combination strategy, and the predominant symptomatology of the individual.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gianfrancesco</LastName><ForeName>Frank D</ForeName><Initials>FD</Initials><AffiliationInfo><Affiliation>HECON Associates, Inc., Montgomery Village, MD 20886, USA. frank_gianfrancesco@heconassoc.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sajatovic</LastName><ForeName>Martha</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Tafesse</LastName><ForeName>Eskinder</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Ruey-Hua</ForeName><Initials>RH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Clin Psychiatry</MedlineTA><NlmUniqueID>8911021</NlmUniqueID><ISSNLinking>1040-1237</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003987">Dibenzothiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>2BMD2GNA4V</RegistryNumber><NameOfSubstance UI="D016651">Lithium Carbonate</NameOfSubstance></Chemical><Chemical><RegistryNumber>2S3PL1B6UJ</RegistryNumber><NameOfSubstance UI="D000069348">Quetiapine Fumarate</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003987" MajorTopicYN="N">Dibenzothiazepines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D038801" MajorTopicYN="N">International Classification of Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016651" MajorTopicYN="N">Lithium Carbonate</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010349" MajorTopicYN="N">Patient Compliance</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069348" MajorTopicYN="N">Quetiapine Fumarate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>2</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>2</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>7</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19239828</ArticleId><ArticleId IdType="pii">acp_2101a</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10569132</PMID><DateCompleted><Year>1999</Year><Month>12</Month><Day>13</Day></DateCompleted><DateRevised><Year>2004</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1091-4269</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>2</Issue><PubDate><Year>1999</Year></PubDate></JournalIssue><Title>Depression and anxiety</Title><ISOAbbreviation>Depress Anxiety</ISOAbbreviation></Journal><ArticleTitle>Chronic depression subtypes: a 257 case study.</ArticleTitle><Pagination><MedlinePgn>81-4</MedlinePgn></Pagination><Abstract><AbstractText>The aim of the study was to compare Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) three subtypes of chronic depression (chronic major depressive episode [MDE] occurring in major depressive and bipolar II disorders, dysthymic disorder with MDE, and MDE without full interepisode recovery occurring in major depressive and bipolar II disorders) with each other, and with nonchronic depression, and to find if this subdivision was supported by clinical data. Two hundred and fifty seven consecutive MDE outpatients were interviewed with the Structured Clinical Interview for DSM-IV, the Montgomery Asberg Depression Rating Scale (MADRS), and the Global Assessment of Functioning (GAF) scale. Clinical variables (age, age at onset, duration of illness, severity, gender, recurrences, atypical and psychotic features, axis I comorbidity, bipolar II, and unipolar diagnoses) were compared among the chronic depression subtypes, and versus nonchronic depression. Chronic MDE had significantly less comorbidity than the other two chronic depression subtypes. All the other variables were not significantly different. Chronic depression subtypes had significantly longer duration of illness, less comorbidity, and more recurrences than nonchronic depression. These findings do not support the DSM-IV subtyping of chronic depression.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Benazzi</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Public Hospital Morgagni, Forlì, Italy. f.benazzi@fo.nettuno.it</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Depress Anxiety</MedlineTA><NlmUniqueID>9708816</NlmUniqueID><ISSNLinking>1091-4269</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000553" MajorTopicYN="N">Ambulatory Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019263" MajorTopicYN="N">Dysthymic Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>11</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>8</Month><Day>12</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>11</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10569132</ArticleId><ArticleId IdType="pii">10.1002/(SICI)1520-6394(1999)10:2&lt;81::AID-DA8&gt;3.0.CO;2-W</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32404258</PMID><DateCompleted><Year>2020</Year><Month>10</Month><Day>27</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2509</ISSN><JournalIssue CitedMedium="Internet"><Volume>222</Volume><PubDate><Year>2020</Year><Month>08</Month></PubDate></JournalIssue><Title>Schizophrenia research</Title><ISOAbbreviation>Schizophr Res</ISOAbbreviation></Journal><ArticleTitle>Coronovirus infection as a novel delusional topic.</ArticleTitle><Pagination><MedlinePgn>541-542</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0920-9964(20)30261-9</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.schres.2020.05.009</ELocationID><Abstract><AbstractText>Delusional topics tend to rapidly incorporate popular hot topical issues. Thus, the current coronavirus COVID-19 pandemic has rapidly reached delusional themes in patients with psychiatric disorders. Here we present the clinical case of a Spanish woman with bipolar disorder that included coronavirus infection in her delusional themes even faster than the real infection reached mainland Spain.</AbstractText><CopyrightInformation>© 2020 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ovejero</LastName><ForeName>Santiago</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Jimenez Diaz Foundation Hospital, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baca-García</LastName><ForeName>Enrique</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Jimenez Diaz Foundation Hospital, Madrid, Spain; Department of Psychiatry, Madrid Autonomous University, Madrid, Spain; Department of Psychiatry, Rey Juan Carlos University Hospital, Móstoles, Spain; Department of Psychiatry, General Hospital of Villalba, Madrid, Spain; Department of Psychiatry, Infanta Elena University Hospital, Valdemoro, Spain; Universidad Catolica del Maule, Talca, Chile; Department of Psychiatry, Centre Hospitalier Universitaire de Nîmes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barrigón</LastName><ForeName>María Luisa</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Jimenez Diaz Foundation Hospital, Madrid, Spain; Department of Psychiatry, Madrid Autonomous University, Madrid, Spain. Electronic address: luisa.barrigon@fjd.es.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Schizophr Res</MedlineTA><NlmUniqueID>8804207</NlmUniqueID><ISSNLinking>0920-9964</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="Y">Coronavirus Infections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="Y">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="Y">Pneumonia, Viral</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">COVID-19</Keyword><Keyword MajorTopicYN="Y">Coronavirus</Keyword><Keyword MajorTopicYN="Y">Delusional topics</Keyword><Keyword MajorTopicYN="Y">Psychosis</Keyword></KeywordList><CoiStatement>None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>04</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>04</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>05</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32404258</ArticleId><ArticleId IdType="pii">S0920-9964(20)30261-9</ArticleId><ArticleId IdType="doi">10.1016/j.schres.2020.05.009</ArticleId><ArticleId IdType="pmc">PMC7205660</ArticleId></ArticleIdList><?pmcsd ?><ReferenceList><Reference><Citation>Lancet Psychiatry. 2020 Apr;7(4):e21</Citation><ArticleIdList><ArticleId IdType="pubmed">32199510</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Feb 29;395(10225):684-685</Citation><ArticleIdList><ArticleId IdType="pubmed">32078803</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Psychiatry. 2020 Apr;7(4):300-302</Citation><ArticleIdList><ArticleId IdType="pubmed">32085840</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Public Health. 2020 May;5(5):e251-e252</Citation><ArticleIdList><ArticleId IdType="pubmed">32199083</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopathology. 2003 Jan-Feb;36(1):6-12</Citation><ArticleIdList><ArticleId IdType="pubmed">12679586</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Netw Open. 2020 Mar 2;3(3):e203976</Citation><ArticleIdList><ArticleId IdType="pubmed">32202646</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Psychiatry. 2020 Apr;7(4):e15-e16</Citation><ArticleIdList><ArticleId IdType="pubmed">32085839</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23449699</PMID><DateCompleted><Year>2013</Year><Month>05</Month><Day>14</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1530-8561</ISSN><JournalIssue CitedMedium="Internet"><Volume>59</Volume><Issue>3</Issue><PubDate><Year>2013</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Clinical chemistry</Title><ISOAbbreviation>Clin Chem</ISOAbbreviation></Journal><ArticleTitle>Increased prolactin concentrations in a patient with bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>473-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1373/clinchem.2011.176925</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of South Carolina, Charleston, SC 29425, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sofronescu</LastName><ForeName>Alina</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Short</LastName><ForeName>Baron</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Nahas</LastName><ForeName>Ziad</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Yusheng</ForeName><Initials>Y</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Clin Chem</MedlineTA><NlmUniqueID>9421549</NlmUniqueID><ISSNLinking>0009-9147</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9002-62-4</RegistryNumber><NameOfSubstance UI="D011388">Prolactin</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Clin Chem. 2013 Mar;59(3):476</RefSource><PMID Version="1">23449700</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Clin Chem. 2013 Mar;59(3):476-7</RefSource><PMID Version="1">23449701</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006966" MajorTopicYN="N">Hyperprolactinemia</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011388" MajorTopicYN="N">Prolactin</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>3</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>3</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23449699</ArticleId><ArticleId IdType="pii">59/3/473</ArticleId><ArticleId IdType="doi">10.1373/clinchem.2011.176925</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19016095</PMID><DateCompleted><Year>2009</Year><Month>02</Month><Day>27</Day></DateCompleted><DateRevised><Year>2009</Year><Month>11</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1440-1614</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>12</Issue><PubDate><Year>2008</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The Australian and New Zealand journal of psychiatry</Title><ISOAbbreviation>Aust N Z J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>In high spirits: some links between alcohol use and bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>1066-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/00048670802512164</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Parker</LastName><ForeName>Gordon</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>University of New South Wales, Australia. g.parker@unsw.edu.au</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Aust N Z J Psychiatry</MedlineTA><NlmUniqueID>0111052</NlmUniqueID><ISSNLinking>0004-8674</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="N">Affect</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000435" MajorTopicYN="N">Alcoholic Intoxication</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000437" MajorTopicYN="N">Alcoholism</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001143" MajorTopicYN="N">Arousal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009042" MajorTopicYN="N">Motivation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012651" MajorTopicYN="N">Self Medication</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012919" MajorTopicYN="N">Social Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>11</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>2</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>11</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19016095</ArticleId><ArticleId IdType="pii">905605216</ArticleId><ArticleId IdType="doi">10.1080/00048670802512164</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11048910</PMID><DateCompleted><Year>2001</Year><Month>02</Month><Day>01</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0149-2918</ISSN><JournalIssue CitedMedium="Print"><Volume>22</Volume><Issue>9</Issue><PubDate><Year>2000</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Clinical therapeutics</Title><ISOAbbreviation>Clin Ther</ISOAbbreviation></Journal><ArticleTitle>Use of lamotrigine in a patient with bipolar disorder and psychiatric comorbidity.</ArticleTitle><Pagination><MedlinePgn>1146-8</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ballasiotes</LastName><ForeName>A A</ForeName><Initials>AA</Initials></Author><Author ValidYN="Y"><LastName>Skaer</LastName><ForeName>T L</ForeName><Initials>TL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Ther</MedlineTA><NlmUniqueID>7706726</NlmUniqueID><ISSNLinking>0149-2918</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014227">Triazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>U3H27498KS</RegistryNumber><NameOfSubstance UI="D000077213">Lamotrigine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017831" MajorTopicYN="Y">Diagnosis, Dual (Psychiatry)</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077213" MajorTopicYN="N">Lamotrigine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019966" MajorTopicYN="N">Substance-Related Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014227" MajorTopicYN="N">Triazines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>10</Month><Day>26</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>2</Month><Day>28</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>10</Month><Day>26</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11048910</ArticleId><ArticleId IdType="pii">S0149-2918(00)80090-9</ArticleId><ArticleId IdType="doi">10.1016/S0149-2918(00)80090-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12676078</PMID><DateCompleted><Year>2003</Year><Month>04</Month><Day>17</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0094-3509</ISSN><JournalIssue CitedMedium="Print"><Volume>Suppl</Volume><PubDate><Year>2003</Year><Month>Mar</Month></PubDate></JournalIssue><Title>The Journal of family practice</Title><ISOAbbreviation>J Fam Pract</ISOAbbreviation></Journal><ArticleTitle>Treating acute mania.</ArticleTitle><Pagination><MedlinePgn>S10-3</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Frye</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>UCLA Bipolar Disorder Research Program, Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles School of Medicine, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gitlin</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Altshuler</LastName><ForeName>Lori L</ForeName><Initials>LL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Fam Pract</MedlineTA><NlmUniqueID>7502590</NlmUniqueID><ISSNLinking>0094-3509</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018020">Lithium Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>3G0285N20N</RegistryNumber><NameOfSubstance UI="D010890">Pirenzepine</NameOfSubstance></Chemical><Chemical><RegistryNumber>614OI1Z5WI</RegistryNumber><NameOfSubstance UI="D014635">Valproic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>N7U69T4SZR</RegistryNumber><NameOfSubstance UI="D000077152">Olanzapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018020" MajorTopicYN="N">Lithium Compounds</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077152" MajorTopicYN="N">Olanzapine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010890" MajorTopicYN="N">Pirenzepine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014635" MajorTopicYN="N">Valproic Acid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>24</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>4</Month><Day>5</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>4</Month><Day>18</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>4</Month><Day>5</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12676078</ArticleId><ArticleId IdType="pii">jfp_0103_5203_S3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22548902</PMID><DateCompleted><Year>2012</Year><Month>08</Month><Day>31</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>3</Issue><PubDate><Year>2012</Year><Month>May</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Six-month outcomes of customized adherence enhancement (CAE) therapy in bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>291-300</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1399-5618.2012.01010.x</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">There are few psychosocial interventions specifically focused on improved treatment adherence in people with bipolar disorder (BD). Customized adherence enhancement (CAE) is a needs-based, manualized approach intended to improve medication adherence in individuals with BD. This was a six-month prospective trial of a CAE among 43 medication non-adherent individuals with BD who were receiving treatment in a community mental health clinic (CMHC).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">CAE was flexibly administered in modules applied as indicated by an initial adherence vulnerabilities screening. Screening identified reasons for non-adherence and modules were then administered using pre-set criteria. CAE effects were evaluated at six-week, three-month, and six-month follow-up. The six-month follow-up was our primary time point of interest. The primary outcome was change from baseline in adherence using the Tablets Routine Questionnaire (TRQ) and pill counts. Secondary outcomes included change from baseline in BD symptoms [Hamilton Depression Rating Scale (HAM-D), Young Mania Rating Scale (YMRS), and Brief Psychiatric Rating Scale (BPRS)].</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Subjects completed 86% of scheduled sessions, with only two individuals (5%) not participating in any sessions. The number of dropouts at six months was 12 (28%). Mean baseline non-adherence by TRQ was 48% [standard error (SE) 4.8%] missed tablets within the previous week and 51% (4.1%) missed tablets within the previous month. At six-month follow-up, mean TRQ non-adherence improved to 25% (6.8%) missed tablets for the previous week (p = 0.002) and 21% (5.5%) for the previous month (p &lt; 0.001). Symptoms improved, with a change in the baseline mean (SE) BPRS of 43.6 (1.8) versus an endpoint of 36.1 (2.3) (p = 0.001), and baseline mean (SE) HAM-D of 17.8 (1.1) versus an endpoint of 15.3 (1.6) (p = 0.044).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">CAE was associated with improvements in adherence, symptoms, and functional status. Controlled trials are needed to confirm these preliminary findings.</AbstractText><CopyrightInformation>© 2012 John Wiley and Sons A/S.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sajatovic</LastName><ForeName>Martha</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry Department of Neurology and Neurological Outcomes Center, Case Western Reserve University, Cleveland, OH 44106, USA. martha.sajatovic@uhhospitals.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levin</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Tatsuoka</LastName><ForeName>Curtis</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Micula-Gondek</LastName><ForeName>Weronika</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Fuentes-Casiano</LastName><ForeName>Edna</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Bialko</LastName><ForeName>Christopher S</ForeName><Initials>CS</Initials></Author><Author ValidYN="Y"><LastName>Cassidy</LastName><ForeName>Kristin A</ForeName><Initials>KA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R34 MH078967-03</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R34 MH078967-02</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R34 MH078967</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R34 MH078967-01A1</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R34MH078967</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000534" MajorTopicYN="Y">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015928" MajorTopicYN="N">Cognitive Behavioral Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010349" MajorTopicYN="N">Patient Compliance</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>5</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>5</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22548902</ArticleId><ArticleId IdType="doi">10.1111/j.1399-5618.2012.01010.x</ArticleId><ArticleId IdType="pmc">PMC3342843</ArticleId><ArticleId IdType="mid">NIHMS365118</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57</Citation><ArticleIdList><ArticleId IdType="pubmed">9881538</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2007 Apr;64(4):419-26</Citation><ArticleIdList><ArticleId IdType="pubmed">17404119</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2002 Dec;4(6):386-92</Citation><ArticleIdList><ArticleId IdType="pubmed">12519098</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2009;70 Suppl 4:1-46; quiz 47-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19686636</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1995 May;166(5):654-9</Citation><ArticleIdList><ArticleId IdType="pubmed">7620753</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Care. 1986 Jan;24(1):67-74</Citation><ArticleIdList><ArticleId IdType="pubmed">3945130</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Schizophr Relat Psychoses. 2010 Apr;4(1):74-91</Citation><ArticleIdList><ArticleId IdType="pubmed">20643631</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 2009 Sep;60(9):1182-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19723732</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2004 Oct 1;56(7):467-75</Citation><ArticleIdList><ArticleId IdType="pubmed">15450781</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1992 Aug;25(4):261-9</Citation><ArticleIdList><ArticleId IdType="pubmed">1430662</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Psychopharmacol. 2010 Jan;25(1):1-16</Citation><ArticleIdList><ArticleId IdType="pubmed">20041478</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 2010 May;198(5):370-2</Citation><ArticleIdList><ArticleId IdType="pubmed">20458200</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacopsychiatry. 1988 May;21(3):121-5</Citation><ArticleIdList><ArticleId IdType="pubmed">3406049</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2002 Nov;159(11):1927-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12411230</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Ment Health Nurs. 2008 Oct;15(8):649-53</Citation><ArticleIdList><ArticleId IdType="pubmed">18803739</ArticleId></ArticleIdList></Reference><Reference><Citation>Adm Policy Ment Health. 2011 Mar;38(2):86-95</Citation><ArticleIdList><ArticleId IdType="pubmed">20549327</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2003 Apr;60(4):402-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12695318</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychopharmacol. 2003 Dec;17(4 Suppl):3-6</Citation><ArticleIdList><ArticleId IdType="pubmed">14964624</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2006 Jun;8(3):232-41</Citation><ArticleIdList><ArticleId IdType="pubmed">16696824</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 2006 Jan;57(1):56-62</Citation><ArticleIdList><ArticleId IdType="pubmed">16399963</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 2006 Jul;57(7):959-65</Citation><ArticleIdList><ArticleId IdType="pubmed">16816280</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychopharmacol. 2007 Aug;27(4):412-4</Citation><ArticleIdList><ArticleId IdType="pubmed">17632236</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1991 Aug;22(4):211-9</Citation><ArticleIdList><ArticleId IdType="pubmed">1939930</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1978 Nov;133:429-35</Citation><ArticleIdList><ArticleId IdType="pubmed">728692</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2008 Apr;107(1-3):53-62</Citation><ArticleIdList><ArticleId IdType="pubmed">17822779</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Ther. 2008 Jul;30(7):1358-74</Citation><ArticleIdList><ArticleId IdType="pubmed">18691997</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2004 Feb;109(2):83-90</Citation><ArticleIdList><ArticleId IdType="pubmed">14725587</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2005 Jul;162(7):1281-90</Citation><ArticleIdList><ArticleId IdType="pubmed">15994710</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacol Bull. 2010;43(3):5-14</Citation><ArticleIdList><ArticleId IdType="pubmed">21150842</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Clin Psychiatry. 2009 Jan-Mar;21(1):3-16</Citation><ArticleIdList><ArticleId IdType="pubmed">19239828</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 2004 Mar;55(3):264-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15001726</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1979 Jul 20;36(8 Spec No):866-9</Citation><ArticleIdList><ArticleId IdType="pubmed">454105</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Pract. 2010 Sep;16(5):306-24</Citation><ArticleIdList><ArticleId IdType="pubmed">20859108</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochrane Database Syst Rev. 2008 Apr 16;(2):CD000011</Citation><ArticleIdList><ArticleId IdType="pubmed">18425859</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Clin Psychopharmacol. 2008 Nov;23(6):305-16</Citation><ArticleIdList><ArticleId IdType="pubmed">18854718</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2002 Apr;159(4 Suppl):1-50</Citation><ArticleIdList><ArticleId IdType="pubmed">11958165</ArticleId></ArticleIdList></Reference><Reference><Citation>CNS Neurosci Ther. 2010 Oct;16(5):308-15</Citation><ArticleIdList><ArticleId IdType="pubmed">21050421</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62</Citation><ArticleIdList><ArticleId IdType="pubmed">14399272</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 2012 Feb 1;63(2):176-8</Citation><ArticleIdList><ArticleId IdType="pubmed">22302337</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2002 May;63(5):384-90</Citation><ArticleIdList><ArticleId IdType="pubmed">12019661</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 2001 Jun;52(6):805-11</Citation><ArticleIdList><ArticleId IdType="pubmed">11376229</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 1993;19(3):609-18</Citation><ArticleIdList><ArticleId IdType="pubmed">7901897</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1998 Jan;55(1):49-55</Citation><ArticleIdList><ArticleId IdType="pubmed">9435760</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropsychiatr. 2000 Sep;12(3):128-30</Citation><ArticleIdList><ArticleId IdType="pubmed">26975270</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 2008 Jul;59(7):753-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18586992</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2006 Feb;67(2):222-32</Citation><ArticleIdList><ArticleId IdType="pubmed">16566617</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2005;7 Suppl 3:5-69</Citation><ArticleIdList><ArticleId IdType="pubmed">15952957</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychosom Res. 2010 Dec;69(6):591-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21109048</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 2009 Mar-Apr;50(2):100-7</Citation><ArticleIdList><ArticleId IdType="pubmed">19216885</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2003 Feb;60(2):145-52</Citation><ArticleIdList><ArticleId IdType="pubmed">12578431</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2000 Sep 15;48(6):582-92</Citation><ArticleIdList><ArticleId IdType="pubmed">11018229</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Pharmacol. 2007 Feb;7(1):22-6</Citation><ArticleIdList><ArticleId IdType="pubmed">17055337</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Geriatr Psychiatry. 2007 Oct;22(10):992-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17323327</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Pract. 2011 Jan;17(1):5-20</Citation><ArticleIdList><ArticleId IdType="pubmed">21266890</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 1994;20(2):297-310</Citation><ArticleIdList><ArticleId IdType="pubmed">7916162</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 2007 Jun;58(6):855-63</Citation><ArticleIdList><ArticleId IdType="pubmed">17535948</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 2008 Sep;16(9):718-26</Citation><ArticleIdList><ArticleId IdType="pubmed">18070834</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1988 Jul 2;2(8601):15-7</Citation><ArticleIdList><ArticleId IdType="pubmed">2898622</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 2005 Jul-Aug;46(4):272-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16175758</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2002 Mar;105(3):164-72</Citation><ArticleIdList><ArticleId IdType="pubmed">11939969</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2007 Jul 1;62(1):7-16</Citation><ArticleIdList><ArticleId IdType="pubmed">17240360</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 1997 Dec 5;73(3):159-71</Citation><ArticleIdList><ArticleId IdType="pubmed">9481807</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2007 Sep;9(6):656-64</Citation><ArticleIdList><ArticleId IdType="pubmed">17845282</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1991 Feb;158:197-200</Citation><ArticleIdList><ArticleId IdType="pubmed">1707323</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Rev Psychiatry. 2007 Apr;19(2):107-12</Citation><ArticleIdList><ArticleId IdType="pubmed">17464788</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2009 Jun;115(3):360-6</Citation><ArticleIdList><ArticleId IdType="pubmed">18996600</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 1988 Aug;78(2):198-200</Citation><ArticleIdList><ArticleId IdType="pubmed">3223319</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">6348035</PMID><DateCompleted><Year>1983</Year><Month>09</Month><Day>20</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>44</Volume><Issue>8 Pt 2</Issue><PubDate><Year>1983</Year><Month>Aug</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Anxiety/depression: current management and future directions. Biologic markers and treatment response.</ArticleTitle><Pagination><MedlinePgn>30-40</MedlinePgn></Pagination><Abstract><AbstractText>The use of biologic markers, particularly the dexamethasone suppression test, in both diagnosis and patient management is reviewed. It is suggested that the DST is best used to support the clinical diagnosis by lending an objectivity similar to that available in other areas of medicine. Guidelines for administration and interpretation of the test are provided.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Carroll</LastName><ForeName>B J</ForeName><Initials>BJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>7S5I7G3JQL</RegistryNumber><NameOfSubstance UI="D003907">Dexamethasone</NameOfSubstance></Chemical><Chemical><RegistryNumber>WI4X0X7BPJ</RegistryNumber><NameOfSubstance UI="D006854">Hydrocortisone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000553" MajorTopicYN="N">Ambulatory Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003907" MajorTopicYN="Y">Dexamethasone</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006854" MajorTopicYN="N">Hydrocortisone</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007031" MajorTopicYN="N">Hypothalamus</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008032" MajorTopicYN="N">Limbic System</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>88</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1983</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1983</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1983</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">6348035</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19018233</PMID><DateCompleted><Year>2009</Year><Month>01</Month><Day>07</Day></DateCompleted><DateRevised><Year>2008</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1473-5873</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>6</Issue><PubDate><Year>2008</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Psychiatric genetics</Title><ISOAbbreviation>Psychiatr Genet</ISOAbbreviation></Journal><ArticleTitle>Phosphodiesterase-4A expression is reduced in cerebella of patients with bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>282-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/YPG.0b013e3283060fb8</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The cAMP-specific phosphodiesterase-4 (PDE4) gene family has four members (PDE4 A, B, C, and D) and is the target of several potential therapeutic inhibitors. Recently, PDE4A5 has been shown to bind with disrupted in schizophrenia 1 (DISC1), which has been identified as a risk factor for schizophrenia, bipolar disorder, and major depression. We sought to examine whether PDE4A5 expression was altered in cerebella of patients with schizophrenia, bipolar disorder, and major depression.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We measured protein levels of PDE4A isoforms in cerebella of patients with schizophrenia, bipolar disorder, and major depression versus matched controls using sodium dodecyl sulfate polyacrylamide gel electrophoresis and western blotting.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We observed that specific isoforms of PDE4A were reduced in cerebella of patients with bipolar disorder, whereas there was no change in patients with schizophrenia or major depression.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our results are the first to show that PDE4A expression is altered in patients with bipolar disorder and provide potential new therapeutic avenues for treatment of this disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fatemi</LastName><ForeName>S Hossein</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Division of Neuroscience Research, University of Minnesota, Minneapolis, Minnesota 55455, USA. fatem002@umn.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reutiman</LastName><ForeName>Teri J</ForeName><Initials>TJ</Initials></Author><Author ValidYN="Y"><LastName>Folsom</LastName><ForeName>Timothy D</ForeName><Initials>TD</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Susanne</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Psychiatr Genet</MedlineTA><NlmUniqueID>9106748</NlmUniqueID><ISSNLinking>0955-8829</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.1.4.17</RegistryNumber><NameOfSubstance UI="D054703">Cyclic Nucleotide Phosphodiesterases, Type 4</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002531" MajorTopicYN="N">Cerebellum</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054703" MajorTopicYN="N">Cyclic Nucleotide Phosphodiesterases, Type 4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004591" MajorTopicYN="N">Electrophoresis, Polyacrylamide Gel</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>11</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>1</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>11</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19018233</ArticleId><ArticleId IdType="doi">10.1097/YPG.0b013e3283060fb8</ArticleId><ArticleId IdType="pii">00041444-200812000-00004</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">32936585</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>01</Day></DateCompleted><DateRevised><Year>2021</Year><Month>09</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-1145</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>5</Issue><PubDate><Year>2020</Year><Month>09</Month></PubDate></JournalIssue><Title>Journal of psychiatric practice</Title><ISOAbbreviation>J Psychiatr Pract</ISOAbbreviation></Journal><ArticleTitle>Pharmacological Treatment for Comorbid Bipolar Disorder and Obsessive-Compulsive Disorder in Adults.</ArticleTitle><Pagination><MedlinePgn>383-393</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/PRA.0000000000000499</ELocationID><Abstract><AbstractText>Comorbidity between bipolar disorder (BD) and obsessive-compulsive disorder (OCD) is fairly common, and the treatment of these conditions when comorbid is challenging. Serotonin reuptake inhibitors, the first option for treatment of OCD, can worsen BD symptoms, and mood stabilizers are generally not efficacious for OCD. Our goal in this article is to assess the clinical effectiveness of pharmacotherapies for comorbid BD-OCD in adults. We searched the Medline, Embase, and Cochrane Central Register of Controlled Trials databases on April 30, 2017, and we also searched the reference lists of identified articles. Studies published beginning January 1, 2007 were included, without language restrictions. Narrative and systematic reviews, letters to the editor, and book chapters were excluded. Two authors independently assessed the quality of the studies and extracted data. Seven studies met our inclusion criteria. Findings from double-blind, randomized, placebo-controlled trials were pooled for analysis. Findings from this pooled analysis indicated that augmentation of mood-stabilizer treatment with glutamate modulator agents (topiramate or memantine) may favor full response of obsessive-compulsive symptoms (risk ratio: 2.62, 95% confidence interval: 1.45-4.74) in patients with BD type I and OCD in the manic phase, and that it does not significantly induce adverse effects (risk ratio: 1.26, 95% confidence interval: 0.53-3.01). Results of a narrative synthesis of observational studies indicated greater efficacy of mood-stabilizer treatment, with serotonin reuptake inhibitors less used. Findings from studies employing different designs were not compared, and our results should be interpreted cautiously.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Netto</LastName><ForeName>Vitor DE Mello</ForeName><Initials>VM</Initials></Author><Author ValidYN="Y"><LastName>Flores</LastName><ForeName>Carolina A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Pallanti</LastName><ForeName>Stefano</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Psychiatr Pract</MedlineTA><NlmUniqueID>100901141</NlmUniqueID><ISSNLinking>1527-4160</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017367">Serotonin Uptake Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009771" MajorTopicYN="N">Obsessive-Compulsive Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017367" MajorTopicYN="N">Serotonin Uptake Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>16</Day><Hour>16</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32936585</ArticleId><ArticleId IdType="doi">10.1097/PRA.0000000000000499</ArticleId><ArticleId IdType="pii">00131746-202009000-00005</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:617–627.</Citation></Reference><Reference><Citation>Nabavi B, Mitchell AJ, Nutt D. A lifetime prevalence of comorbidity between bipolar affective disorder and anxiety disorders: a meta-analysis of 52 interview-based studies of psychiatric population. EBioMedicine. 2015;2:1405–1419.</Citation></Reference><Reference><Citation>Saraf G, Paul I, Viswanath B, et al. Bipolar disorder comorbidity in patients with a primary diagnosis of OCD. Int J Psychiatry Clin Pract. 2017;21:70–74.</Citation></Reference><Reference><Citation>Jeon S, Baek JH, Yang SY, et al. Exploration of comorbid obsessive-compulsive disorder in patients with bipolar disorder: the clinic-based prevalence rate, symptoms nature and clinical correlates. J Affect Disord. 2018;225:227–233.</Citation></Reference><Reference><Citation>Veale D, Miles S, Smallcombe N, et al. Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis. BMC Psychiatry. 2014;14:317.</Citation></Reference><Reference><Citation>Arrojo-Romero M, Tajes Alonso M, de Leon J. Lamotrigine augmentation of serotonin reuptake inhibitors in severe and long-term treatment-resistant obsessive-compulsive disorder. Case Rep Psychiatry. 2013;2013:1–4.</Citation></Reference><Reference><Citation>Hollander E, Osso BD. Topiramate plus paroxetine in treatment-resistant obsessive-compulsive disorder. Int Clin Psychopharmacol. 2006;21:189–191.</Citation></Reference><Reference><Citation>Timpano KR, Rubenstein LM, Murphy DL. Phenomenological features and clinical impact of affective disorders in OCD: a focus on the bipolar disorder and OCD connection. Depress Anxiety. 2012;29:226–233.</Citation></Reference><Reference><Citation>Amerio A, Odone A, Liapis CC, et al. Diagnostic validity of comorbid bipolar disorder and obsessive-compulsive disorder: a systematic review. Acta Psychiatr Scand. 2014;129:343–358.</Citation></Reference><Reference><Citation>Amerio A, Odone A, Marchesi C, et al. Treatment of comorbid bipolar disorder and obsessive-compulsive disorder: a systematic review. J Affect Disord. 2014;166:258–263.</Citation></Reference><Reference><Citation>Todd RD, Botteron KN. Etiology and genetics of early-onset mood disorders. Child Adolesc Psychiatr Clin N Am. 2002;11:499–518.</Citation></Reference><Reference><Citation>Maj M. “Psychiatric comorbidity”: an artefact of current diagnostic systems? Br J Psychiatry. 2005;186:182–184.</Citation></Reference><Reference><Citation>Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statemen. PLoS Med. 2009;6:e1000097.</Citation></Reference><Reference><Citation>Singh J. Mendeley: a free research management tool for desktop and web. J Pharmacol Pharmacother. 2010;1:62–63.</Citation></Reference><Reference><Citation>Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Chichester: Wiley-Blackwell; 2008.</Citation></Reference><Reference><Citation>Viswanathan M, Berkman ND. Development of the RTI item bank on risk of bias and precision of observational studies. J Clin Epidemiol. 2012;65:163–178.</Citation></Reference><Reference><Citation>The Nordic Cochrane Centre. Review Manager (RevMan). The Cochrane Collaboration; 2014.</Citation></Reference><Reference><Citation>Bisol LW, Lara DR. Improvement of obsessive-compulsive disorder with divalproex and lamotrigine in two patients with bipolar II disorder. Pharmacopsychiatry. 2009;42:37–38..</Citation></Reference><Reference><Citation>Laurito LD, Fontenelle LF, Kahn DA. Hoarding symptoms respond to treatment for rapid cycling bipolar II disorder. J Psychiatr Pract. 2016;22:50–55.</Citation></Reference><Reference><Citation>Fornaro M. Obsessive-compulsive disorder with bipolar diathesis following isotretinoin therapy remitting upon treatment with olanzapine and fluvoxamine. Neuropsychiatr Dis Treat. 2010;6:719–722.</Citation></Reference><Reference><Citation>Uguz F. Successful treatment of comorbid obsessive-compulsive disorder with aripiprazole in three patients with bipolar disorder. Gen Hosp Psychiatry. 2010;32:556–558.</Citation></Reference><Reference><Citation>Kim SW, Berk L, Kulkarni J, et al. Impact of comorbid anxiety disorders and obsessive-compulsive disorder on 24-month clinical outcomes of bipolar I disorder. J Affect Disord. 2014;166:243–248.</Citation></Reference><Reference><Citation>Sahraian A, Bigdeli M, Ghanizadeh A, et al. Topiramate as an adjuvant treatment for obsessive compulsive symptoms in patients with bipolar disorder: a randomized double blind placebo controlled clinical trial. J Affect Disord. 2014;166:201–205.</Citation></Reference><Reference><Citation>Sahraian A, Jahromi LR, Ghanizadeh A, et al. Memantine as an adjuvant treatment for obsessive compulsive symptoms in manic phase of bipolar disorder: a randomized, double-blind, placebo-controlled clinical trial. J Clin Psychopharmacol. 2017;37:246–249.</Citation></Reference><Reference><Citation>Amerio A, Tonna M, Odone A, et al. Treatment of comorbid bipolar disorder and anxiety disorders: a great challenge to modern psychiatry. Aust N Z J Psychiatry. 2015;50:699–700.</Citation></Reference><Reference><Citation>Cederlöf M, Lichtenstein P, Larsson H, et al. Obsessive-compulsive disorder, psychosis, and bipolarity: a longitudinal cohort and multigenerational family study. Schizophr Bull. 2015;41:1076–1083.</Citation></Reference><Reference><Citation>Sasson Y, Chopra M, Harrari E, et al. Bipolar comorbidity: from diagnostic dilemmas to therapeutic challenge. Int J Neuropsychopharmacol. 2003;6:139–144.</Citation></Reference><Reference><Citation>Angst J, Gamma A, Endrass J, et al. Obsessive-compulsive syndromes and disorders: significance of comorbidity with bipolar and anxiety syndromes. Eur Arch Psychiatry Clin Neurosci. 2005;255:65–71.</Citation></Reference><Reference><Citation>Darby L, Agius M, Zaman R. Co-morbidity of bipolar affective disorder and obsessive compulsive disorder in a Bedford community psychiatry team. Psychiatr Danub. 2011;23 (suppl 1):S130–S133.</Citation></Reference><Reference><Citation>Machado-Vieira R, Ibrahim L, Henter ID, et al. Novel glutamatergic agents for major depressive disorder and bipolar disorder. Pharmacol Biochem Behav. 2012;100:678–687.</Citation></Reference><Reference><Citation>Schloesser RJ, Martinowich K, Manji HK. Mood-stabilizing drugs: mechanisms of action. Trends Neurosci. 2012;35:36–46.</Citation></Reference><Reference><Citation>Wu K, Hanna GL, Rosenberg DR, et al. The role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorder. Pharmacol Biochem Behav. 2012;100:726–735.</Citation></Reference><Reference><Citation>Soeiro-De-Souza MG, Salvadore G, Moreno RA, et al. Bcl-2 rs956572 polymorphism is associated with increased anterior cingulate cortical glutamate in euthymic bipolar I disorder. Neuropsychopharmacology. 2013;38:468–475.</Citation></Reference><Reference><Citation>Pittenger C. Glutamate modulators in the treatment of obsessive-compulsive disorder. Psychiatr Ann. 2015;45:308–315.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">508887</PMID><DateCompleted><Year>1980</Year><Month>02</Month><Day>28</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0006-3223</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>6</Issue><PubDate><Year>1979</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Biological psychiatry</Title><ISOAbbreviation>Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Correlation between the lithium ratio and Na-dependent Li transport of red blood cells during lithium prophylaxis.</ArticleTitle><Pagination><MedlinePgn>973-7</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Szentistványi</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Janka</LastName><ForeName>Z</ForeName><Initials>Z</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biol Psychiatry</MedlineTA><NlmUniqueID>0213264</NlmUniqueID><ISSNLinking>0006-3223</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical><Chemical><RegistryNumber>9NEZ333N27</RegistryNumber><NameOfSubstance UI="D012964">Sodium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004912" MajorTopicYN="N">Erythrocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012964" MajorTopicYN="N">Sodium</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1979</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1979</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1979</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">508887</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">30145515</PMID><DateCompleted><Year>2019</Year><Month>01</Month><Day>29</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>241</Volume><PubDate><Year>2018</Year><Month>12</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>OpenSIMPLe: A real-world implementation feasibility study of a smartphone-based psychoeducation programme for bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>436-445</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0165-0327(18)30848-6</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2018.08.048</ELocationID><Abstract><AbstractText Label="BACKGROUND">Few evidence-based mental health apps are widely available to patients and, conversely, many of the available apps have not been appropriately evaluated. Given that the ultimate goal is to scale-up and open internet-based platforms (IBP), it is crucial to appropriately evaluate their real-world feasibility beforehand. We aimed to evaluate the implementation feasibility of a smartphone-based psychoeducational programme for bipolar disorder, exploring its long-term retention, usability, perceived helpfulness and satisfaction, alongside its impact on secondary health outcomes.</AbstractText><AbstractText Label="METHODS">Participants were recruited via the project website after completing an online screening questionnaire. They were requested to complete web-based questionnaires before using the app and after 6 months of use which included sociodemographic, illness and treatment variables, the world health organisation-five well-being index (WHO-5) and the short form health survey (SF-36). The follow-up questionnaires also contained satisfaction and usefulness questions.</AbstractText><AbstractText Label="RESULTS">201 participants took part in the study. According to their retention, 66.2% of the participants were classified as noncompleters and 33.8% as completers. The only predictor significantly associated with higher odds of retention was older age (OR = 1.021, p &lt; 0.001). 62% of the users reported they were satisfied with the programme with a higher percentage among completers. Who-5 baseline and follow-up scores showed a significant improvement as well as 6 out of 8 domains of the SF-36.</AbstractText><AbstractText Label="LIMITATIONS">Screening and outcome measures were administered using exclusively self-reported online methods.</AbstractText><AbstractText Label="CONCLUSION">The 6-month attrition rate of the programme was high. Positive outcomes regarding satisfaction were found predominantly among completers. The optimal dosage and retention of IBP mental health programmes remain challenging issues that need further research.</AbstractText><CopyrightInformation>Copyright © 2018. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hidalgo-Mazzei</LastName><ForeName>Diego</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Centre for Affective Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology &amp; Neuroscience, King's College London, London, United Kingdom; Bipolar Disorder Unit, Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reinares</LastName><ForeName>María</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Bipolar Disorder Unit, Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mateu</LastName><ForeName>Ainoa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre for Psychiatry, Division of Brain Sciences, Department of Medicine, Imperial College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nikolova</LastName><ForeName>Viktoriya L</ForeName><Initials>VL</Initials><AffiliationInfo><Affiliation>Centre for Affective Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology &amp; Neuroscience, King's College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonnín</LastName><ForeName>Caterina Del Mar</ForeName><Initials>CDM</Initials><AffiliationInfo><Affiliation>Bipolar Disorder Unit, Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Samalin</LastName><ForeName>Ludovic</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, CHU Clermont-Ferrand, University of Auvergne, EA 7280, Clermont-Ferrand, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>García-Estela</LastName><ForeName>Aitana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Mental Health Group, IMIM (Institut Hospital del Mar d'Investigacions Mèdiques)-Hospital del Mar,CIBERSAM, Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pérez-Solá</LastName><ForeName>Víctor</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Mental Health Group, IMIM (Institut Hospital del Mar d'Investigacions Mèdiques)-Hospital del Mar,CIBERSAM, Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Young</LastName><ForeName>Allan H</ForeName><Initials>AH</Initials><AffiliationInfo><Affiliation>Centre for Affective Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology &amp; Neuroscience, King's College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strejilevich</LastName><ForeName>Sergio</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Bipolar Disorder Programme, Neurosciences Institute, Favaloro University, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vieta</LastName><ForeName>Eduard</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Bipolar Disorder Unit, Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain. Electronic address: evieta@clinic.ub.es.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colom</LastName><ForeName>Francesc</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Mental Health Group, IMIM (Institut Hospital del Mar d'Investigacions Mèdiques)-Hospital del Mar,CIBERSAM, Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>08</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005240" MajorTopicYN="N">Feasibility Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006284" MajorTopicYN="N">Health Plan Implementation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020407" MajorTopicYN="N">Internet</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008603" MajorTopicYN="N">Mental Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="N">Outcome Assessment, Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010353" MajorTopicYN="N">Patient Education as Topic</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011613" MajorTopicYN="N">Psychotherapy</DescriptorName><QualifierName UI="Q000193" MajorTopicYN="Y">education</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068997" MajorTopicYN="Y">Smartphone</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Bipolar disorder</Keyword><Keyword MajorTopicYN="Y">Implementation</Keyword><Keyword MajorTopicYN="Y">Intervention</Keyword><Keyword MajorTopicYN="Y">Psychoeducation</Keyword><Keyword MajorTopicYN="Y">SIMPLe</Keyword><Keyword MajorTopicYN="Y">Smartphone</Keyword><Keyword MajorTopicYN="Y">Upscale</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>04</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>07</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>08</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>8</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>1</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>8</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30145515</ArticleId><ArticleId IdType="pii">S0165-0327(18)30848-6</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2018.08.048</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">9801727</PMID><DateCompleted><Year>1999</Year><Month>05</Month><Day>04</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0306-4603</ISSN><JournalIssue CitedMedium="Print"><Volume>23</Volume><Issue>6</Issue><PubDate><MedlineDate>1998 Nov-Dec</MedlineDate></PubDate></JournalIssue><Title>Addictive behaviors</Title><ISOAbbreviation>Addict Behav</ISOAbbreviation></Journal><ArticleTitle>Alcohol dependence and mood disorders.</ArticleTitle><Pagination><MedlinePgn>933-46</MedlinePgn></Pagination><Abstract><AbstractText>This article explores the complex relationships between alcohol dependence and mood disorders. Although many alcoholics present with substance-induced depressions, once appropriate methodological controls are used, there does not appear to be a significant relationship between independent unipolar depression and alcohol dependence. However, the data support a small, but significant, relationship between bipolar manic-depressive disease and alcoholism. The literature does not support the relevance of self-medication as a course of alcoholism, unless one includes the use of alcohol to alleviate alcohol-induced psychological and neurochemical perturbations. The clinical importance of distinguishing between substance-induced and independent mood disorders is reviewed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Raimo</LastName><ForeName>E B</ForeName><Initials>EB</Initials><AffiliationInfo><Affiliation>University of California, San Diego, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuckit</LastName><ForeName>M A</ForeName><Initials>MA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AA-05526</GrantID><Acronym>AA</Acronym><Agency>NIAAA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AA-08401</GrantID><Acronym>AA</Acronym><Agency>NIAAA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AA-08402</GrantID><Acronym>AA</Acronym><Agency>NIAAA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Addict Behav</MedlineTA><NlmUniqueID>7603486</NlmUniqueID><ISSNLinking>0306-4603</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>3K9958V90M</RegistryNumber><NameOfSubstance UI="D000431">Ethanol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000342" MajorTopicYN="N">Affective Symptoms</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000437" MajorTopicYN="N">Alcoholism</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015984" MajorTopicYN="N">Causality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017831" MajorTopicYN="N">Diagnosis, Dual (Psychiatry)</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000431" MajorTopicYN="N">Ethanol</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012651" MajorTopicYN="N">Self Medication</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>58</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1998</Year><Month>11</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1998</Year><Month>11</Month><Day>5</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1998</Year><Month>11</Month><Day>5</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9801727</ArticleId><ArticleId IdType="pii">S0306-4603(98)00068-9</ArticleId><ArticleId IdType="doi">10.1016/s0306-4603(98)00068-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26954568</PMID><DateCompleted><Year>2016</Year><Month>08</Month><Day>01</Day></DateCompleted><DateRevised><Year>2019</Year><Month>02</Month><Day>19</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>3</Issue><PubDate><Year>2016</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Social Rhythm and Mental Health: A Cross-Cultural Comparison.</ArticleTitle><Pagination><MedlinePgn>e0150312</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0150312</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Social rhythm refers to the regularity with which one engages in social activities throughout the week, and has established links with bipolar disorder, as well as some links with depression and anxiety. The aim of the present study is to examine social rhythm and its relationship to various aspects of health, including physical health, negative mental health, and positive mental health.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Questionnaire data were obtained from a large-scale multi-national sample of 8095 representative participants from the U.S., Russia, and Germany.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Results indicated that social rhythm irregularity is related to increased reporting of health problems, depression, anxiety, and stress. In contrast, greater regularity is related to better overall health state, life satisfaction, and positive mental health. The effects are generally small in size, but hold even when controlling for gender, marital status, education, income, country, and social support. Further, social rhythm means differ across Russia, the U.S., and Germany. Relationships with mental health are present in all three countries, but differ in magnitude.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Social rhythm irregularity is related to mental health in Russia, the U.S., and Germany.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Margraf</LastName><ForeName>Jürgen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Clinical Child and Adolescent Psychology, Ruhr-Universität Bochum, Bochum, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lavallee</LastName><ForeName>Kristen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Clinical Child and Adolescent Psychology, Ruhr-Universität Bochum, Bochum, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Developmental and Personality Psychology, Institute of Psychology, University of Basel, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>XiaoChi</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Clinical Child and Adolescent Psychology, Ruhr-Universität Bochum, Bochum, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinical Child and Adolescent Psychology, Ruhr-Universität Bochum, Bochum, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>03</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001007" MajorTopicYN="N">Anxiety</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008603" MajorTopicYN="Y">Mental Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012426" MajorTopicYN="N" Type="Geographic">Russia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066107" MajorTopicYN="Y">Social Skills</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="Y">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>08</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>02</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>3</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>3</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26954568</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0150312</ArticleId><ArticleId IdType="pii">PONE-D-15-33834</ArticleId><ArticleId IdType="pmc">PMC4783111</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Health Policy. 1990 Dec;16(3):199-208</Citation><ArticleIdList><ArticleId IdType="pubmed">10109801</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Policy. 1996 Jul;37(1):53-72</Citation><ArticleIdList><ArticleId IdType="pubmed">10158943</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sleep Res. 1994 Dec;3(4):196-205</Citation><ArticleIdList><ArticleId IdType="pubmed">10607126</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2000 Sep 15;48(6):593-604</Citation><ArticleIdList><ArticleId IdType="pubmed">11018230</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2000 Sep;30(5):1005-16</Citation><ArticleIdList><ArticleId IdType="pubmed">12027038</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2002 May;32(4):585-94</Citation><ArticleIdList><ArticleId IdType="pubmed">12102373</ArticleId></ArticleIdList></Reference><Reference><Citation>J Sleep Res. 2002 Sep;11(3):183-90</Citation><ArticleIdList><ArticleId IdType="pubmed">12220313</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Methods Psychiatr Res. 2003;12(1):3-21</Citation><ArticleIdList><ArticleId IdType="pubmed">12830306</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 1992 Jun;42(3):221-30</Citation><ArticleIdList><ArticleId IdType="pubmed">1496054</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Health Econ. 2003 Sep;4(3):222-31</Citation><ArticleIdList><ArticleId IdType="pubmed">15609189</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Clin Psychol. 2005 Jun;44(Pt 2):227-39</Citation><ArticleIdList><ArticleId IdType="pubmed">16004657</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2005 Sep;62(9):996-1004</Citation><ArticleIdList><ArticleId IdType="pubmed">16143731</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2006 Jan 30;141(1):103-14</Citation><ArticleIdList><ArticleId IdType="pubmed">16360217</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pers Assess. 1985 Feb;49(1):71-5</Citation><ArticleIdList><ArticleId IdType="pubmed">16367493</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2006 Apr;188:359-65</Citation><ArticleIdList><ArticleId IdType="pubmed">16582063</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Psychol Rev. 2006 Oct;26(6):679-94</Citation><ArticleIdList><ArticleId IdType="pubmed">16904251</ArticleId></ArticleIdList></Reference><Reference><Citation>J Health Psychol. 2006 Sep;11(5):643-54</Citation><ArticleIdList><ArticleId IdType="pubmed">16908463</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2007 Apr;64(4):419-26</Citation><ArticleIdList><ArticleId IdType="pubmed">17404119</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2007 Sep;164(9):1340-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17728418</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2008 Jun;10(4):520-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18452448</ArticleId></ArticleIdList></Reference><Reference><Citation>Chronobiol Int. 2009 Feb;26(2):337-47</Citation><ArticleIdList><ArticleId IdType="pubmed">19212845</ArticleId></ArticleIdList></Reference><Reference><Citation>Encephale. 2009 Jan;35 Suppl 2:S72-5</Citation><ArticleIdList><ArticleId IdType="pubmed">19268175</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Ther. 2009 Jun;40(2):131-41</Citation><ArticleIdList><ArticleId IdType="pubmed">19433144</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 1991 Feb;36(2):195-207</Citation><ArticleIdList><ArticleId IdType="pubmed">2017534</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Soc Psychiatry. 2012 Mar;58(2):166-71</Citation><ArticleIdList><ArticleId IdType="pubmed">21106604</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2011 Dec;135(1-3):384-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21708409</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 2012 Feb;121(1):282-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21842958</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2012 Aug;139(3):264-72</Citation><ArticleIdList><ArticleId IdType="pubmed">22381951</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 1990 Feb;178(2):120-6</Citation><ArticleIdList><ArticleId IdType="pubmed">2299336</ArticleId></ArticleIdList></Reference><Reference><Citation>Qual Life Res. 2013 Sep;22(7):1717-27</Citation><ArticleIdList><ArticleId IdType="pubmed">23184421</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Public Health. 2013;34:119-38</Citation><ArticleIdList><ArticleId IdType="pubmed">23514317</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 2013 Nov;21(11):1144-53</Citation><ArticleIdList><ArticleId IdType="pubmed">23567367</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Sci (Basel). 2014 Aug 06;4(3):265-77</Citation><ArticleIdList><ArticleId IdType="pubmed">25379281</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Psychol. 2014 Dec 23;2(1):58</Citation><ArticleIdList><ArticleId IdType="pubmed">25628891</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Psychol. 2016 Feb 10;4:8</Citation><ArticleIdList><ArticleId IdType="pubmed">26865173</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Assess. 2017 Apr;29(4):408-421</Citation><ArticleIdList><ArticleId IdType="pubmed">27322203</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1988 Oct;45(10):948-52</Citation><ArticleIdList><ArticleId IdType="pubmed">3048226</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Clin Health Psychol. 2015 Jan-Apr;15(1):8-17</Citation><ArticleIdList><ArticleId IdType="pubmed">30487817</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Res Ther. 1995 Mar;33(3):335-43</Citation><ArticleIdList><ArticleId IdType="pubmed">7726811</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 1994 Jan;51(1):33-49</Citation><ArticleIdList><ArticleId IdType="pubmed">8197270</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 1996 May 17;62(2):161-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8771613</ArticleId></ArticleIdList></Reference><Reference><Citation>Anxiety. 1994;1(2):90-5</Citation><ArticleIdList><ArticleId IdType="pubmed">9160553</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2136866</PMID><DateCompleted><Year>1990</Year><Month>02</Month><Day>12</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>18</Volume><Issue>1</Issue><PubDate><Year>1990</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>A randomized clinical trial of inpatient family intervention. V. Results for affective disorders.</ArticleTitle><Pagination><MedlinePgn>17-28</MedlinePgn></Pagination><Abstract><AbstractText>This paper reports the results at follow-up of a randomized clinical trial of combining family intervention with drug treatment during hospitalization for patients with affective disorder. The results suggest that female bipolar patients and their families benefited from family intervention, whereas unipolar patients and families did not. Patient outcome was positively correlated with the achievement of the goals of family intervention.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Clarkin</LastName><ForeName>J F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Cornell University Medical College, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glick</LastName><ForeName>I D</ForeName><Initials>ID</Initials></Author><Author ValidYN="Y"><LastName>Haas</LastName><ForeName>G L</ForeName><Initials>GL</Initials></Author><Author ValidYN="Y"><LastName>Spencer</LastName><ForeName>J H</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>Lewis</LastName><ForeName>A B</ForeName><Initials>AB</Initials></Author><Author ValidYN="Y"><LastName>Peyser</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>DeMane</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Good-Ellis</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Harris</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Lestelle</LastName><ForeName>V</ForeName><Initials>V</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>507-RR05396</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH34466</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005196" MajorTopicYN="Y">Family Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011619" MajorTopicYN="N">Psychotropic Drugs</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1990</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1990</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1990</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2136866</ArticleId><ArticleId IdType="pii">0165-0327(90)90113-M</ArticleId><ArticleId IdType="doi">10.1016/0165-0327(90)90113-m</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17242623</PMID><DateCompleted><Year>2007</Year><Month>02</Month><Day>22</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0890-8567</ISSN><JournalIssue CitedMedium="Print"><Volume>46</Volume><Issue>2</Issue><PubDate><Year>2007</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Journal of the American Academy of Child and Adolescent Psychiatry</Title><ISOAbbreviation>J Am Acad Child Adolesc Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Childhood-onset bipolar disorder: Evidence for increased familial loading of psychiatric illness.</ArticleTitle><Pagination><MedlinePgn>197-204</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine whether childhood-onset bipolar disorder (BP) is associated with an increased psychiatric family history compared with adolescent-onset BP.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Semistructured psychiatric interviews were conducted for 438 youth with BP spectrum disorders. To evaluate the effects of age at onset and psychiatric family history, the sample was divided into childhood-onset BP (age and BP onset &lt;12 years; n = 192), adolescents with early-onset BP (age &gt; or =12 years and BP onset &lt;12 years; n = 136), and adolescents with late-onset BP (age and BP onset &gt; or =12 years; n = 110). Lifetime family history of psychiatric illness was ascertained for first- and second-degree relatives through both direct interview of caretakers and the Family History Screen.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">After significant demographic and clinical factors were controlled for, children and adolescents with childhood-onset BP showed higher percentages of positive first-degree family history for depression, anxiety, attention-deficit/hyperactivity, conduct, and substance dependence disorders and suicidal behaviors compared with adolescents with late onset. Subjects with childhood-onset BP also showed elevated familial loading for depression and attention-deficit/hyperactive disorder in second-degree relatives.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These data support a model that postulates a higher density of familial risk for a broad range of psychopathology in childhood-onset BP.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rende</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Human Behavior, Brown Medical School, Providence, RI, USA. Richard_Rende@Brown.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Birmaher</LastName><ForeName>Boris</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Axelson</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Strober</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Gill</LastName><ForeName>Mary Kay</ForeName><Initials>MK</Initials></Author><Author ValidYN="Y"><LastName>Valeri</LastName><ForeName>Sylvia</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Chiappetta</LastName><ForeName>Laurel</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Neal</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Leonard</LastName><ForeName>Henrietta</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Hunt</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Iyengar</LastName><ForeName>Satish</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Keller</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH059977-04</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH059691</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH059977-01A1</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH59691</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH59977</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH059929</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH059977-03</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH059977-01A1S1</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH059977-06A2</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH059977</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH59929</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH059977-05</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH059977-02</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH051415</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Acad Child Adolesc Psychiatry</MedlineTA><NlmUniqueID>8704565</NlmUniqueID><ISSNLinking>0890-8567</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005820" MajorTopicYN="N">Genetic Testing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>1</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>2</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>1</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17242623</ArticleId><ArticleId IdType="doi">10.1097/01.chi.0000246069.85577.9e</ArticleId><ArticleId IdType="pii">S0890-8567(09)61827-X</ArticleId><ArticleId IdType="pmc">PMC2041890</ArticleId><ArticleId IdType="mid">NIHMS24510</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arch Gen Psychiatry. 2004 May;61(5):459-67</Citation><ArticleIdList><ArticleId IdType="pubmed">15123490</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1992 Sep;49(9):703-8</Citation><ArticleIdList><ArticleId IdType="pubmed">1514875</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1987 May;44(5):441-7</Citation><ArticleIdList><ArticleId IdType="pubmed">3579495</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1985 Jul;42(7):696-702</Citation><ArticleIdList><ArticleId IdType="pubmed">4015311</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2000 Jul;57(7):675-82</Citation><ArticleIdList><ArticleId IdType="pubmed">10891038</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2002 Feb;159(2):307-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11823277</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2003 Jun 1;53(11):970-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12788242</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2003 Aug;5(4):243-56</Citation><ArticleIdList><ArticleId IdType="pubmed">12895202</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Adolesc Psychopharmacol. 2003 Winter;13(4):453-62</Citation><ArticleIdList><ArticleId IdType="pubmed">14977458</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2004 May 1;55(9):875-81</Citation><ArticleIdList><ArticleId IdType="pubmed">15110730</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1992 Jul;31(4):606-10</Citation><ArticleIdList><ArticleId IdType="pubmed">1644721</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1988 Nov-Dec;15(3):255-68</Citation><ArticleIdList><ArticleId IdType="pubmed">2975298</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1997 Apr;36(4):466-73</Citation><ArticleIdList><ArticleId IdType="pubmed">9100420</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1997 Jul;36(7):980-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9204677</ArticleId></ArticleIdList></Reference><Reference><Citation>Soc Psychiatry Psychiatr Epidemiol. 2005 Feb;40(2):106-13</Citation><ArticleIdList><ArticleId IdType="pubmed">15685401</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2005 Apr;7(2):111-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15762851</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2005 Sep;44(9):846-71</Citation><ArticleIdList><ArticleId IdType="pubmed">16113615</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2005;66 Suppl 7:21-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16124838</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2005 Dec;7(6):598-609</Citation><ArticleIdList><ArticleId IdType="pubmed">16403185</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2006 Feb;163(2):240-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16449477</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2006 Feb;63(2):175-83</Citation><ArticleIdList><ArticleId IdType="pubmed">16461861</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2006 Oct;63(10):1139-48</Citation><ArticleIdList><ArticleId IdType="pubmed">17015816</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21109306</PMID><DateCompleted><Year>2011</Year><Month>10</Month><Day>06</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>130</Volume><Issue>3</Issue><PubDate><Year>2011</Year><Month>May</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Screening for bipolar disorder in patients consulting general practitioners in France.</ArticleTitle><Pagination><MedlinePgn>492-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2010.10.037</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Recently, an unexpected 3-fold higher screen positive rate for bipolar disorder was found among low-income American patients who were seeking primary care at an urban general medicine clinic as compared with the general population of the United States. The social health system in France is characterized by its open access, where most bipolar patients ask for care and where the major problem is diagnosis by the general practitioner (GP). Therefore, we investigated the prevalence of bipolar disorder among patients attending GP offices in France.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This observational, single visit survey was performed among 10,265 patients (47.2±18.0 years old, 40% males) attending primary care in 95 GP offices in France. The participating GP made available an MDQ-French version questionnaire to all patients aged 15 years and over, going to his office during a full week, independently of the reason for medical consulting. In addition to the MDQ-French version questionnaire, patients answered items concerning sex, age, professional situation and marital state.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">One thousand twenty-five (1025) patients did not complete the questionnaire and were excluded from the analysis. Of the 9240 analyzed questionnaires, 8.3% were classified as MDQ positives (MDQ+). MDQ+ patients were significantly younger (41.6 years versus 46.6 years for MDQ- patients, p&lt;0.0001), more frequently divorced or separated (19.2% versus 8.6%, p&lt;0.0001) and more frequently unemployed (15.2% versus 6.4%, p&lt;0.0001). The gender distribution was not significantly different between the two groups.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The prevalence of receiving positive screening results for bipolar disease in 9240 patients consulting 95 randomly selected french general practitioners was 8.3%, as assessed by the MDQ questionnaire. This is a similar and unexpected high value as that reported for low-income american patients (9.8%). Besides low socioeconomic status, other factors should explain the high screen positive rate for bipolar disorder in patients attending primary care.</AbstractText><CopyrightInformation>Copyright © 2010 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rouillon</LastName><ForeName>Frédéric</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>CMME, Centre hospitalier Sainte-Anne, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gasquet</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Garay</LastName><ForeName>Ricardo P</ForeName><Initials>RP</Initials></Author><Author ValidYN="Y"><LastName>Lancrenon</LastName><ForeName>Sylvie</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>11</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058005" MajorTopicYN="N">General Practitioners</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011320" MajorTopicYN="N">Primary Health Care</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012017" MajorTopicYN="N">Referral and Consultation</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>03</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2010</Year><Month>10</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>10</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>10</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21109306</ArticleId><ArticleId IdType="pii">S0165-0327(10)00666-X</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2010.10.037</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">29698907</PMID><DateCompleted><Year>2019</Year><Month>02</Month><Day>11</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1090-2147</ISSN><JournalIssue CitedMedium="Internet"><Volume>124</Volume><PubDate><Year>2018</Year><Month>07</Month></PubDate></JournalIssue><Title>Brain and cognition</Title><ISOAbbreviation>Brain Cogn</ISOAbbreviation></Journal><ArticleTitle>Using an emotional saccade task to characterize executive functioning and emotion processing in attention-deficit hyperactivity disorder and bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>1-13</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0278-2626(17)30416-5</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bandc.2018.04.002</ELocationID><Abstract><AbstractText>Despite distinct diagnostic criteria, attention-deficit hyperactivity disorder (ADHD) and bipolar disorder (BD) share cognitive and emotion processing deficits that complicate diagnoses. The goal of this study was to use an emotional saccade task to characterize executive functioning and emotion processing in adult ADHD and BD. Participants (21 control, 20 ADHD, 20 BD) performed an interleaved pro/antisaccade task (look toward vs. look away from a visual target, respectively) in which the sex of emotional face stimuli acted as the cue to perform either the pro- or antisaccade. Both patient groups made more direction (erroneous prosaccades on antisaccade trials) and anticipatory (saccades made before cue processing) errors than controls. Controls exhibited lower microsaccade rates preceding correct anti- vs. prosaccade initiation, but this task-related modulation was absent in both patient groups. Regarding emotion processing, the ADHD group performed worse than controls on neutral face trials, while the BD group performed worse than controls on trials presenting faces of all valence. These findings support the role of fronto-striatal circuitry in mediating response inhibition deficits in both ADHD and BD, and suggest that such deficits are exacerbated in BD during emotion processing, presumably via dysregulated limbic system circuitry involving the anterior cingulate and orbitofrontal cortex.</AbstractText><CopyrightInformation>Copyright © 2018 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yep</LastName><ForeName>Rachel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Centre for Neuroscience Studies, Queen's University, Kingston, ON, Canada. Electronic address: 12ry@queensu.ca.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soncin</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centre for Neuroscience Studies, Queen's University, Kingston, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brien</LastName><ForeName>Donald C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>Centre for Neuroscience Studies, Queen's University, Kingston, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coe</LastName><ForeName>Brian C</ForeName><Initials>BC</Initials><AffiliationInfo><Affiliation>Centre for Neuroscience Studies, Queen's University, Kingston, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marin</LastName><ForeName>Alina</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre for Neuroscience Studies, Queen's University, Kingston, ON, Canada; Department of Psychiatry, Hotel Dieu Hospital, Kingston, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Munoz</LastName><ForeName>Douglas P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>Centre for Neuroscience Studies, Queen's University, Kingston, ON, Canada; Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON, Canada. Electronic address: doug.munoz@queensu.ca.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MOP-FDN-148418</GrantID><Agency>CIHR</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>04</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Brain Cogn</MedlineTA><NlmUniqueID>8218014</NlmUniqueID><ISSNLinking>0278-2626</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001289" MajorTopicYN="N">Attention Deficit Disorder with Hyperactivity</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003342" MajorTopicYN="N">Corpus Striatum</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004644" MajorTopicYN="Y">Emotions</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056344" MajorTopicYN="Y">Executive Function</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005149" MajorTopicYN="Y">Facial Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006179" MajorTopicYN="N">Gyrus Cinguli</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007266" MajorTopicYN="N">Inhibition, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008032" MajorTopicYN="N">Limbic System</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009415" MajorTopicYN="N">Nerve Net</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017397" MajorTopicYN="N">Prefrontal Cortex</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012438" MajorTopicYN="Y">Saccades</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Antisaccade</Keyword><Keyword MajorTopicYN="Y">Attention-deficit hyperactivity disorder</Keyword><Keyword MajorTopicYN="Y">Bipolar disorder</Keyword><Keyword MajorTopicYN="Y">Emotion processing</Keyword><Keyword MajorTopicYN="Y">Executive functioning</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>11</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>04</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>04</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>4</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>2</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>4</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29698907</ArticleId><ArticleId IdType="pii">S0278-2626(17)30416-5</ArticleId><ArticleId IdType="doi">10.1016/j.bandc.2018.04.002</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16625524</PMID><DateCompleted><Year>2006</Year><Month>09</Month><Day>19</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-6222</ISSN><JournalIssue CitedMedium="Print"><Volume>21</Volume><Issue>3</Issue><PubDate><Year>2006</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Human psychopharmacology</Title><ISOAbbreviation>Hum Psychopharmacol</ISOAbbreviation></Journal><ArticleTitle>Clinical outcome in patients with bipolar I disorder, obsessive compulsive disorder or both.</ArticleTitle><Pagination><MedlinePgn>189-93</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Bipolar disorder (BPD) is often comorbid with obsessive-compulsive (OCD) and other anxiety disorders, but the impact of such comorbidity on long-term outcome has not been evaluated systematically.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Extensive follow-up assessments were carried out at 4.3 years after index hospitalizations in a mixed BPD-OCD group (N=20) compared to matched groups with BPD (N=22) or OCD (N=20) alone.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">At follow-up, ratings of functional status were similar across groups. Rehospitalizations were similar among BPD-OCD and BPD subjects, but 2.9-times more frequent among comorbid than OCD patients. OCD symptoms averaged 150% more severe in OCD than comorbid subjects, and were not measured in BPD subjects.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Despite potential sampling bias with previously hospitalized subjects, the findings suggest that comorbid BPD-OCD patients may be clinically more similar to BPD than OCD patients, and that BPD-OCD comorbidity may not negatively impact the long-term clinical outcome.</AbstractText><CopyrightInformation>Copyright (c) 2006 John Wiley &amp; Sons, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Centorrino</LastName><ForeName>Franca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Schizophrenia and Bipolar Disorder Program, McLean Hospital, Belmont 02478, and Department of Psychiatry, Harvard Medical School, Cambridge, MA, USA. fcentorrino@mclean.harvard.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hennen</LastName><ForeName>John</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Mallya</LastName><ForeName>Gopinath</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Egli</LastName><ForeName>Samy</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Clark</LastName><ForeName>Tim</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Baldessarini</LastName><ForeName>Ross J</ForeName><Initials>RJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH-47370</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Hum Psychopharmacol</MedlineTA><NlmUniqueID>8702539</NlmUniqueID><ISSNLinking>0885-6222</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007406" MajorTopicYN="N">Interview, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009771" MajorTopicYN="N">Obsessive-Compulsive Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="Y">Outcome Assessment, Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>4</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>9</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>4</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16625524</ArticleId><ArticleId IdType="doi">10.1002/hup.760</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">3930019</PMID><DateCompleted><Year>1985</Year><Month>11</Month><Day>08</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0376-2491</ISSN><JournalIssue CitedMedium="Print"><Volume>65</Volume><Issue>6</Issue><PubDate><Year>1985</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Zhonghua yi xue za zhi</Title><ISOAbbreviation>Zhonghua Yi Xue Za Zhi</ISOAbbreviation></Journal><ArticleTitle>[Clinical study of 86 cases of manic-depressive psychosis].</ArticleTitle><Pagination><MedlinePgn>325-8</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>J B</ForeName><Initials>JB</Initials></Author></AuthorList><Language>chi</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Zhonghua Yi Xue Za Zhi</MedlineTA><NlmUniqueID>7511141</NlmUniqueID><ISSNLinking>0376-2491</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1985</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1985</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1985</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3930019</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">26775167</PMID><DateCompleted><Year>2016</Year><Month>10</Month><Day>11</Day></DateCompleted><DateRevised><Year>2019</Year><Month>01</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-7123</ISSN><JournalIssue CitedMedium="Internet"><Volume>236</Volume><PubDate><Year>2016</Year><Month>Feb</Month><Day>28</Day></PubDate></JournalIssue><Title>Psychiatry research</Title><ISOAbbreviation>Psychiatry Res</ISOAbbreviation></Journal><ArticleTitle>Neurological soft signs in euthymic bipolar I patients: A comparative study with healthy siblings and controls.</ArticleTitle><Pagination><MedlinePgn>173-178</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0165-1781(15)30755-1</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.psychres.2015.11.047</ELocationID><Abstract><AbstractText>Neurological Soft Signs (NSS) are endophenotypic markers widely studied in schizophrenia and remain poorly evaluated in bipolar disorder. The aims of this paper were to determine the prevalence and scores of NSS in bipolar I patients, compared to healthy siblings and controls and to explore correlations with socio-demographic and clinical features of patients. This was a case-control study comparing 92 euthymic bipolar I patients, 44 of their healthy siblings and 60 control subjects. The neurological assessment was performed through the NSS scale validated by Krebs et al. (2000). Bipolar I patients were also assessed with the Bech-Rafaelsen Mania Scale (MAS), the Hamilton Depression Rating Scale (HDRS) and the Global Assessment of Functioning (GAF). The raters were not blinded to groups. The prevalence and the total score of NSS were significantly higher in bipolar I patients compared to their healthy siblings and controls. The sibling group had significantly higher NSS prevalence and total score than controls. No correlation was found between NSS total score and socio-demographic and clinical features of patients, except a negative correlation with the school level and the GAF score. In conclusion, bipolar I patients have motor and sensory signs, which are unrelated to their clinical features. </AbstractText><CopyrightInformation>Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mrad</LastName><ForeName>Amel</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Research Laboratory "Vulnerability to Psychotic Disorders", Department of Psychiatry, Fattouma Bourguiba University Hospital, Monastir, Tunisia. Electronic address: mrad_amel2003@yahoo.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wassim Krir</LastName><ForeName>Mohamed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Research Laboratory "Vulnerability to Psychotic Disorders", Department of Psychiatry, Fattouma Bourguiba University Hospital, Monastir, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ajmi</LastName><ForeName>Inès</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Research Laboratory "Vulnerability to Psychotic Disorders", Department of Psychiatry, Fattouma Bourguiba University Hospital, Monastir, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaha</LastName><ForeName>Lotfi</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Research Laboratory "Vulnerability to Psychotic Disorders", Department of Psychiatry, Fattouma Bourguiba University Hospital, Monastir, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mechri</LastName><ForeName>Anwar</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Research Laboratory "Vulnerability to Psychotic Disorders", Department of Psychiatry, Fattouma Bourguiba University Hospital, Monastir, Tunisia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>11</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Psychiatry Res</MedlineTA><NlmUniqueID>7911385</NlmUniqueID><ISSNLinking>0165-1781</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006304" MajorTopicYN="N">Health Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009422" MajorTopicYN="N">Nervous System Diseases</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009460" MajorTopicYN="N">Neurologic Examination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035781" MajorTopicYN="Y">Siblings</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bipolar I disorder</Keyword><Keyword MajorTopicYN="N">Case control study</Keyword><Keyword MajorTopicYN="N">Healthy siblings</Keyword><Keyword MajorTopicYN="N">Neurodevelopmental hypothesis</Keyword><Keyword MajorTopicYN="N">Neurological soft signs</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>01</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>07</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>11</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>1</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>1</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26775167</ArticleId><ArticleId IdType="pii">S0165-1781(15)30755-1</ArticleId><ArticleId IdType="doi">10.1016/j.psychres.2015.11.047</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17167340</PMID><DateCompleted><Year>2007</Year><Month>04</Month><Day>17</Day></DateCompleted><DateRevised><Year>2006</Year><Month>12</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0955-8829</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><Issue>1</Issue><PubDate><Year>2007</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Psychiatric genetics</Title><ISOAbbreviation>Psychiatr Genet</ISOAbbreviation></Journal><ArticleTitle>Polymorphisms in the neuronal isoform of tryptophan hydroxylase 2 are associated with bipolar disorder in French Canadian pedigrees.</ArticleTitle><Pagination><MedlinePgn>17-22</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Tryptophan hydroxylase is the rate-limiting enzyme in the serotonin biosynthetic pathway and plays an important role in the regulation of serotonin levels. Recently, a brain-specific isoform, tryptophan hydroxylase 2 or n-tryptophan hydroxylase, has been discovered. Some studies reported genetic and functional associations between this isoform and bipolar disorder and/or major depressive disorder. The aim of this study was to investigate further association of genetic variants in French Canadian samples with bipolar disorders.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Genetic variants in the tryptophan hydroxylase 2 gene were genotyped in a case-control sample consisting of 225 affected individuals (191 bipolar I and 34 bipolar II) and 221 controls and in a collection of extended pedigrees and trios from the same population 357 nuclear families (201 bipolar I, 64 bipolar II, 79 recurrent major depressive disorder).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We determined linkage disequilibrium structure in our isolated population and analyzed six tagged single nucleotide polymorphisms in the case-control sample. Whereas no single, single nucleotide polymorphism gave any significant result, a three single nucleotide polymorphism haplotype gave a global P=0.01. Family-based association showed significant association (P=0.004) of one polymorphism (rs4290270) with the major allele overtransmitted to affected offspring.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Case-control and family-based association studies further support the presence of a susceptibility locus for bipolar disorder in tryptophan hydroxylase 2 by showing statistically significant associations with both, single nucleotide polymorphism alone and haplotype of single nucleotide polymorphism markers.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Harvey</LastName><ForeName>Mario</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, CHUL Research Centre and Laval University, Sainte-Foy, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gagné</LastName><ForeName>Bernard</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Labbé</LastName><ForeName>Michel</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Barden</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Psychiatr Genet</MedlineTA><NlmUniqueID>9106748</NlmUniqueID><ISSNLinking>0955-8829</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 1.14.16.4</RegistryNumber><NameOfSubstance UI="C494784">TPH2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.16.4</RegistryNumber><NameOfSubstance UI="D014365">Tryptophan Hydroxylase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N" Type="Geographic">Canada</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010375" MajorTopicYN="N">Pedigree</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="Y">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014365" MajorTopicYN="N">Tryptophan Hydroxylase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>12</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>4</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>12</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17167340</ArticleId><ArticleId IdType="doi">10.1097/YPG.0b013e3280111877</ArticleId><ArticleId IdType="pii">00041444-200702000-00008</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19034756</PMID><DateCompleted><Year>2009</Year><Month>03</Month><Day>11</Day></DateCompleted><DateRevised><Year>2008</Year><Month>11</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1547-3325</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>4</Issue><PubDate><MedlineDate>2008 Oct-Dec</MedlineDate></PubDate></JournalIssue><Title>Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists</Title><ISOAbbreviation>Ann Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Case report of an interaction of a vagal nerve stimulation system with a microwave current from a body fat analyzer.</ArticleTitle><Pagination><MedlinePgn>229-30</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/10401230802435542</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Abnoosian</LastName><ForeName>Arin</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Maguire</LastName><ForeName>Gerald</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Clin Psychiatry</MedlineTA><NlmUniqueID>8911021</NlmUniqueID><ISSNLinking>1040-1237</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001823" MajorTopicYN="Y">Body Composition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017097" MajorTopicYN="N">Electric Impedance</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008872" MajorTopicYN="N">Microwaves</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055536" MajorTopicYN="N">Vagus Nerve Stimulation</DescriptorName><QualifierName UI="Q000295" MajorTopicYN="Y">instrumentation</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>11</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>3</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>11</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19034756</ArticleId><ArticleId IdType="pii">906004718</ArticleId><ArticleId IdType="doi">10.1080/10401230802435542</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">3120858</PMID><DateCompleted><Year>1988</Year><Month>01</Month><Day>29</Day></DateCompleted><DateRevised><Year>2019</Year><Month>05</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0267-0623</ISSN><JournalIssue CitedMedium="Print"><Volume>295</Volume><Issue>6605</Issue><PubDate><Year>1987</Year><Month>Oct</Month><Day>24</Day></PubDate></JournalIssue><Title>British medical journal (Clinical research ed.)</Title><ISOAbbreviation>Br Med J (Clin Res Ed)</ISOAbbreviation></Journal><ArticleTitle>Mania induced by biochemical imbalance resulting from low energy diet in a patient with undiagnosed myxoedema.</ArticleTitle><Pagination><MedlinePgn>1026-7</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zolese</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Shenley Hospital, Radlett, Hertfordshire.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henryk-Gutt</LastName><ForeName>R</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br Med J (Clin Res Ed)</MedlineTA><NlmUniqueID>8302911</NlmUniqueID><ISSNLinking>0267-0623</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004038" MajorTopicYN="N">Diet, Reducing</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009230" MajorTopicYN="N">Myxedema</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1987</Year><Month>10</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1987</Year><Month>10</Month><Day>24</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1987</Year><Month>10</Month><Day>24</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3120858</ArticleId><ArticleId IdType="pmc">PMC1248072</ArticleId><ArticleId IdType="doi">10.1136/bmj.295.6605.1026</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Acta Psychiatr Scand. 1970;46(1):1-13</Citation><ArticleIdList><ArticleId IdType="pubmed">4914345</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychosomatics. 1985 May;26(5):394-6, 399, 402</Citation><ArticleIdList><ArticleId IdType="pubmed">2581283</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1978 Nov;35(11):1333-9</Citation><ArticleIdList><ArticleId IdType="pubmed">757997</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">454105</PMID><DateCompleted><Year>1979</Year><Month>09</Month><Day>01</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-990X</ISSN><JournalIssue CitedMedium="Print"><Volume>36</Volume><Issue>8 Spec No</Issue><PubDate><Year>1979</Year><Month>Jul</Month><Day>20</Day></PubDate></JournalIssue><Title>Archives of general psychiatry</Title><ISOAbbreviation>Arch Gen Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Patient and physician attitudes toward lithium: relationship to compliance.</ArticleTitle><Pagination><MedlinePgn>866-9</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jamison</LastName><ForeName>K R</ForeName><Initials>KR</Initials></Author><Author ValidYN="Y"><LastName>Gerner</LastName><ForeName>R H</ForeName><Initials>RH</Initials></Author><Author ValidYN="Y"><LastName>Goodwin</LastName><ForeName>F K</ForeName><Initials>FK</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Gen Psychiatry</MedlineTA><NlmUniqueID>0372435</NlmUniqueID><ISSNLinking>0003-990X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001291" MajorTopicYN="Y">Attitude of Health Personnel</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009042" MajorTopicYN="N">Motivation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010349" MajorTopicYN="Y">Patient Compliance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010820" MajorTopicYN="N">Physicians</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011613" MajorTopicYN="N">Psychotherapy</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1979</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1979</Year><Month>7</Month><Day>20</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1979</Year><Month>7</Month><Day>20</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">454105</ArticleId><ArticleId IdType="doi">10.1001/archpsyc.1979.01780080040011</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19745659</PMID><DateCompleted><Year>2010</Year><Month>05</Month><Day>05</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1533-712X</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>5</Issue><PubDate><Year>2009</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of clinical psychopharmacology</Title><ISOAbbreviation>J Clin Psychopharmacol</ISOAbbreviation></Journal><ArticleTitle>Possible lamotrigine-induced mania in a child with autism spectrum disorder and epilepsy.</ArticleTitle><Pagination><MedlinePgn>508-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/JCP.0b013e3181b6017f</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Coskun</LastName><ForeName>Murat</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Bozkurt</LastName><ForeName>Hasan</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Zoroglu</LastName><ForeName>Salih</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychopharmacol</MedlineTA><NlmUniqueID>8109496</NlmUniqueID><ISSNLinking>0271-0749</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014227">Triazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>U3H27498KS</RegistryNumber><NameOfSubstance UI="D000077213">Lamotrigine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002659" MajorTopicYN="N">Child Development Disorders, Pervasive</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004827" MajorTopicYN="N">Epilepsy</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077213" MajorTopicYN="N">Lamotrigine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014227" MajorTopicYN="N">Triazines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19745659</ArticleId><ArticleId IdType="doi">10.1097/JCP.0b013e3181b6017f</ArticleId><ArticleId IdType="pii">00004714-200910000-00022</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19755202</PMID><DateCompleted><Year>2010</Year><Month>07</Month><Day>26</Day></DateCompleted><DateRevised><Year>2010</Year><Month>04</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>123</Volume><Issue>1-3</Issue><PubDate><Year>2010</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Distinct neuronal oscillatory responses between patients with bipolar and unipolar disorders: a magnetoencephalographic study.</ArticleTitle><Pagination><MedlinePgn>270-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2009.08.020</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Bipolar disorder (BD) and major depressive disorder (MDD) have distinct pathophysiologies but similar depressive appearances. The present study aimed at the differentiation of the brain responses between BD and MDD patients. We hypothesized that different affective disorder patients may have distinct patterns of oscillatory cortical activities in response to negative emotional stimuli.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Twenty BD patients, twenty MDD patients, and twenty age- and gender-matched healthy normal subjects were recruited. We adopted an implicit emotional task with facial image stimuli. The acquired event-related magnetoencephalographic signals were processed by the time-frequency analysis and beamformer-based source imaging techniques followed by statistical inference.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We found that there were gamma oscillation decreases in the frontal regions of both BD and MDD patients, gamma oscillation increases in the bilateral temporal regions of MDD, and alpha-beta rhythm increases in BD patients. Relative to the cortical activation in the control group, the BD patients displayed more widely increased oscillatory activities over the fronto-parieto-occipital regions than MDD patients.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our results demonstrate the distinct neuropathological patterns of emotional responses in BD and MDD patients. The findings suggest that the dysfunction of emotion regulation in BD may result from the increased sensitivity to emotionally salient information, implicating the potential cause of the emotion lability. The present study also suggests that the implicit emotional task is an effective approach to differentiate bipolar from unipolar disorders and their distinct neuropathological patterns to emotional stimuli may provide objective and quantitative measures for potential diagnostic significance.</AbstractText><CopyrightInformation>Copyright 2009 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Pin-Shiuan</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Institute of Brain Science, National Yang-Ming University, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yong-Sheng</ForeName><Initials>YS</Initials></Author><Author ValidYN="Y"><LastName>Hsieh</LastName><ForeName>Jen-Chuen</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Tung-Ping</ForeName><Initials>TP</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Li-Fen</ForeName><Initials>LF</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>09</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000513" MajorTopicYN="N">Alpha Rhythm</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001611" MajorTopicYN="N">Beta Rhythm</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004292" MajorTopicYN="N">Dominance, Cerebral</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004644" MajorTopicYN="N">Emotions</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005071" MajorTopicYN="N">Evoked Potentials</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005149" MajorTopicYN="Y">Facial Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015225" MajorTopicYN="Y">Magnetoencephalography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010364" MajorTopicYN="N">Pattern Recognition, Visual</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>06</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2009</Year><Month>08</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>08</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>9</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>9</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>7</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19755202</ArticleId><ArticleId IdType="pii">S0165-0327(09)00398-X</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2009.08.020</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17171602</PMID><DateCompleted><Year>2007</Year><Month>01</Month><Day>25</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0303-7339</ISSN><JournalIssue CitedMedium="Print"><Volume>48</Volume><Issue>12</Issue><PubDate><Year>2006</Year></PubDate></JournalIssue><Title>Tijdschrift voor psychiatrie</Title><ISOAbbreviation>Tijdschr Psychiatr</ISOAbbreviation></Journal><ArticleTitle>[Psychotherapeutic treatment options for bipolar disorders. A review of randomized controlled studies].</ArticleTitle><Pagination><MedlinePgn>905-13</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Until recently research into the efficacy of treatment of bipolar disorders focused mainly on the pharmacological treatment. Over the last few years more and more research has concentrated on the psychological treatments for bipolar disorders. aim To review published, controlled and randomised studies dealing with the efficacy of forms of psychotherapeutic treatment for bipolar disorders.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">By searching Medline and Embase using the search terms, 'psychotherapy', 'cognitive (behavioural) therapy', 'family therapy' and 'psychoeducation' we found eight relevant reports of randomised, controlled trials, which described the interventions that were undertaken and recorded the relapse rates.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The following forms of treatment were investigated: Relapse-Prevention Plan, Cognitive Behavioural Therapy, Interpersonal and Social Rhythm Therapy, Family-Focused Treatment and Group Psychoeducation. These forms of treatment were used in addition to standard pharmacological treatment. The addition of psychotherapeutic treatment was found to reduce lower the relapse rate, to lead to less hospitalisation and to improve functioning.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The authors recommend that patients with bipolar disorders be offered psychotherapeutic treatment because it is likely to lower the risk of relapse.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>van den Berg</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>b.vandenberg@ggzduinenbollenstreek.nl</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knoppert-van der Klein</LastName><ForeName>E A M</ForeName><Initials>EA</Initials></Author><Author ValidYN="Y"><LastName>van Zaane</LastName><ForeName>J</ForeName><Initials>J</Initials></Author></AuthorList><Language>dut</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Psychotherapeutische behandelmogelijkheden voor bipolaire stoornissen. Een overzicht van gerandomiseerde en gecontroleerde onderzoeken.</VernacularTitle></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Tijdschr Psychiatr</MedlineTA><NlmUniqueID>0423731</NlmUniqueID><ISSNLinking>0303-7339</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015928" MajorTopicYN="Y">Cognitive Behavioral Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019317" MajorTopicYN="N">Evidence-Based Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005196" MajorTopicYN="Y">Family Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010353" MajorTopicYN="N">Patient Education as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011613" MajorTopicYN="Y">Psychotherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>23</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>12</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>1</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>12</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17171602</ArticleId><ArticleId IdType="pii">TVPart_1574</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21352930</PMID><DateCompleted><Year>2011</Year><Month>07</Month><Day>25</Day></DateCompleted><DateRevised><Year>2011</Year><Month>05</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-9572</ISSN><JournalIssue CitedMedium="Internet"><Volume>56</Volume><Issue>3</Issue><PubDate><Year>2011</Year><Month>Jun</Month><Day>01</Day></PubDate></JournalIssue><Title>NeuroImage</Title><ISOAbbreviation>Neuroimage</ISOAbbreviation></Journal><ArticleTitle>Familial and disease specific abnormalities in the neural correlates of the Stroop Task in Bipolar Disorder.</ArticleTitle><Pagination><MedlinePgn>1677-84</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuroimage.2011.02.052</ELocationID><Abstract><AbstractText>Patients with Bipolar Disorder (BD) perform poorly on tasks of selective attention and inhibitory control. Although similar behavioural deficits have been noted in their relatives, it is yet unclear whether they reflect dysfunction in the same neural circuits. We used functional magnetic resonance imaging and the Stroop Colour Word Task to compare task related neural activity between 39 euthymic BD patients, 39 of their first-degree relatives (25 with no Axis I disorders and 14 with Major Depressive Disorder) and 48 healthy controls. Compared to controls, all individuals with familial predisposition to BD, irrespective of diagnosis, showed similar reductions in neural responsiveness in regions involved in selective attention within the posterior and inferior parietal lobules. In contrast, hypoactivation within fronto-striatal regions, implicated in inhibitory control, was observed only in BD patients and MDD relatives. Although striatal deficits were comparable between BD patients and their MDD relatives, right ventrolateral prefrontal dysfunction was uniquely associated with BD. Our findings suggest that while reduced parietal engagement relates to genetic risk, fronto-striatal dysfunction reflects processes underpinning disease expression for mood disorders.</AbstractText><CopyrightInformation>Copyright © 2011 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pompei</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Section of Neurobiology of Psychosis, Institute of Psychiatry, Kings College, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jogia</LastName><ForeName>Jigar</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Tatarelli</LastName><ForeName>Roberto</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Girardi</LastName><ForeName>Paolo</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Rubia</LastName><ForeName>Katya</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Kumari</LastName><ForeName>Veena</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Frangou</LastName><ForeName>Sophia</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>02</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuroimage</MedlineTA><NlmUniqueID>9215515</NlmUniqueID><ISSNLinking>1053-8119</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001288" MajorTopicYN="N">Attention</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="N">Image Processing, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011597" MajorTopicYN="N">Psychomotor Performance</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011930" MajorTopicYN="N">Reaction Time</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012959" MajorTopicYN="N">Socioeconomic Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057190" MajorTopicYN="Y">Stroop Test</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>10</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>02</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>02</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>3</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>3</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>7</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21352930</ArticleId><ArticleId IdType="pii">S1053-8119(11)00208-4</ArticleId><ArticleId IdType="doi">10.1016/j.neuroimage.2011.02.052</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12716255</PMID><DateCompleted><Year>2003</Year><Month>07</Month><Day>01</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>64</Volume><Issue>4</Issue><PubDate><Year>2003</Year><Month>Apr</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Possible antidepressant-associated activation of mania and psychosis in the mentally retarded: four case reports.</ArticleTitle><Pagination><MedlinePgn>481-2</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sahay</LastName><ForeName>Neayka</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Muscat</LastName><ForeName>Etienne</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Bowers</LastName><ForeName>Malcolm B</ForeName><Initials>MB</Initials><Suffix>Jr</Suffix></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008607" MajorTopicYN="N">Intellectual Disability</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011605" MajorTopicYN="N">Psychoses, Substance-Induced</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>4</Month><Day>29</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>7</Month><Day>2</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>4</Month><Day>29</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12716255</ArticleId><ArticleId IdType="doi">10.4088/jcp.v64n0420c</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">7932276</PMID><DateCompleted><Year>1994</Year><Month>10</Month><Day>24</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-3956</ISSN><JournalIssue CitedMedium="Print"><Volume>28</Volume><Issue>2</Issue><PubDate><MedlineDate>1994 Mar-Apr</MedlineDate></PubDate></JournalIssue><Title>Journal of psychiatric research</Title><ISOAbbreviation>J Psychiatr Res</ISOAbbreviation></Journal><ArticleTitle>Mood and behavioral effects of four-week light treatment in winter depressives and controls.</ArticleTitle><Pagination><MedlinePgn>135-45</MedlinePgn></Pagination><Abstract><AbstractText>This study investigated (1) the time-course and durability of antidepressant effects of bright light in winter depressives, and (2) the effects of bright light on mood and behavior in normal controls in a 4-week open treatment paradigm. Twelve subjects in a major depressive episode during recurrent major depressive or bipolar disorder with seasonal pattern and 12 control subjects received 2,500 lux light between 0600 and 0800 hours, while 12 controls arose at 0600 hours for quiet activities without exposure to bright light. In depressives, maximal decrements in depression ratings were not reached until the fourth week of treatment. Four depressives experienced clinically significant hypomanic symptoms. Controls treated with light demonstrated significantly higher clinician ratings of hypomanic symptoms than no-light controls. When depressives and controls were combined, seasonality, but not diagnosis, predicted the emergence of manic-like symptoms. Implications for bright light treatment in the clinical setting are discussed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bauer</LastName><ForeName>M S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Veterans Affairs Medical Center, Brown University Department of Psychiatry and Human Behavior, Providence, Rhode Island.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurtz</LastName><ForeName>J W</ForeName><Initials>JW</Initials></Author><Author ValidYN="Y"><LastName>Rubin</LastName><ForeName>L B</ForeName><Initials>LB</Initials></Author><Author ValidYN="Y"><LastName>Marcus</LastName><ForeName>J G</ForeName><Initials>JG</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K11-MH00720</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D018848">Controlled Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Psychiatr Res</MedlineTA><NlmUniqueID>0376331</NlmUniqueID><ISSNLinking>0022-3956</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="Y">Affect</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001143" MajorTopicYN="Y">Arousal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002940" MajorTopicYN="N">Circadian Rhythm</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010555" MajorTopicYN="N">Personality Inventory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010789" MajorTopicYN="Y">Phototherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016574" MajorTopicYN="N">Seasonal Affective Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012892" MajorTopicYN="N">Sleep Deprivation</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1994</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1994</Year><Month>3</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1994</Year><Month>3</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7932276</ArticleId><ArticleId IdType="pii">0022-3956(94)90025-6</ArticleId><ArticleId IdType="doi">10.1016/0022-3956(94)90025-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8067486</PMID><DateCompleted><Year>1994</Year><Month>09</Month><Day>16</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>151</Volume><Issue>9</Issue><PubDate><Year>1994</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Suicidality in patients with pure and depressive mania.</ArticleTitle><Pagination><MedlinePgn>1312-5</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">A previous comprehensive literature review indicated that suicide accounted for 18.9% of the deaths of 9,389 individuals with manic-depressive illness. The literature associates these deaths with the depressed phase of the disease. This study was designed to determine the rate and severity of suicidality among patients with pure and depressive mania.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">The patients were 93 persons who met the Research Diagnostic Criteria (RDC) for bipolar I disorder (N = 75) or schizoaffective disorder (N = 18). All met the RDC for primary mania and the DSM-III-R criteria for bipolar disorder, manic or mixed. Patients with depressive mania met the RDC for mania and major depressive disorder concurrently. Severity of current suicidality was measured by using the Schedule for Affective Disorders and Schizophrenia suicide subscale. Differences in the mean suicidality scores between any two groups were assessed with the Kruskal-Wallis test. Relationships of age, gender, type of affective illness (bipolar I versus schizoaffective disorder), psychosis, race, and mania subtype to suicidality were assessed by using multivariate logistic regression analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">One (2.0%) of the 49 patients with pure mania was suicidal. In contrast, 24 (54.5%) of the 44 patients with depressive mania were suicidal. This difference was highly significant. Gender and psychosis were not related to suicidality. African-Americans were less likely to be suicidal than Caucasians. Subtype of mania had the strongest relationship to suicidality.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">A subgroup of manic patients are severely suicidal. Presentation in the manic state is an indication for careful assessment of depressive symptoms and suicidality.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dilsaver</LastName><ForeName>S C</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, University of Texas Medical School at Houston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Y W</ForeName><Initials>YW</Initials></Author><Author ValidYN="Y"><LastName>Swann</LastName><ForeName>A C</ForeName><Initials>AC</Initials></Author><Author ValidYN="Y"><LastName>Shoaib</LastName><ForeName>A M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Krajewski</LastName><ForeName>K J</ForeName><Initials>KJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044469" MajorTopicYN="N">Continental Population Groups</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016017" MajorTopicYN="N">Odds Ratio</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013405" MajorTopicYN="N">Suicide</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013406" MajorTopicYN="N">Suicide, Attempted</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1994</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1994</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1994</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8067486</ArticleId><ArticleId IdType="doi">10.1176/ajp.151.9.1312</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16861047</PMID><DateCompleted><Year>2006</Year><Month>10</Month><Day>18</Day></DateCompleted><DateRevised><Year>2006</Year><Month>09</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1525-5050</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>2</Issue><PubDate><Year>2006</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Epilepsy &amp; behavior : E&amp;B</Title><ISOAbbreviation>Epilepsy Behav</ISOAbbreviation></Journal><ArticleTitle>Clinical experience with anticonvulsant medication in pediatric epilepsy and comorbid bipolar spectrum disorder.</ArticleTitle><Pagination><MedlinePgn>327-34</MedlinePgn></Pagination><Abstract><AbstractText>Anticonvulsant drugs are first-line treatments for both bipolar mood disorder and epilepsy; however, few studies have explored treatment options when these disorders co-occur. The aim of this study was to identify bipolar disorder symptoms common in pediatric epilepsy and to determine whether anticonvulsant monotherapy might be a practical treatment consideration. A retrospective chart review identified 38 children with bipolar spectrum disorder and epilepsy comorbidity. Two mental health clinicians independently assessed psychiatric diagnoses, symptoms, and assigned retrospective CGI-I ratings for psychiatric symptoms. Common bipolar symptoms included impulsivity, psychomotor agitation, and explosive rage. Forty-two medication trials with 11 different anticonvulsants were identified. Of the 30 instances in which anticonvulsant monotherapy was attempted, carbamazepine, divalproex sodium, lamotrigine, and oxcarbazepine were associated with better psychiatric CGI-I ratings than other monotherapies (P&lt;0.01). Results suggest that in many cases, selected anticonvulsants appeared to simultaneously treat both epilepsy and mood disorder. Controlled trials are necessary to further ascertain optimal anticonvulsant usage.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Salpekar</LastName><ForeName>Jay A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Children's National Medical Center, The George Washington University School of Medicine, Washington, DC, USA. jsalpeka@cnmc.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Conry</LastName><ForeName>Joan A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Doss</LastName><ForeName>Wright</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Cushner-Weinstein</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Pearl</LastName><ForeName>Phillip L</ForeName><Initials>PL</Initials></Author><Author ValidYN="Y"><LastName>Weinstein</LastName><ForeName>Steven L</ForeName><Initials>SL</Initials></Author><Author ValidYN="Y"><LastName>Gaillard</LastName><ForeName>William D</ForeName><Initials>WD</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>07</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Epilepsy Behav</MedlineTA><NlmUniqueID>100892858</NlmUniqueID><ISSNLinking>1525-5050</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004827" MajorTopicYN="N">Epilepsy</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>04</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2006</Year><Month>06</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>06</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>7</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>10</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>7</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16861047</ArticleId><ArticleId IdType="pii">S1525-5050(06)00212-5</ArticleId><ArticleId IdType="doi">10.1016/j.yebeh.2006.06.004</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15225151</PMID><DateCompleted><Year>2004</Year><Month>10</Month><Day>28</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1398-5647</ISSN><JournalIssue CitedMedium="Print"><Volume>6</Volume><Issue>4</Issue><PubDate><Year>2004</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>MMPI as a measure of subthreshold and residual psychopathology among the offspring of lithium responsive and non-responsive bipolar parents.</ArticleTitle><Pagination><MedlinePgn>323-8</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">In bipolar adults, the Minnesota Multiphasic Personality Inventory (MMPI) can detect residual symptoms and confirm completeness of remission, thus helping to predict response to lithium prophylaxis. In the high-risk and early onset bipolar populations, the association of the MMPI with clinical course and treatment response has not yet been studied. The present study compares MMPI profiles completed by the well or remitted offspring of two groups of bipolar parents divided on the basis of parental response to long-term lithium.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">As part of an ongoing prospective longitudinal high-risk study, offspring of bipolar parents determined to either respond or not respond to long-term lithium monotherapy completed the MMPI. At the time of MMPI completion, offspring were determined to be either well (unaffected) or clinically remitted (affected but euthymic) based on repeated prospective KSADS-PL format interviews conducted by a research psychiatrist and reviewed on a blind consensus basis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">While there was no difference in the MMPI scores between subgroups of unaffected offspring, there was a significant difference in profiles between remitted offspring. Specifically, affected offspring of lithium non-responders showed significantly higher average scores on scales 6, 8 and 0 compared with affected offspring of lithium responders. These findings are consistent with the differences in MMPI profiles taken at optimum between the respective parent subgroups.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The findings confirm the clinical observation that the affected offspring of lithium responders suffer from episodic fully remitting mood disorders, while the affected offspring of lithium non-responders suffer from mood disorders with incomplete remission. Further, the nature of the residual symptoms as indicated by the abnormal MMPIs support the view of heterogeneity of the bipolar diagnosis. The relevance to treatment response is discussed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Demidenko</LastName><ForeName>Natasha</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Bipolar Disorders Research Unit, Royal Ottawa Hospital, Ottawa, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grof</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Alda</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Deshauer</LastName><ForeName>Dorian</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Duffy</LastName><ForeName>Anne</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>2BMD2GNA4V</RegistryNumber><NameOfSubstance UI="D016651">Lithium Carbonate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016241" MajorTopicYN="N">Child of Impaired Parents</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004351" MajorTopicYN="Y">Drug Resistance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016651" MajorTopicYN="N">Lithium Carbonate</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008950" MajorTopicYN="Y">MMPI</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010290" MajorTopicYN="N">Parents</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010554" MajorTopicYN="N">Personality Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>7</Month><Day>1</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>10</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>7</Month><Day>1</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15225151</ArticleId><ArticleId IdType="doi">10.1111/j.1399-5618.2004.00130.x</ArticleId><ArticleId IdType="pii">BDI130</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16511730</PMID><DateCompleted><Year>2006</Year><Month>07</Month><Day>06</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0303-4259</ISSN><JournalIssue CitedMedium="Print"><Volume>33 Suppl 1</Volume><PubDate><Year>2006</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Psychiatrische Praxis</Title><ISOAbbreviation>Psychiatr Prax</ISOAbbreviation></Journal><ArticleTitle>[Differential diagnosis and pharmacotherapy of juvenile mania -- a review].</ArticleTitle><Pagination><MedlinePgn>S40-6</MedlinePgn></Pagination><Abstract><AbstractText>Manic disorders and bipolar psychoses have long been underdiagnosed in child and adolescent psychiatry. Scientific research has been rare as well. In particular in adolescence and young adulthood bipolar disorders are not easy to diagnose. Therefore these disorders should be included in differential diagnosis as research from the U. S. shows that there is a significant number of these treatable patients. Being untreated sufficiently major setback in social development and quality of life occur, as severe as in schizophrenia. Adequate medication and psychotherapy in the early phases of these chronic disorders ameliorate the overall prognosis. Special attention should be drawn to hypomanic phases and phenomena as rapid cycling.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Braun-Scharm</LastName><ForeName>Hellmuth</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Klinik für Kinder- und Jugendpsychiatrie und Psychotherapie, Vivantes-Humboldt-Klinikum, Berlin.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bilke</LastName><ForeName>Oliver</ForeName><Initials>O</Initials></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Differenzielle Diagnostik und Pharmakotherapie der juvenilen Manie -- eine Ubersicht.</VernacularTitle></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Psychiatr Prax</MedlineTA><NlmUniqueID>0423204</NlmUniqueID><ISSNLinking>0303-4259</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>2BMD2GNA4V</RegistryNumber><NameOfSubstance UI="D016651">Lithium Carbonate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001289" MajorTopicYN="N">Attention Deficit Disorder with Hyperactivity</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016651" MajorTopicYN="N">Lithium Carbonate</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>95</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>3</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>7</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>3</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16511730</ArticleId><ArticleId IdType="doi">10.1055/s-2005-915327</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20193647</PMID><DateCompleted><Year>2010</Year><Month>04</Month><Day>22</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1555-2101</ISSN><JournalIssue CitedMedium="Internet"><Volume>71</Volume><Issue>2</Issue><PubDate><Year>2010</Year><Month>Feb</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Benzodiazepine use and risk of recurrence in bipolar disorder: a STEP-BD report.</ArticleTitle><Pagination><MedlinePgn>194-200</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4088/JCP.09m05019yel</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Benzodiazepines are widely prescribed to patients with bipolar disorder, but their impact on relapse and recurrence has not been examined.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">We examined prospective data from a cohort of DSM-IV bipolar I and II patients who achieved remission during evidence-guided naturalistic treatment in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) study (conducted in the United States between 1999 and 2005). Risk for recurrence among individuals who did or did not receive benzodiazepine treatment was examined using survival analysis. Cox regression was used to adjust for clinical and sociodemographic covariates. Propensity score analysis was used in a confirmatory analysis to address the possible impact of confounding variables.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 1,365 subjects, 349 (25.6%) were prescribed a benzodiazepine at time of remission from a mood episode. After adjusting for potential confounding variables, the hazard ratio for mood episode recurrence among benzodiazepine-treated patients was 1.21 (95% CI, 1.01-1.45). The effects of benzodiazepine treatment on relapse remained significant after excluding relapses occurring within 90 days of recovery, or stratifying the sample by propensity score, a summary measure of likelihood of receiving benzodiazepine treatment. In an independent cohort of 721 subjects already in remission at study entry, effects of similar magnitude were observed.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Benzodiazepine use may be associated with greater risk for recurrence of a mood episode among patients with bipolar I and II disorder. The prescribing of benzodiazepines, at a minimum, appears to be a marker for a more severe course of illness.</AbstractText><CopyrightInformation>Copyright 2010 Physicians Postgraduate Press, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Perlis</LastName><ForeName>Roy H</ForeName><Initials>RH</Initials><AffiliationInfo><Affiliation>Bipolar Clinic and Research Programs, 50 Staniford St, 5th Floor, Boston, MA 02114, USA. rperlis@partners.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ostacher</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Miklowitz</LastName><ForeName>David J</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>Smoller</LastName><ForeName>Jordan W</ForeName><Initials>JW</Initials></Author><Author ValidYN="Y"><LastName>Dennehy</LastName><ForeName>Ellen B</ForeName><Initials>EB</Initials></Author><Author ValidYN="Y"><LastName>Cowperthwait</LastName><ForeName>Colleen</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Nierenberg</LastName><ForeName>Andrew A</ForeName><Initials>AA</Initials></Author><Author ValidYN="Y"><LastName>Thase</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials></Author><Author ValidYN="Y"><LastName>Sachs</LastName><ForeName>Gary S</ForeName><Initials>GS</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH100286</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01MH80001</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055502" MajorTopicYN="N">Secondary Prevention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>01</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>04</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20193647</ArticleId><ArticleId IdType="doi">10.4088/JCP.09m05019yel</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">30747428</PMID><DateCompleted><Year>2019</Year><Month>08</Month><Day>02</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0065-2598</ISSN><JournalIssue CitedMedium="Print"><Volume>1118</Volume><PubDate><MedlineDate>2019</MedlineDate></PubDate></JournalIssue><Title>Advances in experimental medicine and biology</Title><ISOAbbreviation>Adv Exp Med Biol</ISOAbbreviation></Journal><ArticleTitle>Metabolomic Biomarkers in Mental Disorders: Bipolar Disorder and Schizophrenia.</ArticleTitle><Pagination><MedlinePgn>271-293</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/978-3-030-05542-4_14</ELocationID><Abstract><AbstractText>Psychiatric disorders are some of the most impairing human diseases. Among them, bipolar disorder and schizophrenia are the most common. Both have complicated diagnostics due to their phenotypic, biological, and genetic heterogeneity, unknown etiology, and the underlying biological pathways, and molecular mechanisms are still not completely understood. Given the multifactorial complexity of these disorders, identification and implementation of metabolic biomarkers would assist in their early detection and diagnosis and facilitate disease monitoring and treatment responses. To date, numerous studies have utilized metabolomics to better understand psychiatric disorders, and findings from these studies have begun to converge. In this chapter, we briefly describe some of the metabolomic biomarkers found in these two disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Quintero</LastName><ForeName>Melissa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory of Chemical Biology, Department of Organic Chemistry, Institute of Chemistry, University of Campinas (UNICAMP), Campinas, São Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stanisic</LastName><ForeName>Danijela</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Laboratory of Chemical Biology, Department of Organic Chemistry, Institute of Chemistry, University of Campinas (UNICAMP), Campinas, São Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cruz</LastName><ForeName>Guilherme</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Laboratory of Chemical Biology, Department of Organic Chemistry, Institute of Chemistry, University of Campinas (UNICAMP), Campinas, São Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pontes</LastName><ForeName>João G M</ForeName><Initials>JGM</Initials><AffiliationInfo><Affiliation>Laboratory of Microbial Chemical Biology, Institute of Chemistry, University of Campinas (UNICAMP), Campinas, São Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Costa</LastName><ForeName>Tássia Brena Barroso Carneiro</ForeName><Initials>TBBC</Initials><AffiliationInfo><Affiliation>Laboratory of Chemical Biology, Department of Organic Chemistry, Institute of Chemistry, University of Campinas (UNICAMP), Campinas, São Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tasic</LastName><ForeName>Ljubica</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Laboratory of Chemical Biology, Department of Organic Chemistry, Institute of Chemistry, University of Campinas (UNICAMP), Campinas, São Paulo, Brazil. ljubica@unicamp.br.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Adv Exp Med Biol</MedlineTA><NlmUniqueID>0121103</NlmUniqueID><ISSNLinking>0065-2598</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><MeshHeadingList><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="Y">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055432" MajorTopicYN="Y">Metabolomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Biomarkers</Keyword><Keyword MajorTopicYN="N">Bipolar disorder</Keyword><Keyword MajorTopicYN="N">Mental disorders</Keyword><Keyword MajorTopicYN="N">Metabolomics</Keyword><Keyword MajorTopicYN="N">Psychiatric illness</Keyword><Keyword MajorTopicYN="N">Schizophrenia</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>2</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>2</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>8</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30747428</ArticleId><ArticleId IdType="doi">10.1007/978-3-030-05542-4_14</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23774055</PMID><DateCompleted><Year>2014</Year><Month>07</Month><Day>17</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1533-4112</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>4</Issue><PubDate><Year>2013</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The journal of ECT</Title><ISOAbbreviation>J ECT</ISOAbbreviation></Journal><ArticleTitle>Transient febrile reaction after electroconvulsive therapy (ECT) in a young adult with intellectual disability and bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>e63-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/YCT.0b013e3182972b8c</ELocationID><Abstract><AbstractText>We report the case of a 27-year-old man with mild-moderate intellectual disability (ID) and bipolar disorder treated with electroconvulsive therapy (ECT). He was psychiatrically hospitalized for agitation, aggression, and manic symptoms including insomnia, rapid and pressured speech, and hyperactivity. After multiple medication trials, ECT was recommended. The treatment was delayed owing to the need to obtain evaluation for incapacity and then substituted consent from the patient's mother. He received 2 ECT treatments with marked improvement but complicated by transient fevers, which resolved without treatment. Fever workup was unremarkable. The patient became calm and cooperative and was discharged home. He was readmitted 3 weeks later, again in an agitated manic state. He received 5 additional ECT treatments, but this time with no post-ECT fevers. Once again, his manic symptoms resolved, and he was safely discharged. Whereas patients with ID pose special challenges, our case is in keeping with the previous literature, which supports the use of ECT in patients with ID and comorbid psychiatric disorders. </AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Majeske</LastName><ForeName>Matthew F</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>From the Departments of *Psychiatry and †Anesthesiology, Mount Sinai School of Medicine, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garakani</LastName><ForeName>Amir</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Maloutas</LastName><ForeName>Eleni</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Bryson</LastName><ForeName>Ethan O</ForeName><Initials>EO</Initials></Author><Author ValidYN="Y"><LastName>Kellner</LastName><ForeName>Charles H</ForeName><Initials>CH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J ECT</MedlineTA><NlmUniqueID>9808943</NlmUniqueID><ISSNLinking>1095-0680</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004565" MajorTopicYN="N">Electroconvulsive Therapy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005334" MajorTopicYN="N">Fever</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008607" MajorTopicYN="N">Intellectual Disability</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>6</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>6</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>7</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23774055</ArticleId><ArticleId IdType="doi">10.1097/YCT.0b013e3182972b8c</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27676126</PMID><DateCompleted><Year>2017</Year><Month>03</Month><Day>23</Day></DateCompleted><DateRevised><Year>2017</Year><Month>05</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1440-1819</ISSN><JournalIssue CitedMedium="Internet"><Volume>71</Volume><Issue>2</Issue><PubDate><Year>2017</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Psychiatry and clinical neurosciences</Title><ISOAbbreviation>Psychiatry Clin Neurosci</ISOAbbreviation></Journal><ArticleTitle>Search for plasma biomarkers in drug-free patients with bipolar disorder and schizophrenia using metabolome analysis.</ArticleTitle><Pagination><MedlinePgn>115-123</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/pcn.12461</ELocationID><Abstract><AbstractText Label="AIM" NlmCategory="OBJECTIVE">There is an urgent need for diagnostic biomarkers of bipolar disorder (BD) and schizophrenia (SZ); however, confounding effects of medication hamper biomarker discovery. In this study, we conducted metabolome analyses to identify novel plasma biomarkers in drug-free patients with BD and SZ.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We comprehensively analyzed plasma metabolites using capillary electrophoresis time-of-flight mass spectrometry in patients with SZ (n = 17), BD (n = 6), and major depressive disorder (n = 9) who had not received psychotropics for at least 2 weeks, and in matched healthy controls (n = 19). The results were compared with previous reports, or verified in an independent sample set using an alternative analytical approach.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Lower creatine level and higher 2-hydroxybutyric acid level were observed in SZ than in controls (uncorrected P = 0.016 and 0.043, respectively), whereas they were unaltered in a previously reported dataset. Citrulline was nominally significantly decreased in BD compared to controls (uncorrected P = 0.043); however, this finding was not replicated in an independent sample set of medicated patients with BD. N-methyl-norsalsolinol, a metabolite of dopamine, was suggested as a candidate biomarker of BD; however, it was not detected by the other analytical method. Levels of betaine, a previously reported candidate biomarker of schizophrenia, were unchanged in the current dataset.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our preliminary findings suggest that the effect of confounding factors, such as duration of illness and medication, should be carefully controlled when searching for plasma biomarkers. Further studies are required to establish robust biomarkers for these disorders.</AbstractText><CopyrightInformation>© 2016 The Authors. Psychiatry and Clinical Neurosciences published by John Wiley &amp; Sons Australia, Ltd on behalf of Japanese Society of Psychiatry and Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kageyama</LastName><ForeName>Yuki</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Laboratory for Molecular Dynamics of Mental Disorders, RIKEN Brain Science Institute, Saitama, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuropsychiatry, Graduate School of Medicine, Osaka City University, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kasahara</LastName><ForeName>Takaoki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Laboratory for Molecular Dynamics of Mental Disorders, RIKEN Brain Science Institute, Saitama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morishita</LastName><ForeName>Hiromasa</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Research Resources Center, RIKEN Brain Science Institute, Saitama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mataga</LastName><ForeName>Nobuko</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Research Resources Center, RIKEN Brain Science Institute, Saitama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deguchi</LastName><ForeName>Yasuhiko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neuropsychiatry, Graduate School of Medicine, Osaka City University, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tani</LastName><ForeName>Munehide</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Tani Mental Clinic, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuroda</LastName><ForeName>Kenji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Hannan Hospital, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hattori</LastName><ForeName>Kotaro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Medical Genome Center, National Center of Neurology and Psychiatry, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoshida</LastName><ForeName>Sumiko</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Medical Genome Center, National Center of Neurology and Psychiatry, Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Laboratory Medicine, National Center of Neurology and Psychiatry Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Inoue</LastName><ForeName>Koki</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neuropsychiatry, Graduate School of Medicine, Osaka City University, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kato</LastName><ForeName>Tadafumi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Laboratory for Molecular Dynamics of Mental Disorders, RIKEN Brain Science Institute, Saitama, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>11</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Psychiatry Clin Neurosci</MedlineTA><NlmUniqueID>9513551</NlmUniqueID><ISSNLinking>1323-1316</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Psychiatry Clin Neurosci. 2017 May;71(5):346</RefSource><PMID Version="1">28470913</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019075" MajorTopicYN="N">Electrophoresis, Capillary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013058" MajorTopicYN="N">Mass Spectrometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055442" MajorTopicYN="N">Metabolome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">biomarker</Keyword><Keyword MajorTopicYN="N">bipolar disorder</Keyword><Keyword MajorTopicYN="N">capillary electrophoresis time-of-flight mass spectrometry</Keyword><Keyword MajorTopicYN="N">major depressive disorder</Keyword><Keyword MajorTopicYN="N">schizophrenia</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>06</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>08</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>09</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27676126</ArticleId><ArticleId IdType="doi">10.1111/pcn.12461</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">1527239</PMID><DateCompleted><Year>1992</Year><Month>10</Month><Day>22</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0271-0749</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>4</Issue><PubDate><Year>1992</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of clinical psychopharmacology</Title><ISOAbbreviation>J Clin Psychopharmacol</ISOAbbreviation></Journal><ArticleTitle>The palimpsest phenomenon.</ArticleTitle><Pagination><MedlinePgn>301</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ostow</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016420">Comment</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychopharmacol</MedlineTA><NlmUniqueID>8109496</NlmUniqueID><ISSNLinking>0271-0749</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>J Clin Psychopharmacol. 1992 Feb;12(1 Suppl):2S-6S</RefSource><PMID Version="1">1541714</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1992</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1992</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1992</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1527239</ArticleId><ArticleId IdType="doi">10.1097/00004714-199208000-00028</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29722935</PMID><DateCompleted><Year>2018</Year><Month>12</Month><Day>13</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2155-7780</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>3</Issue><PubDate><Year>2018</Year><Month>May</Month><Day>03</Day></PubDate></JournalIssue><Title>The primary care companion for CNS disorders</Title><ISOAbbreviation>Prim Care Companion CNS Disord</ISOAbbreviation></Journal><ArticleTitle>Are Mixed Symptoms a Red Flag for Conversion of Postpartum Depression to Bipolar Disorder?</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.4088/PCC.17l02201</ELocationID><ELocationID EIdType="pii" ValidYN="Y">17l02201</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Verinder</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>vsharma@uwo.ca.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of Western Ontario, Ontario, Canada .</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>05</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Prim Care Companion CNS Disord</MedlineTA><NlmUniqueID>101547532</NlmUniqueID><ISSNLinking>2155-7780</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019052" MajorTopicYN="N">Depression, Postpartum</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011644" MajorTopicYN="N">Puerperal Disorders</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>5</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>5</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29722935</ArticleId><ArticleId IdType="doi">10.4088/PCC.17l02201</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>